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Depression is a major debilitating disorder and the key aim of the current project was to investigate 
some of the molecular/biochemical mechanisms of antidepressant drugs with an emphasis on the 
relatively unexplored role of sphingolipids.  For this purpose, the current study used two antidepressant 
drugs: the tricyclic antidepressant desipramine, and the selective serotonin re-uptake inhibitor 
paroxetine.  The effects of the drugs in rat brain regions implicated in depression: the prefrontal cortex 
(PFC), hippocampus (HP) and striatum (ST) were investigated both acutely (single administration) and 
chronically (daily treatment for 15 days). In Chapter Three, ¹H NMR spectroscopy was used to explore 
the metabolic response of acute and chronic administration of desipramine and paroxetine. These 
experiments showed significant changes in a number of water-soluble metabolites (i.e. N-
acetylaspartylglutamate, glutamate, glutamine, lactate and creatine) following acute but not chronic 
treatment of the drugs. Sphingolipids including ceramide and its main metabolite sphingosine are key 
modulators of numerous cellular functions and in Chapter Four, it was shown by using liquid 
chromatography with mass spectrometry (LC-MS) that chronic but not acute administration of the 
antidepressant drugs decreased sphingosine levels in the HP and PFC but not in the ST.  The effect of 
the drugs (e.g. paroxetine) on ceramide levels was also tested (HP only) by benzoylation of ceramide 
using high-performance liquid chromatography with ultraviolet detection (HPLC-UV) and in Chapter 
Four, it was shown that hippocampal levels of ceramide were as for sphingosine decreased by chronic 
paroxetine treatment.  This chapter also demonstrated a highly significant correlation for the two 
sphingolipids in both controls and drug-treated animals. In Chapter Five , the effect of chronic 
paroxetine and desipramine administration was investigated on gene expression for two key enzymes 
of the brain sphingolipid pathway namely, acid sphingomyelinase (ASM) and acid ceramidase (AC). By 
using real-time quantitative polymerase chain reaction (RT-qPCR) it was shown that paroxetine and 
desipramine significantly reduced mRNA levels of ASM in the HP while effects in the PFC and ST did not 
reach significance.  Similar effect was seen for desipramine but not paroxetine on mRNA levels for AC 
in the HP. 
Recent studies indicate that ceramide modifies monoaminergic neurotransmission.  In Chapter Six, the 
effect of carmofur, a potent inhibitor of acid ceramidase (AC) was investigated on monoamine 
 II 
neurotransmitters levels and their corresponding metabolites in rat brain regions by using HPLC with 
electrochemical detection (HPLC-ECD).  Carmofur significantly increased 5-HT and decreased its 
metabolite 5-hydroxyindole-3-acetic acid (5-HIAA) in tissue samples from the PFC, HP and ST.  In 
contrast, carmofur failed to significantly alter brain levels of dopamine, noradrenaline and the 
dopamine metabolite 3, 4- dihydroxyphenylacetic acid (DOPAC).  
 
In conclusion, findings of this project are supportive of a putative role for sphingolipids in the 
mechanism of action by antidepressant drugs.  The potential clinical significance of these findings 
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1.1. Depression:  
Depression is a major psychiatric condition with a prevalence of approximately 4.4% worldwide and 
is associated with a substantial risk of social dysfunction, psychological disability and suicide 
(Ambresin et al., 2014; Lan et al., 2009; Organization, 2017; Shneker et al., 2009).  It is one of the 
most common illnesses in the developed countries and according to the world health organisation 
(WHO), it will  constitute the second most important cause of disease induced disability in 2020 
(Figure 1.1) (Haenisch and Bönisch, 2011; Moussavi et al., 2007; Murray and Lopez, 1997; Kastrup, 
2011). Depression is manifested by a range of emotional symptoms including episodes of consistent 
low mood, lack of interest in any activity, anhedonia, low self-esteem and loss of cognitive function.  
In addition, sufferers often develop numerous physical symptoms such as insomnia, restlessness, 
anorexia and loss of libido (Haase and Brown, 2015).  Moreover, the recurrence of symptoms is 
commonly a feature of major depressive disorder (Jacobs, 2004).  
  
 






1.2. Historical background: 
In Ancient Greece, depression was known as "melancholia" and was described as a distinctive illness 
with a prolonged feeling of sadness and fear. According to the Greek physician Hippocrates, often 
referred to as “the father of modern medicine” it was suggested that this mental state was caused 
by a condition of imbalance in the four essential body fluids or humors with an excessive black bile, 
and was mentioned as the humoral theory of melancholia in the 4th and 5th  centuries BC (Liddell 
et al., 1996).  In the late sixteenth-century the disease was identified as a serious occupancy of the 
mind with sadness predominantly affecting specific subgroups of the population, including the 
creative painters and artists (Britton, 2003).  During the 17th century it was proposed that 
melancholia could be cured by performing a “meaningful work”, together with  providing a healthy 
diet, adequate sleep, music as well as discussing the causative problem with a friend (Kent, 2003).  
Further, in the 18th century the humoral theory of melancholia was challenged by electrical and 
mechanical explanatory ideas including energy depletion and slowness of circulation (Jackson, 
1983).  Initially, depression as a term was derived from a Latin word (deprimere, meaning “ to press 
down”) and was primarily used in 1856 by Louis Delasiauve, a French psychiatrist when referring to 
this psychiatric condition (Berrios, 1988).  At the end of the 19th century, the English psychiatrist, 
Henry Maudsley was the first to use this term in a clinical sense (Lewis, 1934). Eventually, with the 
beginning of the 20th century and the start of scientific and biomedical discoveries a new concept 
of depression emerged, and it now began to be considered as a somatic disease along with other 
organ pathologies such as the heart and kidney (Jacobs, 2004). More recently, in the mid-20th 
century the monoamine theory of depression evolved. This theory was originally based on a clinical 
observation that two structurally unrelated medications, namely imipramine (originally used as an 
antipsychotic drug) and iproniazid (an antituberculosis drug) reduced depressive symptoms 
(Krishnan and Nestler, 2008).  Later, these drugs were found to enhance monoamine 
neurotransmitter levels particularly noradrenaline (see also section 1.3.1 for further explanation) 







1.3. Pathogenesis of depression: 
1.3.1. The monoamine hypothesis:                                                                                                                                                                                                                   
The monoamine theory of depression was one of the first theories attempting to elucidate the 
aetiology of depression.  This theory is partly based on the finding from the 1950s that two drugs 
originally developed for other medical purposes, were found to have antidepressant actions 
(Schildkraut, 1965). The first one was an anti-tuberculosis drug, iproniazid which was later 
discovered to increase extracellular monoamine levels by inhibiting the main monoamine degrading 
enzyme, monoamine oxidase (MAO). The second drug, imipramine was originally developed for the 
treatment of schizophrenia and subsequently became the archetypal tricyclic antidepressant 
compound (TCA). This class of drugs raise extracellular monoamine concentrations by blocking the 
monoamine neuronal transporters including the serotonin transporter (SERT) and the noradrenaline 
transporter (NET). These observations led to the development of a simplistic hypothesis of 
depression, the monoamine hypothesis which postulates that depression is associated with the 
deficiency of  monoamine neurotransmitters in the central nervous system (CNS) and subsequently 
that the increased monoamine neurotransmission induced by antidepressant drugs is responsible 
for the corresponding alleviation of the depressive symptoms (Schildkraut, 1965). The three 
centrally acting monoamines implicated in this theory are: noradrenaline (NA), serotonin (also called 
5-hydroxytryptamine, 5-HT) and dopamine (DA).  However, this theory was conflicted with the fact 
that the neurochemical effects induced by antidepressant drugs occur much before the onset of 
their clinical action which is often not seen until approximately 2 weeks of treatment (Mitchell, 
2006; Tylee and Walters, 2007), however the full therapeutic action can even be delayed up to 4-6 
weeks after starting the treatment (Trivedi et al., 2006).  In addition, it was challenged by another 
contradictory observation that not all depressed patients (i.e. 60-70%) responded to antidepressant 
drug treatment namely, imipramine (Al-Harbi, 2012; Klerman and Cole, 1965; Rush et al., 2006).  
Hence, although the monoamine theory gained popularity and support, its validity remains 
questionable. 
 
1.3.2. The neurotrophic hypothesis: 
The concept of neurogenesis, which refers to the ongoing process of generating new neurons from 
neural progenitor cells in the adult brain, was first established by Altman (1965).  In this early study, 
he demonstrated that neurogenesis occurs continuously in two specific areas of the adult brain: the 
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subgranular zone of the hippocampal dentate gyrus and the subventricular zone of the lateral 
ventricles where the newly generated neurons migrate to the olfactory bulb (Altman and Das, 1965; 
Ming and Song, 2011).  Suppression of neurogenesis by stress results in neuronal and glial atrophy 
specifically in the hippocampus (McEwen et al., 2016). This is proposed to be a critical contributory 
factor in the aetiology of depression (Krishnan and Nestler, 2008).  It has been reported that brain 
derived neurotrophic factor (BDNF) plays an essential role in regulating the process of neurogenesis. 
Furthermore, depression may result from a decrease in the expression of BDNF in the limbic areas 
of the brain, resulting in a reduced neurogenesis in the hippocampus (Lee et al., 2013), which may 
trigger the detected reduction in the volume of this brain region in depressed patients (Malykhin et 
al., 2010). These changes can be reversed by the chronic administration of antidepressant drugs 
(Duman and Li, 2012). In addition, it has been demonstrated that chronic antidepressant drug 
treatment including noradrenaline-selective reuptake inhibitors (NSRIs) and serotonin-selective 
reuptake inhibitors (SSRIs) when given for 2-3 weeks increases both BDNF expression and 
neurogenesis namely in the dentate gyrus of the hippocampus, whereas stress exerts an opposing 
effect by decreasing hippocampal neurogenesis (Lee et al., 2013; Sahay and Hen, 2007).  
Additionally, it was reported that the dorsal raphe nucleus of the brain stem (origin of serotonergic 
neurons) which is implicated in depression (Michelsen et al., 2008) and in mediating the 
antidepressant drug actions (Rajkumar and Mahesh, 2008) shows a high gene expression level of 
both BDNF and its receptor, tropomyosin receptor kinase B  also known as tyrosine receptor kinase 
B (TrKB). Thus, it has been suggested that BDNF is not only involved in neurogenesis but might also 
have a direct neurotrophic action on 5-HT neurons (Madhav et al., 2001).  
 
1.3.3. The lipid hypothesis: 
 
Membrane lipids exert an essential role for neuronal activity of the brain through their function as 
a physical barrier that separates the intracellular and extracellular compartments. They are also 
involved in regulating the function and distribution of membrane proteins including 
neurotransmitter receptors, ion channels, transport proteins (transporters) and membrane 
enzymes (ceramide activated protein phosphatase) (Alberts et al., 2002), thereby modulating cell 
signalling and neurotransmission, membrane permeability and cellular growth arrest and apoptosis 
(Dinoff et al., 2017). Cholesterol, glycerophospholipids and sphingolipids are the major lipid 
components of the cell membrane in the brain (Fantini and Barrantes, 2009; Jain et al., 2014). 
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Sphingomyelin is an important membrane sphingolipid which constitutes the main source of 
ceramide in neuronal cell membranes and undergoes hydrolysis through activation of the enzyme 
acid sphingomyelinase (ASM) within lysosomes.  Interestingly, this process has been shown to be 
elevated during stress (Kitatani et al., 2008).  In this context, a recent animal study demonstrated 
that chronic stress during a four week period induced a significant up-regulation of ceramide 
content in the hippocampus and the prefrontal cortex of rats, this with a concomitant decrease of 
sphingomyelin levels (Oliveira et al., 2016). Furthermore, ceramide levels are also increased through 
inhibition of the lysosomal acid ceramidase enzyme (AC) which facilitates the conversion of 
ceramide to sphingosine and free fatty acids in the brain.  Importantly, the increased ceramide level 
has been suggested to be implicated in cell growth arrest and apoptosis (programmed cell death) 
(Strelow et al., 2000).  Further and consistent with a proposed role for ceramide in depression, the 
lysosomal hydrolysis of sphingomyelin to ceramide through stimulation of ASM, has been reported 
to be enhanced in patients suffering from major depressive illness (Kornhuber et al., 2008).  In 
addition, a recent study showed that chronic stress to rats (4 weeks of exposure to stressful 
conditions such as overcrowding, exposure to hot air stream, cold water at 18°C or vibration) 
induced a behavioural animal pattern associated with depression and this coincided with increased 
ceramide levels in the hippocampus and prefrontal cortex (Oliveira et al., 2016).  Also in support of 
a role for ceramide in the symptoms of depression are some previous studies demonstrating that 
antidepressant drugs including the TCA desipramine and the SSRI fluoxetine, inhibit ASM of the 
mouse hippocampus and consequently modify behaviours associated with antidepressant drug 
action in mice models (Gulbins et al., 2013; Kölzer et al., 2004). Further, sphingolipids and 
cholesterol exert an important role for receptor-mediated signaling action as they together form 
membrane lipid rafts (also referred to as macrodomains or platforms).  Such lipid rafts are enriched 
in various receptors including G-protein coupled receptors (for example the monoamine receptors).  
Therefore, any change in the composition of these lipid compartments may directly alter the 
receptors’ affinity for ligands as well as their corresponding signaling action (Veiga et al., 2001).  
Moreover, these macrodomains are important for the activation of the sphingomyelin hydrolysing 
enzyme, ASM and subsequently could be involved in the generation of ceramide content in the cell 
membranes in response to stress (Cremesti et al., 2002).  Interestingly, a previous study conducted 
on ASM deficient mice reported a significant reduction of ceramide level in the hippocampus with 
reduced depressive behaviours (Gulbins et al., 2013).  Importantly, the same study also 
demonstrated another relevant finding that acid ceramidase (AC) deficient mice showed a 
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significant down-regulation of neurogenesis, neuronal maturation and neuronal survival with an 
increase of depression-like behaviours (suppressed forced swim test, sucrose preference test and 
open field test) (Gulbins et al., 2013).  Albeit in need of more investigations, these initial and critical 
observations underpin a newly adopted hypothesis of depression and its treatment which is based 
on the up-regulation of ceramide level as one of the underlying biological mechanism of depression.   
 
1.3.4. The neuroendocrine hypothesis (The corticosteroid receptor hypothesis): 
Dysregulation of the hypothalamic-pituitary-adrenal axis (HPA) (a system composed of the following 
structures: the paraventricular nucleus of the hypothalamus (PVN), the anterior pituitary lobe and 
the adrenal gland) is implicated in mediating the stress response and may also represent a 
contributory factor in the pathogenesis of depression (Duval et al., 2005; Smith and Vale, 2006; 
Snyder et al., 2011).  In response to stress, corticotropin-releasing hormone (CRH, also referred to 
as corticotropin-releasing factor CRF), is the major regulator of the HPA axis and it is synthesized 
and released by the hypophysiotropic neurons which are located in the PVN of the hypothalamus 
(Smith and Vale, 2006).  Then, the released CRH binds to the CRH type 1 receptors which are situated 
on the corticotropic cells in the anterior lobe of the pituitary gland, thus inducing the secretion of 
adrenocorticotropic hormone (ACTH, also known as corticotropin) into the systemic circulation (Rot 
et al., 2009; Smith and Vale, 2006; Taylor et al., 2005).  Subsequently, the circulating ACTH stimulates 
the zona fasciculata in the adrenal cortex to release the glucocorticoid hormone (cortisol or 
corticosterone) through activating the glucocorticoid receptors (Rot et al., 2009).  Recent studies 
suggested that a finding of cortisol hypersecretion was often reflected in depressive patients 
(Holsboer, 2000; Krishnan and Nestler, 2008).  In addition, an enhancement of cortisol secretion has 
also been detected in rats following exposure to psychological stress (Holsboer, 2000).   
1.3.5. The cytokine hypothesis: 
It was hypothesized that depression is associated with a concomitantly enhanced production of 
inflammatory biomarkers namely the pro-inflammatory cytokines (small protein molecules released 
by specific cells within the immune system to mediate the inflammatory response) including tumour 
necrosis factor-alpha (TNF-α), interferon-gamma (INF-gamma), interleukin-1beta (IL-1beta) (Maes, 
2008; Schiepers et al., 2005).  This hypothesis was supported by the observation that chronic 
autoimmune or inflammatory diseases (e.g. hepatitis C, cancer, rheumatoid arthritis or diabetes 
mellitus) were often accompanied by depressive symptoms (Schiepers et al., 2005).  In this respect, 
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a preclinical study reported that pro-inflammatory cytokine administration induced depression-like 
behaviours in rodent models (reduced sexual and exploratory behaviours, loss of appetite, elevated 
sensitivity of pain as well as social withdrawal) (Schiepers et al., 2005). Additionally, a clinical study 
indicated that  approximately 30% of individuals who received treatment with a synthetic interferon 
(used for treatment of certain types of leukaemia and skin cancers) developed depression as a 
common side effect during the course of treatment (Krishnan and Nestler, 2008).  Furthermore, the 
detected increase in cytokine levels may account for the reduced 5-HT levels as well as the increased 
5-HT turnover (i.e. increased 5-HIAA/5-HT ratio) which are observed during depression, possibly 
through activating the tryptophan metabolising enzyme (indoleamine-2, 3-dioxygenase, IDO).  
Thereby, reducing the tryptophan (the primary amino-acid precursor of 5-HT) and consequently, 5-
HT synthesis and levels in the brain (Felger and Lotrich, 2013; Schiepers et al., 2005).  In this context, 
a previous animal study reported that acute treatment with the inflammatory cytokines (e.g. 
interferon-gamma) or activating the immune response by acute administration of 
lipopolysaccharide (a cytokine inducer) enhanced the expression of depression-like behaviours in 
mice (e.g. prolonged immobility in the tail suspension test and  forced swim test with a suppressed 
sexual behaviour) (Lestage et al., 2002; O’Connor et al., 2009).  This effect is likely to be mediated 
by activating the IDO enzyme, therefore increasing tryptophan catabolism and subsequently, 
reducing 5-HT synthesis (Felger and Lotrich, 2013; O’Connor et al., 2009). Further, the same study 
showed that administration of 1-methyltryptophan (the IDO antagonist) resulted in attenuation of 
the depression related behaviours in mice through blockade of IDO activation (O’Connor et al., 
2009).  In addition, recent studies demonstrated that antidepressant drugs namely the SSRIs 
including paroxetine, citalopram and sertraline suppress the pro-inflammatory cytokines 
production, thereby mediating an immunosuppressive effect (Gobin et al., 2014; Shenoy et al., 
2013). 
 
1.4. Monoamine neurotransmitters: 
1.4.1. Serotonin (5-hydroxytryptamine, 5-HT): 
Serotonin (5-HT) is an important neurotransmitter, identified in the late 1940s by Rapport (Rapport 
et al., 1948) and is known to be responsible for maintaining a broad range of physiological functions 
including mood, sleep, memory, learning, aggressive behaviour, emotion, appetite, pain, 










Figure 1.2: Chemical structure of serotonin. 
 
5-HT is an indolamine (Figure 1.2) derived from the dietary amino acid, tryptophan and 
approximately 90% of the total body 5-HT content is found outside the brain where it is mainly  
synthetized by the enterochromaffin cells of the GI tract (Berger et al., 2009).  In the brain, 5-HT is 
produced by serotonergic neurons originating in the median and dorsal raphe nuclei of the brain 
stem, where they send their axonal projections throughout almost the whole brain (Hornung, 2003).  
Particularly, high levels of 5-HT are detected in brain regions including the prefrontal cortex, nucleus 
accumbens, hippocampus, striatum and hypothalamus (Zangen et al., 1997).  This neurotransmitter 
is initially biosynthesized from tryptophan in two steps: the first step catalyzes the hydroxylation of 
the precursor amino acid to form 5-hydroxytryptophan by the action of the rate limiting enzyme 
tryptophan hydroxylase (TPH) (Welford et al., 2016). TPH is found in two isoforms TPH1 and TPH2, 
the TPH1 is mainly expressed in the pineal gland and peripheral organs (gut, pancreatic islets of 
Langerhans, bone, bone marrow, liver and mammary gland) (Amireault et al., 2012), whereas TPH2 
is predominantly expressed in the central nervous system (CNS) (Walther and Bader, 2003).  Further, 
the 5-HT synthetic pathway involves decarboxylation of 5-hydroxytryptophan (5-HTP) by the 
aromatic amino acid decarboxylase enzyme (AADC) to produce 5-hydroxytryptamine (5-HT). 
Subsequently, the neurotransmitter undergoes further degradation into the final metabolite 
namely 5-hydroxyindoleacetic acid (5-HIAA) via a combined action of monoamine oxidase (MAO) 
and aldehyde dehydrogenase enzymes.  Finally, 5-HIAA is then excreted in the urine (Figure 1.3) 
(Berumen et al., 2012; Welford et al., 2016). Following 5-HT biosynthesis, the neurotransmitter is 
transported to the synaptic vesicles for storage by means of the vesicular monoamine transporter 
(VMAT). Then, serotonergic transmission is triggered by the release of the stored 5-HT from the 
presynaptic nerve terminals after the initiation of the action potential and activating the voltage-
dependent Ca2+ channels (Alekseyenko et al., 2010).  Subsequently, Ca2+ ions enter into the cell and 
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bind with the synaptic vesicles membrane, which cause the  vesicular compartment to fuse with the 
cell membrane and release 5-HT into the synaptic cleft by a process of exocytosis (Alekseyenko et 
al., 2010).  Further, the released 5-HT diffuses into the synaptic cleft and binds to the different 
transmembrane presynaptic and postsynaptic 5-HT receptors. Currently, 7 distinct classes of 5-HT 
receptors encoded by different genes have been identified including 5-HT1 (5-HT1A, 5-HT1B, 5-
HT1D, 5-HT1E and 5-HT1F), 5-HT2 (5-HT2A, 5-HT2B and 5-HT2C), 5-HT3, 5-HT4, 5-HT5 (5-HT5A and 
5-HT5B), 5-HT6 and 5-HT7 receptor subtypes (Charnay and Leger, 2010).  It was recognized that all 
the 5-HT receptors are G protein-coupled receptors except the 5-HT3 which form a ligand-gated ion 
channel (permeable to Na+, K+ and Ca+2 ions) (Berumen et al., 2012).  Additionally, the function of 
5-HT in the synapse is terminated via high affinity uptake of 5-HT from the synapse by the serotonin 
transporter (SERT) which is a target of many effective antidepressant drugs including the SSRIs (see 
section 1.6.1.1) (Ramamoorthy et al., 2011). The monoamine transporters are protein structures 
situated on the cell membrane of the monoaminergic presynaptic nerve terminals. Further, they are 
Na+ and Cl¯ dependent transporters that constitute important members of the SLC6 gene 
transporter family.  Specifically, these protein transporters act to regulate the concentration of the 
released monoamine neurotransmitters within the synaptic cleft (maintaining a low extracellular 
level of approximately 5-10 nM for 5-HT) (Calcagno et al., 2009; Crespi et al., 1988).  Also, it was 
reported that 5-HT receptors appeared to have a high affinity state in a nanomolar range (e.g. 5-
HT1A receptors in rat cortical tissues showed a high binding affinity of nearly 1 nM for 5-HT) (Daws, 
2009; Watson et al., 2000). Thus, SERT modulates signals transmitted by the receptor via regulating 
the amount of the ligand available to bind to a presynaptic or postsynaptic 5-HT receptor at the 
specific site of action (Duan and Wang, 2010).  In addition, the SERT has a high affinity 
(approximately 1 nM binding affinity) and selectivity for 5-HT and so strictly regulates the extent 
and duration of serotonergic neurotransmission (Lundgren et al., 2009; Rudnick, 2006). Therefore, 
it is considered as a key factor in modulating 5-HT neurotransmission in the CNS.  Thus, alteration 
in SERT function is associated with the treatment of psychological diseases including anxiety and 





Figure 1.3: 5-HT synthesis and catabolism. Serotonin (5-HT) is synthesized from tryptophan by the 
rate-limiting enzyme tryptophan hydroxylase (TPH) to form 5-hydroxytryptophan (5-HTP) which in 
turn decarboxylated by the aromatic amino acid decarboxylase enzyme to produce 5-HT.  Then, the 
neurotransmitter undergoes catabolism into 5-hydroxyindoleacetic acid (5-HIAA) via actions of 
monoamine oxidase (MAO) and aldehyde dehydrogenase enzymes to be excreted in the urine 
(Morgan et al., 2012). 
 
1.4.1.1. Serotonin receptors: 
Previous pharmacological and biochemical studied indicated that 5-HT receptors (six out of seven 
groups) are coupled with different types of G proteins, thereby modulating different signaling 
pathways. Furthermore, 5-HT3 receptors are ligand-gated ion channels (i.e. ionotropic receptors) 
which mediate a neuronal depolarization through a transient opening of the cations channel with 
an inward flow of these ions (Frazer and Hensler, 1999).  The 5-HT1 and 5-HT5 receptors interact 
with Gαi/o proteins, thus activating two distinct mechanisms including a decrease in the production 
of the intracellular cyclic adenylate monophosphate (cAMP, a second messenger) via inhibiting the 
adenylyl cyclase activity (AC), or mediating a neuronal hyperpolarization which is caused by opening 
of the K+ channels and the out flow of K+ ions to the extracellular space (Frazer and Hensler, 1999).  
In comparison, 5-HT2 receptors are coupled with Gαq protein activating the phospholipase C, 
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leading to the production of inositol triphosphate (IP3) and diacylglycerol (DAG), eventually 
producing an increase of the intracellular calcium release (McCorvy and Roth, 2015).  Additionally, 
it was observed that, 5-HT4, 5-HT6 and 5-HT7 receptors interact with Gαs proteins activating the AC 
activity, hence stimulating the production of cAMP and the subsequent activation of other cellular 
proteins including the protein kinase A enzyme (PKA) (McCorvy and Roth, 2015) and thereby, 
activating CREB (cAMP response element binding protein) a cellular transcription factor which 
modifies the level of gene expression) (Berumen et al., 2012).  A number of pharmacological and 
structural studies established that 5-HT receptor subtypes are found to have both a presynaptic 
localisation (i.e. 5-HT1A, 5-HT1B and 5-HT1D) and a postsynaptic localisation (i.e. 5-HT1A, 5-HT1B, 
5-HT1D, 5-HT2A and 5-HT7) (Berumen et al., 2012). In addition, the 5-HT receptor families show a 
wide neuroanatomical distribution with different expression levels in various brain regions including 
the cortex, hippocampus, raphe nuclei, substantia nigra, amygdala, hypothalamus, frontal cortex, 
striatum, nucleus accumbens, olfactory tubercle and thalamus (Charnay and Leger, 2010; Frazer and 
Hensler, 1999; Taylor et al., 2005).  Furthermore, 5-HT1A autoreceptors are abundant 
somatodendritic presynaptic inhibitory receptors expressed in the raphe nuclei of the mid brain, 
whereas the 5-HT1A receptors that spread widely in other brain areas mainly in cortico-limbic 
structures such as the hippocampus are postsynaptic receptors (Celada et al., 2004). Activating 
these autoreceptors by 5-HT allows opening of the cell membrane potassium channels and pumping 
the potassium ions out of the cells producing a neuronal hyperpolarization. Therefore, reducing the 
firing of serotonergic neurons as well as 5-HT biosynthesis and release, hence mediating a negative 
feedback mechanism that regulates 5-HT release (reducing the terminal release of 5-HT, 
consequently attenuating excessive increase of extracellular 5-HT level) (Celada et al., 2004; 
Rajkumar and Mahesh, 2008). It has also been shown that 5-HT1A autoreceptors exert an important 
role in modulating many behavioural and cognitive functions including learning, sleep, mood, 
anxiety and depression (Jafurulla et al., 2008).  Thus, they represent an important target of various 
antidepressant drugs such as the SSRIs, TCAs and MAOIs (Celada et al., 2004; Müller et al., 2007).  
Interestingly, these receptors may interact with membrane lipids (lipid-protein interaction) which 
may trigger conformational changes that are essential to maintain their structural integrity and 





1.4.2. Noradrenaline (NA): 
Noradrenaline (NA) is a catecholamine (Figure 1.4) that modulates various behavioural and 
physiological functions in the brain as well as in the periphery including: heart rate, blood pressure, 
appetite, mood, sleep, attention, alertness, anxiety and general interest in life (Bönisch and Brüss, 
2006).   





Figure 1.4: Chemical structure of noradrenaline.  
Locus coeruleus (LC) of the brain stem is the main site where noradrenergic cell bodies are 
predominantly located and send their ascending projections to almost the whole of the brain 
including the prefrontal cortex and the hippocampus (brain regions implicated in the pathology of 
depressive disorder) (Ramamoorthy et al., 2011). NA is synthesized from its initial precursor, the 
essential amino acid tyrosine (under tyrosine deficiency, phenylalanine is hydroxylated into tyrosine 
by phenylalanine hydroxylase enzyme). Then, tyrosine is hydroxylated by the action of the rate 
limiting cytosolic enzyme tyrosine hydroxylase (TH) to form dihydroxyphenylalanine (DOPA) (Figure 
1.5). This reaction is the rate-limiting step in NA biosynthetic pathway and is followed by 
decarboxylation of DOPA into dopamine via the cytosolic enzyme DOPA decarboxylase (Vieira-
Coelho et al., 2009). Then, the neurotransmitter dopamine (DA) is transported via the vesicular 
monoamine transporter (VMAT) into the synaptic vesicles within the presynaptic nerve terminal.  
Subsequently, DA is converted by dopamine β-hydroxylase enzyme to NA within the synaptic 
vesicles to be released following the initiation of an action potential and via a process of exocytosis 
(Ca2+-dependent exocytosis) into the synaptic cleft.  The released NA exerts its action by binding to 
postsynaptic noradrenergic receptors (also known as adrenoceptors including α₁ α₂ and β₁ β₂ β3) and 
the inhibitory presynaptic α2 autoreceptor (inhibit further NA release) (Gannon et al., 2015; Torres 
et al., 2003).  The α2 autoreceptor, likewise the serotonin 5-HT1A autoreceptor modulates the 
chemical signals of the postsynaptic neuron by regulating the amount of neurotransmitter available 
for the postsynaptic receptors located on it. NA undergoes metabolic degradation via two main 
enzymes including monoamine oxidase (MAO) and catechol-O-methyl transferase (COMT), giving 
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rise to its main excretory product 3-methoxy-4-hydroxyphenylglycol (MHPG) which is associated 
with NA in the brain.  MHPG is then further converted to vanillylmandelic acid (VMA) which is the 
main NA metabolite in the peripheral nervous system.  VMA is the biologically inactive end product 
of NA and is excreted by the kidneys (Figure 1.3) (Fernstrom, 1983).  The main termination of the 
physiological action by NA in the synapse is by reuptake of the monoamine transmitter back into 
the presynaptic nerve terminals through the action of the plasma membrane noradrenaline 
transporter (also known as norepinephrine transporter, NET) where NA is either recycled (restored) 
or undergoes enzymatic degradation by MAO and possibly also COMT into its biologically inactive 
metabolic products (Eisenhofer et al., 2004; Fernstrom, 1983; Lambert et al., 2001).  
 
 
Figure 1.5: Catecholamines biosynthesis. Dopamine (DA) is synthesized from tyrosine that is 
converted to L-DOPA by tyrosine hydroxylase enzyme (rate-limiting step) and eventually into DA via 
aromatic amino acid decarboxylase. Then, DA is converted to noradrenaline (NA) via dopamine β-
hydroxylase enzyme (Windahl, 2009). 
 
1.4.2.1. Adrenergic receptors: 
Detailed studies of the noradrenergic system revealed that effects of NA are mediated via three 
classes of adrenergic receptors which all belong to the G-protein coupled receptor family including 
α1, α2 and β receptors (Gannon et al., 2015; Sofuoglu and Sewell, 2009).  The α1 subtypes (α1A, α1B 
and α1D) are excitatory postsynaptic receptors that are coupled to Gq proteins, thus activating the 
secondary messengers: phospholipase C and phosphoinositol (IP3) and thereby increasing 
intracellular calcium levels (Philipp et al., 2002; Sofuoglu and Sewell, 2009).  The α2 adrenergic group 
includes α2A, α2B and α2C subtypes which are located at both presynaptic and postsynaptic 
localisations.  They are coupled to Gi/o proteins, hence inhibiting the second messenger adenylate 
cyclase and consequently, reducing the cAMP and  calcium levels (Gannon et al., 2015).  As already 
mentioned, the α2 receptors when located on presynaptic noradrenergic nerve terminals act as 
inhibitory autoreceptors which modulate NA level through inhibiting further NA release (Gannon et 




the Gs proteins, activating these receptors result in the increase of adenylate cyclase and cAMP 
levels (Gannon et al., 2015; Sofuoglu and Sewell, 2009).  
 
1.4.3. Dopamine (DA): 
Dopamine is likewise NA, a catecholamine neurotransmitter (Figure 1.6) and plays a critical role in 
several behavioural and physiological processes including motivation, cognition, attention, reward, 
learning, memory, sleep, mood and locomotor activity, therefore it is also likely to be involved in 
the pathophysiology of depressive disorder (Elsworth and Roth, 1997; Hussein, 2016).  
 
 
Figure 1.6: Chemical structure of dopamine. 
Within the brain, dopaminergic cell bodies are located in two main areas: the substantia nigra 
of the midbrain (SN) and the ventral tegmental area (VTA) (Brookshire, 2017).  The principal 
dopaminergic pathways implicated in depression are the mesolimbic pathway which originates in 
the VTA and projects to the nucleus accumbens (also known as ventral striatum) and the 
mesocortical pathway which also begins in the VTA and innervates the prefrontal cortex (Speed, 
2010).  After synthesis (Figure 1.5), DA is transported into the synaptic vesicles by the vesicular 
monoamine transporter (VMAT), and after triggering an action potential the stored DA is released 
into the synaptic cleft by a process of exocytosis where it interacts with pre and postsynaptic 
dopamine receptors (D1-D5) (Beaulieu and Gainetdinov, 2011). The dopamine transporter (DAT) 
located on the cell membrane of presynaptic nerve terminals mediates the termination of 
dopaminergic neurotransmission by a rapid neuronal reuptake of the released DA back into these 
presynaptic nerve terminals to be recycled (restored) or to be broken down by enzymatic 
depredation (MAO-B) (Meiser et al., 2013). Eventually, the released DA is catalysed via the 
combined action of the two enzymes: MAO and COMT (predominantly a membrane bound form) 
mainly to dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) which are excreted in 




1.4.3.1. Dopamine receptors: 
The neurotransmitter dopamine regulates dopaminergic neurotransmission by binding with 5 types 
of dopamine receptors: D1-D5 which are G protein-coupled receptors (Beaulieu and Gainetdinov, 
2011). A number of structural, biochemical and pharmacological studies revealed that dopamine 
receptors were classified into two main classes: the D1-class which includes the D1 and D5 
subfamilies of dopamine receptors and the D2-class including D2, D3 and D4 subtypes of dopamine 
receptors (Vallone et al., 2000). The D1-class dopamine receptors (D1 and D5) are coupled to Gαs/olf 
type of G proteins, thus stimulating adenylyl cyclase (AC) and subsequently, activating cAMP 
production. These receptors are predominantly expressed postsynaptically within the striatum, 
substantia nigra, nucleus accumbens, amygdala, frontal cortex and the olfactory bulb (Beaulieu and 
Gainetdinov, 2011).  In contrast, the D2-class dopamine receptors (D2, D3 and D4) are coupled to 
Gαi/o proteins, hence inhibiting the AC activity and cAMP production.  It was established that the 
D2-class dopamine receptors are expressed significantly at both presynaptic and post synaptic 
localisations within the striatum, substantia nigra, nucleus accumbens, ventral tegmental area, 
olfactory tubercle, amygdala and hippocampus (Beaulieu and Gainetdinov, 2011; Vallone et al., 
2000).  The D2-class dopamine receptors when located presynaptically on DA nerve terminals act as 
inhibitory autoreceptors.  Thus, activation of these receptors provide an important negative 
feedback mechanism that modulates the firing rate of dopaminergic neurones, DA synthesis and 
release in response to the increased extracellular DA level (Beaulieu and Gainetdinov, 2011).  
 
1.5. Antidepressant drugs:  
The use of the currently prescribed antidepressant medications was originally based (as already 
mentioned in section 1.3.1) on the early accidental discovery (nearly 70 years ago) of the mood 
elevating properties of drugs that were initially developed for different medical purposes 
(Schildkraut, 1965).  These drugs were subsequently discovered to enhance the monoamines 
function in the brain (Hirschfeld, 2000; Mulinari, 2012).  Later, they were classified into two main 
groups of antidepressants including the monoamine oxidase inhibitors (MAOIs) and the tricyclic 
antidepressant drugs (TCAs).  These early observations form the basis of the subsequently 
postulated proposal of a monoamine hypothesis of depression (Berton and Nestler, 2006; 
Schildkraut, 1965).  In 1987, the first selective serotonin reuptake inhibitor (SSRI) namely zimelidine 
aimed at a selective enhancement of serotonin neurotransmission in the brain was discovered.  
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Albeit, it was not used clinically due to its severe side effect, specifically a serious neurological 
consequence known as Guillain-Barre syndrome (a progressive autoimmune neuropathy which 
affects the nerve cells, resulting in muscular weakness, pain and paralysis) (Fagius et al., 1985; 
Ramachandraih et al., 2011).  Subsequently, the increased knowledge of drug design and the diverse 
role of the monoamines in the brain led to the development of many new drugs that represent 
different antidepressant classes based on their chemical structures and their effects on different 
monoamine targets. 
1.5.1. Classification: 
• Monoamine uptake inhibitors: 
1. Selective serotonin reuptake inhibitors (SSRIs) 
2. Noradrenaline reuptake inhibitors (NARIs) 
3. Serotonin-noradrenaline reuptake inhibitors (SNRIs) 
4. Tricyclic antidepressant drugs (TCAs) 
• Monoamine oxidase inhibitors (MAOIs) 
                1. Reversible monoamine oxidase inhibitors 
                2. Irreversible monoamine oxidase inhibitors 
• Monoamine receptor antagonists 
 
1.5.1.1. Monoamine uptake inhibitors: 
• Selective serotonin reuptake inhibitors (SSRIs): 
One of the mainstays in the treatment of depression is the use of the SSRIs which represent 
according to the published data, the most commonly used group of antidepressant drugs.  These 
medications show a high selectivity for serotonin reuptake by blocking the serotonin transporter 
action (Figure 1.7) and thereby increasing the synaptic as well as the extracellular concentration of 
5-HT (Cheung et al., 2006). The following drugs are members of the SSRI group of antidepressant 
drugs: paroxetine, fluoxetine, sertraline and citalopram (Pies, 2010).  Although, they are relatively 
safe in drug overdose, they are not ideal due to a number of unpleasant side effects including: 
nausea, sexual dysfunction, gastro-intestinal problems and insomnia.  In particular, the use in 
children has been deemed to be unsuitable, which is due to the increased risk of suicidal attempt 
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and only fluoxetine is recommended for the treatment of depression in children in the UK (Cheung 
et al., 2006; Suchard, 2008).   
• Noradrenaline reuptake inhibitors (NARIs): 
Previous preclinical and clinical studies reported that these antidepressant drugs enhance the brain 
noradrenaline (NA) neurotransmission via their high affinity and selectivity to block the 
noradrenaline transporter (NET), therefore inhibiting the extracellular reuptake of noradrenaline. 
Examples of this group of antidepressant drugs include reboxetine and atomoxetine (Hajós et al., 
2004). 
• Serotonin-noradrenaline reuptake inhibitors (SNRIs): 
This class of antidepressant drug show likewise the TCAs (albeit chemically different from this group 
of drugs) a combined action (dual mode of action) to inhibit the reuptake of both 5-HT and NA 
neurotransmitters by blocking their transporters activity, thus increasing their concentrations in the 
synaptic cleft (Figure 1.7).  It is however, well established that these medications have a variable 
degree of affinity and selectivity for 5-HT and NA transporters.  Venlafaxine for example, shows a 
higher affinity (30-fold) toward SERT compared to the NET (high potency to inhibit the SERT even at 
low dose and a lower potency to block NET only at high dose), whereas duloxetine has only 10-fold 
higher affinity in inhibiting the SERT in comparison with NET (Celikyurt et al., 2012). Unlike the TCAs, 
SNRIs show a low affinity toward other brain receptors including histamine (H1), cholinergic and α-
adrenergic receptors, therefore they lack most of the TCA adverse effects (Celikyurt et al., 2012). 
• Tricyclic antidepressants (TCAs): 
The TCAs represents the first group of antidepressant medications which were “accidently” 
discovered and then successfully used in a clinical trial for depression in the late 1950s. This drug 
class is divided into two main groups including tertiary amines (amitriptyline and imipramine) and 
secondary amines (nortriptyline and desipramine) which result from metabolizing the tertiary 
amines.  The secondary amines have a better tolerability compared to the tertiary amines and hence 
showing a better compliance due to less incidence of unwanted side effects.  It has been suggested 
that the TCAs exert some of their therapeutic actions by inhibiting the presynaptic reuptake of 
monoamines, mostly NA and to a lesser extent 5-HT via a competitive blockade of the monoamine 
transporter binding sites (Figure 1.7) and hence enhancing the transmission of NA and 5-HT 
(Gillman, 2007). The direct antidepressant effect induced by this mechanism, has however been 
questioned recently and a number of other hypothesis apart from the monoamine hypothesis 
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(based on the enhancement of extracellular monoamine levels) have been postulated including the 
ceramide hypothesis which is in line with the current thesis (see section 1.3.3).  Furthermore, it was 
noted that desipramine shows a higher affinity for NET as compared to SERT, whereas clomipramine 
has more affinity to bind with SERT comparing with NET (Brunton et al., 2011).  Furthermore, these 
medications may produce a wide range of adverse reactions through their inhibitory effects on other 
brain receptors such as cholinergic receptors (dry mouth, retention of urine, constipation and 
blurred vision), α1 adrenoceptors (postural hypotension), 5-HT receptors and histamine receptors 
(drowsiness) with a scarce incidence of galactorrhoea, gynaecomastia and cardiac arrhythmias 
(Gillman, 2007).   
 
 
Figure 1.7: Mode of action of antidepressant drugs.  Selective serotonin reuptake inhibitors (SSRIs) 
selectively inhibit the reuptake of serotonin. Serotonin-noradrenaline reuptake inhibitors (SNRIs) 
block the reuptake of both 5-HT and noradrenaline (NA) by inhibiting their transporters. Tricyclic 
antidepressant drugs (TCA) inhibit the presynaptic reuptake of NA and 5-HT (Brunton et al., 2011). 
 
1.5.1.2. Monoamine oxidase inhibitors (MAOIs): 
Monoamine oxidase (MAO) represents the main enzyme that is responsible for the metabolism and 
subsequent inactivation of the monoamine neurotransmitters.  It is highly expressed within the 
brain and outside the central nervous system (gastrointestinal tract, liver and platelets) (Fiedorowicz 
and Swartz, 2004; Finberg and Rabey, 2016).  This enzyme exists in two subtypes including MAO-A 
and MAO-B. The MAO-A isoform specifically metabolizes serotonin and noradrenaline, whereas the 
MAO-B enzyme catabolizes dopamine, thus inhibition of MAO-A subtype is found to be mainly 
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correlated with the antidepressant activity of MAOIs (Figure 1.7) (Fiedorowicz and Swartz, 2004).  
Most first-generation MAOIs act by inducing irreversible inhibition of the monoamine metabolizing 
enzyme MAO (induce a strong and irreversible linking with MAO, thus irreversibly inhibiting the 
protein until new enzyme is synthesized to replace it, approximately within two weeks) thereby, 
preventing monoamine catabolism and hence enhancing their vesicular storage. The commonly 
prescribed first-generation MAOIs included tranylcypromine, phenelzine and isocarboxazid (Fowler 
et al., 2009). In addition, moclobemide represents a second-generation reversible MAO-A inhibitor 
that is currently used in the treatment of depression, while selegeline is a selective MAO-B inhibitor 
that was approved to be effective in treating parkinsonism (Fiedorowicz and Swartz, 2004; Finberg 
and Rabey, 2016).  Furthermore, the use of first-generation MAOIs  was shown to be associated with 
many undesirable side effects such as insomnia, postural hypotension, weight gain, sexual 
dysfunction and rarely hypertensive crises and hepatotoxicity (Fiedorowicz and Swartz, 2004).  
 
1.5.1.3. Monoamine receptor antagonists: 
• Mirtazapine: Mirtazapine enhances NA and 5-HT release by blockade of α2 adrenoceptors 
and 5-HT2C receptors. 
• Trazodone: This antagonist blocks 5-HT2A and 5-HT2C receptors as well as inhibiting 5-HT 
reuptake. 
• Mianserin: An α2 and 5-HT2 receptor antagonist which is due to a considerable bone marrow 
depressing effect has been ceased from clinical use (Harvey et al., 2008). 
 
1.6. Anatomical and neurophysiological aspects: 
Several neuropathological and neuroimaging studies have shown that dysfunction within neural 
networks in particular within some brain regions are implicated in the pathophysiology of 
depressive disorder including the prefrontal cortex, hippocampus and the striatum (Figure 1.8) 
(Drevets et al., 2008; McEwen and Morrison, 2013).  
 
1.6.1. The prefrontal cortex:  
The prefrontal cortex (PFC) represents a cortical brain area that lies in the anterior frontal lobe, 
possessing many subdivisions including orbitofrontal, dorsolateral and ventromedial cortices. 
Several neuroimaging studies indicated that the PFC receives input from several brain regions such 
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as widespread areas of the cerebral cortex (occipital, parietal and temporal cortices), also from the 
limbic system and the brain stem.  In addition,  it  projects to different brain regions including the 
hypothalamus, brainstem, amygdala and striatum (Siegel and Sapru, 2010). Regarding the 
monoamine neurotransmitters, the PFC is prominently innervated by serotonergic neurons, also it 
receives dopaminergic and noradrenergic innervations (Abernathy et al., 2010). It has a high 
expression level of 5-HT receptors particularly 5-HT1A, 5-HT2A and 5-HT3 receptor subtypes. In 
addition to the monoamine system, the PFC receives  glutamatergic as well as cholinergic inputs 
from various brain areas (i.e. thalamus, hippocampus and amygdala) (Mattinson et al., 2011; 
Mesulam et al., 1983; Pirot et al., 1994).  Thus, suggesting that this brain region is implicated in the 
pathogenesis of many psychiatric disorders including depression and schizophrenia possibly through 
a disruption in serotonergic neurotransmission (Abernathy et al., 2010; Puig and Gulledge, 2011). 
Functionally, this area is involved in regulating many behavioural and physiological functions 
through its dense neural network connections including: emotion, memory, learning, attention, 
decision making and motor response (Euston et al., 2012). 
 
1.6.2. The hippocampus:  
The hippocampus is an important region that constitutes one of the brain areas forming the limbic 
system, it lies under the cerebral cortex within the temporal lobes and adjacent to the amygdala. 
This limbic structure communicates through dense neural connections with widespread cortical and 
hypothalamic regions, therefore it is involved in modulating multiple vital functions including 
memory, learning, motivation, emotional response and cognitive abilities (Amaral and Witter, 
1989).  Indeed, it was indicated that the hippocampus is highly innervated by serotonergic neurons 
arising in the raphe nuclei (Moore and Halaris, 1975).  Also, it receives a dense noradrenergic 
innervation from the locus coeruleus, the location of the noradrenergic cell bodies. In total, it has 
been estimated that the noradrenergic innervation of the hippocampus is approximately twice the 
noradrenergic connections within the cerebral cortex (Ermine et al., 2016; Oleskevich et al., 1989). 
The hippocampus is composed of the dentate gyrus (DG) and its principal cell layer consists of 
granule cells (also known as stratum granulosum).  The hippocampus is further subdivided into 5 
regions; CA1-CA4 (also referred to as the cornu ammonis) and the subiculum.  Additionally, the 
principal cells within the hippocampal CA layers and the subiculum are all pyramidal cell types 
(Wible, 2013).  Interestingly, many studies in both animals and humans show that hippocampus is 
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implicated in depression and its treatment (Campbell and MacQueen, 2004; Lee et al., 2013; 
Sapolsky, 2001). Specifically, a number of imaging studies utilizing magnetic resonance imaging 
(MRI) and multiple post mortem tissue studies have reported a reduction in  hippocampal volume 
in depressed patients compared to healthy controls, a major finding that may be related to the 
reduction in neurogenesis (see section 1.3.2) within the hippocampal dentate gyrus, dendritic 
atrophy and glial cells loss (Campbell and MacQueen, 2004; Sapolsky, 2001; Sheline, 2011).   
 
1.6.3. The striatum:  
The striatum is considered to be less involved in the symptoms of depression compared to the 
prefrontal cortex and the hippocampus (Drevets et al., 2008).  This region constitutes one of the 
four main structures forming the basal ganglia which also contains the substantia nigra, the globus 
pallidus and the subthalamic nucleus. The striatum is composed of three major nuclei including the 
caudate nucleus, putamen (both are known as the neostriatum) and the ventral striatum which 
contains the nucleus accumbens (Andersson et al., 2002). This important subcortical structure 
participates in motor planning and control as it represents the main input area of the basal ganglia 
which commonly mediates this action, also it exerts a significant role in reward, motivation, 
attention, learning, cognitive functions and social behaviours (Lakraj et al., 2014). Moreover, many 
psychological/neurological conditions including Parkinson’s disease, schizophrenia and attention 
deficit hyperactivity disorder (ADHD) are successfully treated by drugs affecting DA 
neurotransmission in the striatum. These drugs include psychostimulant drugs such as 
methylphenidate that block the striatal dopamine transporter (DAT) for ADHD, DA antagonists for 
schizophrenia and DA enhancing drugs like L-DOPA, MAO and COMT inhibitors for Parkinson’s 


















Figure 1.8: Brain regions implicated in depression (A) A representation of rat brain (Dauth et al., 
2017). (B) Human brain (Clapp et al., 2008).   
 
1.7. Sphingolipids and depression: 
Growing evidence from extensive previous preclinical (Dinoff et al., 2017; Gulbins et al., 2013; 
Müller et al., 2015; Powell et al., 2012; Schneider et al., 2017) and clinical studies (Demirkan et al., 
2013; Dinoff et al., 2017; Kornhuber et al., 2005; Rhein et al., 2017) implies that sphingolipids 
particularly ceramide could have a role in the pathogenesis of depression and other serious 
psychiatric disorders such as anxiety and schizophrenia (Schneider et al., 2017). One of the reported 
findings in depression is a reduction in the volume of the hippocampus (hippocampal atrophy) which 
possibly could be related to a reduced hippocampal neurogenesis (new formation of neurons) in 
particular in the dentate gyrus of the hippocampus (see section 1.3.2) (Jacobs et al., 2000; Videbech 
and Ravnkilde, 2004).  This process depends entirely on the initial ability of proliferation and 
differentiation involving both progenitor cells and neuronal stem cells to produce the mature 
neurons in this particular brain region (Dinoff et al., 2017; Ming and Song, 2011).  In this respect, a 
recent study which utilized a tissue culture of a neuronal pheochromocytoma cell line showed that 
the application of a specific sphingolipid, namely ceramide resulted in the inhibition of the 
proliferating activity of these cells (Gulbins et al., 2016).  Further, emerging evidence suggests that 
sphingolipids particularly ceramide is involved in the process of apoptosis of neuronal stem cells in 
the hippocampus (Dinoff et al., 2017; Wang et al., 2012). Thus, playing an important role in the 
inhibition of hippocampal neurogenesis which as mentioned already is believed to be implicated in 
the pathogenesis of depression and possibly the relevant reduction in hippocampal volume (Dinoff 
et al., 2017; Jacobs et al., 2000; Videbech and Ravnkilde, 2004).  Furthermore, another critical 






particularly 5-HT neurotransmission (Belmaker and Agam, 2008; Hirschfeld, 2000).  Indeed, several 
antidepressant medications exert their therapeutic mode of action by regulating the extracellular 
levels of monoamines (Hirschfeld, 2000). Sphingolipids, in particular ceramide may promote 
alteration in cell signaling and monoamine neurotransmission functions via the formation of a 
ceramide enriched macrodomains that allow clustering of specific proteins including G-protein 
coupled monoamine receptors (GPCRs) within the cell membrane (see section 1.9.1) (Dinoff et al., 
2017; Müller et al., 2015; Schneider et al., 2017).  In addition, ceramide has been suggested to 
contribute in the process of exocytosis and the subsequent neurotransmitter release to the synaptic 
cleft by aggregating various proteins (i.e. syntaxin 1A and syntaxin 3) that are involved in this process 
(see section 1.9.1) (Chamberlain et al., 2001; Tsui-Pierchala et al., 2002).  Moreover, ceramide may 
affect serotonin binding to the 5-HT receptors including 5-HT1A receptor subtype, hence 
modulating serotonergic neurotransmission (Jafurulla et al., 2008). Further, increasing experimental 
evidence now points to the possible direct involvement of ceramide in depression.  This encompass 
an earlier recorded observation that mice injected with ceramide into the hippocampus showed a 
marked increase in depression-like behaviours (Gulbins et al., 2013). These depression-related 
behaviours included: a reduced sucrose consumption in the sucrose preference test, a markedly 
delayed eating in the novelty suppressed feeding test as well as the apparent neglect of the animal 
coats in the coat test (Gulbins et al., 2013). Interestingly, another important finding concerning the 
ceramide role in depression is the fact that many currently used antidepressant drugs inhibit the 
acid sphingomyelinase enzyme (ASM) when administered chronically (Gulbins et al., 2013). This 
enzyme catalyzes the degradation of sphingomyelin into ceramide and phosphoryl-choline, a 
process that is predominantly activated in the membrane lipid rafts (Müller et al., 2015; Reichel et 
al., 2014; Schneider et al., 2017).  Additionally, an important observation is that many SSRIs 
(paroxetine, fluoxetine and sertraline) and TCAs (e.g. desipramine and nortriptyline) act by inhibiting 
ASM activity, subsequently reducing brain ceramide level (a possible mechanism of antidepressant 
action) (see Chapter Five, section 5.1.1.2) (Kornhuber et al., 2008, 2010). This effect is closely 
associated with the cationic amphiphilic property of these drugs (i.e. the antidepressant drugs such 
as desipramine and paroxetine) (Funk and Krise, 2012). These small molecules are typically 
containing both hydrophobic and hydrophilic domains (amphiphilic compounds).  Therefore, they 
have the ability to accumulate inside the acidic lysosomes, thus resulting in a detachment and a 
subsequent inactivation of the lysosomal enzymes (i.e. ASM). Hence, enhancing high intra-lysosomal 
accumulation of various lipid species such as sphingomyelin (Kornhuber et al., 2010; Lübke et al., 
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2009).  Furthermore, a recent study demonstrated that a reduction in hippocampal ceramide level 
was associated with an inhibition of acid sphingomyelinase activity, concomitantly the mice showed 
an improvement in their depression-like behaviours following treatment with fluoxetine and 
amitriptyline in animal models of depression (Gulbins et al., 2013).  An important correlation was 
identified between the reduction in ceramide level which develops after 2-3 weeks of treatment 
(until the antidepressant drugs accumulate sufficiently within the neuronal lysosomes to inhibit the 
ASM enzyme) and the period that is consistent with the required time for the onset of the 
antidepressant action (Kornhuber et al., 2009). Accordingly, the sum of accumulating evidence 
suggests the concept that sphingolipids, in particular ceramide exerts an important role in the 
pathogenesis of depression as well as the mechanism of its medical intervention. 
 
1.8. The functional role of sphingolipids in biological membranes: 
Lipid bilayers are basic structural components of all the cell membranes which form a critical 
physical barrier which are mainly composed of four particular phospholipid containing molecules 
including: sphingomyelin, phosphatidylcholine, phosphatidylserine and phosphatidylethanolamine. 
Phospholipids are divided into two major classes: glycerophospholipids and sphingophospholipids 
also termed sphingolipids (Alberts et al., 2002).  In an aqueous environment, the lipid bilayers within 
the cell membrane (3-5 nm in thickness) are spontaneously formed (without energy requirement) 
with a special organisation of the lipid molecules; the polar hydrophilic heads (readily dissolved in 
water) facing the exterior aqueous sites while the non-polar hydrophobic tails (water insoluble) are 
buried in the interior core of the lipid bilayers (Figure 1.9) (Cooper, 2000).  Within biological 
membranes, the packed phospholipids are amphiphilic (also known as amphipathic) molecules that 
have a polar or hydrophilic head containing a phosphate group and two non-polar or hydrophobic 
tails which are usually composed of long fatty acid chains that contain a variable number of carbon 
atoms (14-24) (Alberts et al., 2002).  In addition to the other structural constituents of the cell 
membrane (cholesterol and carbohydrates), the second main component of the cell membrane 
together with the phospholipids are proteins.  These membrane proteins are divided into two main 
types: transmembrane proteins (also known as integral membrane proteins) and the peripheral 
membrane proteins (interact indirectly with the transmembrane proteins). The integral proteins are 
immersed within the lipid bilayers and they are responsible for a variety of specialized functions 
(Cooper, 2000).  Some proteins facilitate membrane permeability and aid the selective transport of 
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specific particles across the cell membrane such as the ion channels particularly the calcium release-
activated channels and the potassium channel Kv 1.3 subtype (Gulbins et al., 1997; Lepple-Wienhues 
et al., 1999).  Others mediate cell signaling actions and subsequent neurotransmission through their 
functions as neurotransmitter receptors (e.g. G-protein coupled receptors).  Additionally, some 
proteins participate in vital cellular processes serving as enzymes including the intracellular protein 
phosphatases and protein kinase C enzymes that are for example, involved in stress-induced 
apoptosis or programmed cell death (Cooper, 2000; Dinoff et al., 2017). The integral membrane 
proteins are also amphiphilic in nature and will interact strongly through their hydrophobic ends 
with the lipid bilayers.  Not surprisingly, any change in the lipid composition may directly affect 
properties of the associated proteins, hence their functions will be modulated such as the alteration 
in receptor affinity, receptor-mediated signaling actions and the selective transporting activity 
achieved via the membrane ion channels (Alberts et al., 2002; Cooper, 2000). 
 








                                                                                                                                                                                                                                                       
 
Figure 1.9: Three-dimensional structural models of cell membrane, representing A, B a 
phospholipid bilayer (Boundless, 2016), and C a phospholipid molecule with a hydrophilic head and 
two hydrophobic tails (Alberts et al., 2002). 
 
It is well established that sphingolipids are one of the main phospholipid classes within brain 
membranes and exists in different types including ceramide and sphingosine both of which playing  
significant roles in modulating neurotransmission and receptor-mediated signal transduction 
(Dinoff et al., 2017). Within lipid rafts, sphingomyelin (a principal lipid component of the cell 
membrane) can be catalysed to ceramide and phosphoryl choline by action of the main 
sphingomyelin catabolizing enzyme, acid sphingomyelinase (ASM) (also known as sphingomyelin 










2014; Müller et al., 2015; Reichel et al., 2014; Schneider et al., 2017).  Interestingly, the released 
ceramide molecules have a dramatic ability of spontaneous self-association that result in the 
formation of small ceramide enriched microdomains (nanoscale) that can further merge producing 
larger ceramide enriched macrodomains or platforms termed lipid rafts (Figure 1.10) (Dobrowsky, 
2000; Hering et al., 2003). These ceramide macrodomains represent tightly packed hydrophobic 
structures aggregated within the cell membrane that participate in a subsequent re-modelling of 
the membrane platforms or lipid rafts (Cremesti et al., 2002; Müller et al., 2015; Schneider et al., 
2017).  Emerging evidence suggests that these lipid rafts (containing the ceramide enriched 
macrodomains) consequently permit clustering and re-organization of signaling molecules and 
neurotransmitter receptors including G-protein coupled receptors (GPCRs) (Müller et al., 2015; 
Schneider et al., 2017).  Thus, altering the lipid composition within these membrane macrodomains 
may directly contribute to a subsequent change in receptor localization and affinity, their signaling 
action and the synaptic transmission (Fantini and Barrantes, 2009).   
 
 
Figure 1.10: The mechanism of ceramide action in biological membranes (Kornhuber et al., 
2014). 
 
1.9. The role of lipid raft-sphingolipids in neuronal functions: 
1.9.1. Synaptic neurotransmission: 
Recent studies indicate that lipid rafts form critical signaling macrodomains within the cell 
membrane (Dinoff et al., 2017; Müller et al., 2015; Schneider et al., 2017; Tsui-Pierchala et al., 2002). 
Consequently, these important membrane structures may directly affect cell signaling, synaptic 
neurotransmission and receptor mediated signal transduction (Fantini and Barrantes, 2009; Hering 
et al., 2003) (see also section 1.8). Importantly, in addition to clustering of neurotransmitter 
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receptors resulting in a very high receptor density within the ceramide enriched macrodomains of 
the cell membranes.  These membrane lipid rafts may contribute to synaptic transmission through 
regulating trafficking and the calcium-dependent fusion of the synaptic vesicles (exocytosis 
process), and the subsequent neurotransmitter release into the synaptic cleft (Tsui-Pierchala et al., 
2002).  Recently, it was found that many regulatory biomolecules and proteins implicated in 
membrane fusion of the synaptic vesicles are densely located within lipid rafts such as syntaxin 1A 
and syntaxin 3.  These presynaptic plasma membrane proteins have been shown to be involved in 
the process of neuronal exocytosis possibly by forming a stable complex that provides the energy 
required for the vesicle fusion with the plasma membrane of neuronal cells.  Also, they could be 
implicated in the regulation of calcium influx by binding with both neuronal N- and L-types calcium 
channels (Kang et al., 2002; Wiser et al., 1996).  Accordingly, lipid rafts could promote monoamine 
neurotransmitter release and consequently, the synaptic neurotransmission function (Chamberlain 
et al., 2001). It is well established that an important pathophysiological observation in depression is 
the reduction in serotonergic neurotransmission (Belmaker and Agam, 2008; Hirschfeld, 2000). 
Further evidence observed that sphingolipids including ceramide may alter monoamine reuptake 
and signaling, in particular serotonergic transmission either through direct binding to the 
transporter molecules, hence modulating their transport and functions (i.e. increasing the reuptake 
of 5-HT) (Gangoiti et al., 2010; Riddle et al., 2003) or by indirect effect via binding and activation of 
several intracellular proteins and enzymes including phosphatases and kinases (Dinoff et al., 2017; 
Westwick et al., 1995).  In this respect, It was also noted that ceramide may alter serotonin signaling 
via modulating 5-HT binding to the serotonergic receptors specifically the 5-HT1A subtype (Jafurulla 
et al., 2008).  A previous cell study conducted on a tissue culture of Chinese hamster ovarian cells 
following sphingomyelinase treatment (using different enzyme concentrations: 25 or 50 IU/L for 90 
minutes) reported that sphingolipids, particularly ceramide may affect serotonergic 
neurotransmission by enhancing the ligand binding activity of 5-HT1A receptors (see section 
1.4.1.1). Thus, opens up the possibility that ceramide could modulate brain extracellular 5-HT levels 
via an inhibition of serotonergic neuronal firing (Jafurulla et al., 2008; Singh et al., 2012). 
Consequently, growing evidence suggests that a dysregulation in the metabolism of brain 
membrane sphingolipids particularly ceramide may contribute to alteration in multiple neuronal 
functions including cell signaling and monoamine neurotransmission. Hence, sphingolipids could be 




1.9.2. Apoptosis (programmed cell death): 
Apoptosis represents a planned process of intrinsic cellular death (Reed, 2000).  It is a vital 
physiological phenomenon possessing a number of morphological and biochemical variations 
initiated during both early prenatal development and late adult life. However, many 
histopathological studies indicates that a defect in this regulated intracellular mechanism with a 
misbalance between cellular death and growth may contribute to the underlying pathogenesis 
responsible for various CNS disorders such as depression and Parkinson’s disease which are 
expressing apoptotic changes (Eilat et al., 1999; Liu et al., 2017; Wong, 2011), whereas other 
pathologies may involve a reduced level of apoptosis as in many malignant cancer conditions (Wong, 
2011).  This critical physiological process is characterized by a series of ordered morphological 
changes including cellular shrinkage, increased cytoplasmic density, DNA condensation, destruction 
of the nucleus and finally the formation of apoptotic bodies which undergo phagocytosis by the 
macrophages (Elmore, 2007; Imajoh et al., 2004). Concomitantly, the main biochemical apoptotic 
changes include DNA degradation and the activation of particular protease enzymes known as 
caspases that cleave various cellular proteins to initiate the process of apoptosis (Boatright and 
Salvesen, 2003; Iglesias-Guimarais et al., 2012; Reed, 2000).  
 
1.9.2.1. Implication of ceramide and sphingosine in apoptosis: 
The known membrane sphingolipids, ceramide and sphingosine were recently identified as 
important mediators of apoptosis (Pettus et al., 2002; Ruvolo, 2003). However, the exact molecular 
mechanism underlying their contribution to apoptosis is still not fully understood. Recent evidence 
however, implies that hydrolysis of the sphingolipid molecule, sphingomyelin into the metabolic 
products: ceramide and sphingosine is increased under stressful conditions (Woodcock, 2006).  
Consequently, the accumulation of ceramide within the cell membrane results in the formation of 
lipid rafts containing the ceramide-enriched macrodomains which permit clustering of various 
proteins, enzymes and receptors (see section 1.8), therefore potentiating the apoptotic mechanisms 
(Dobrowsky, 2000). In addition, emerging evidence proposes that during programmed cell death 
ceramide content within the mitochondrial cell membrane is significantly elevated, together with 
increased permeability of the outer mitochondrial membrane which is due to increased formation 
of membrane pores, a process triggered by ceramide action.  Consequently, these permeable pores 
may function as ceramide channels that regulate the permeability of the outer mitochondrial 
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membrane (Siskind, 2005). Thus, allowing the mitochondrial release of pro-apoptotic proteins 
including procaspases, cytochrome C and other proteins which are important for activating the 
enzymes (DNase and caspases) that are crucial to initiate the apoptotic mechanism (Siskind, 2005; 
Woodcock, 2006).  Moreover, it has been found that ceramide directly binds to a particular 
proenzyme known as cathepsin D, hence allowing the release of the active form of the enzyme and 
subsequently activating a pro-apoptotic protein termed as BID.  This protein exerts a critical role in 
the induction of programmed cell death via promoting the mitochondrial release of cytochrome C 
into the cytosol (Heinrich et al., 2004; Woodcock, 2006). Interestingly, it has further been reported 
that ceramide may activate various enzymes involved in  apoptosis including protein phosphatases 
(protein phosphatase 1, PP1 and protein phosphatase 2A, PP2A) and protein kinases (stress-
activated protein kinases, SAPKs) (Ruvolo, 2003).  In this respect, it was shown that sphingosine may 
act as a second messenger that mediates programmed cell death by potently inhibiting the protein 
kinase C enzyme and thereby triggering the apoptotic mechanism (Taha et al., 2006).  Sphingosine 
was also found to promote the activation of BID protein and thereby inducing the mitochondrial 
release of cytochrome C, hence triggering the mechanism of cellular suicide (Cuvillier et al., 2001; 
Taha et al., 2006). 
 
1.9.3. Selective transport across the cell membrane:  
Recent studies provided evidence that ceramide within membrane lipid rafts may affect selective 
transport processes and permeability across cell membranes.  This is achieved by interacting with 
certain ion channels that are specifically located in lipid rafts, in particular the potassium channel Kv 
1.3 and Kv 2.1 subtypes (Gulbins et al., 1997; Tsui-Pierchala et al., 2002) as well as the presynaptic 
P/Q-type (Cav 2.1) calcium channels (Lepple-Wienhues et al., 1999; Taverna et al., 2004). Based on 
these findings, it has been hypothesized that membrane lipid rafts may be required for clustering 
and localization of these important ion channels, therefore influencing the membrane permeability 
function (Tsui-Pierchala et al., 2002). 
 
1.10. Aim and objectives of this study:    
The overall aim of the present study was to enhance our understanding of the molecular and 
biochemical actions of two currently prescribed antidepressant drugs namely, paroxetine and 
desipramine with an emphasis of their effects on the brain sphingolipid pathway.  To achieve this 
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principal aim, the following objectives were pursued by means of a variety of methodologies, using 
a rat model:  
• To assess the regional brain metabolic profile following acute and chronic administration of 
two different types of antidepressant medications using 1HNMR spectroscopy (Chapter 
Three). 
• To investigate both the drug and region-specific effects of antidepressant treatment on 
bioactive sphingolipid levels using the methods of: LC-MS and HPLC-UV detection (Chapter 
Four).  
• To investigate the effect of chronic antidepressant drug treatment on the gene expression 
level of the key enzymes in the brain sphingolipids pathway using RT-qPCR (Chapter Five).  
• To examine the effect of the acid ceramidase inhibitor, carmofur on brain level of 
sphingolipids and monoamines in brain regions implicated in depression by means of LC-















































2.1. Animals and drug treatment: 
2.1.1. Habitation and environmental conditions: 
Adult male Sprague-Dawley rats weighing (290-300 g) were used for the acute (single injections) 
experimental part of the current project (Table 2.1).  For the chronic experiments, (daily injections 
for 15 days at 10 am) the body weights ranged from 180-200 g at the start of the treatment (Table 
2.2).  All rats were purchased from (Charles River, UK) and were housed four or six animals per cage 
under automatically controlled environmental temperature (20-22°C), lighting condition (light 
07:00-19:00) and humidity (45-50%).  All the animals had free access to food and drinking water and 
were maintained in this environment with regular handling for one week before the start of the 
experiment.  All procedures involving animals described in this study were carried out in strict 
accordance with UK Home Office regulations and Animals Scientific Procedures Act (1986) under 
requisite project and personal licence authority and were approved by DMU Ethical Review 
Committee.  In total, 126 male Sprague-Dawley rats were used to perform the experimental work 
of the present study, 60 rats were used for the acute administration groups, whereas the remaining 
66 animals were used for chronic treatment, which included both control and drug treated groups. 
 
 
Figure 2.1: A growth diagram showing the increase in body weight in grams of the total chronically 
treated animals in this project including both control and drug-treated rats across the 
experimental days (1-15 days). A total of 66 rats were used for the chronic treatments, which 
included both control (saline-treated) and drug-treated (paroxetine and desipramine) groups. 
Generally, at the end of the treatment period, body weights of control animals (average body weight 
= 270 g, n = 30) were slightly higher compared to the drug-treated rats (average body weight for 
paroxetine = 262 g and for desipramine = 256 g, for both groups n = 18), however, the difference 























2.1.2. Drug treatment:  
Animals were randomly separated into two groups (control and drug treated) and each group 
depending on the experimental protocol and the analytical/molecular technique used comprised of 
either six or twelve animals.  Chronically treated animals were weighed every day, the body weights 
were recorded, and the injection volume adjusted accordingly.  The body weights of the rats injected 
chronically with antidepressant drugs were not statistically different from their corresponding 
controls during the period of injections (Figure 2.1).  Rats in control groups received either a single 
intraperitoneal (i.p) injection of saline (0.9% of sodium chloride, 1 ml/kg) (acute group) or were 
injected once daily with saline at 10 am for 15 days (chronic group). The corresponding drug 
treatment groups received injections of either: paroxetine (5 mg/kg, i.p), a selective serotonin 
reuptake inhibitor (SSRI) or desipramine (10 mg/kg, i.p), a tricyclic antidepressant (TCA).  
Immediately prior to injections, both paroxetine and desipramine were dissolved (solutions made 
up daily) in saline at 5 mg/ml and 10 mg/ml respectively.  In man, plasma concentration of 
desipramine associated with clinical efficacy is usually between 50-300 ng/ml (Gillman, 2007), 
whereas the reported therapeutic plasma level for paroxetine is 30-120 ng/ml (Hiemke et al., 2011).  
In the present study, chosen doses of the utilised antidepressant drugs were selected, in accordance 
with previously published data (Detke et al., 1997; Hajós-Korcsok et al., 2000; Mathes and Spector, 
2011) where detectable biochemical and behavioural changes were indicated following similar drug 
regimes in animal models of depression. Furthermore, a preclinical study conducted in rats reported 
that paroxetine administration in a dose of 5 mg/kg, i.p (identical to the dose used in this study)  
resulted in plasma concentration of 55-100 ng/ml which is well within the range of the therapeutic 
plasma concentration of 30-120 ng/ml measured in patients treated with paroxetine (Benmansour 
et al., 1999). Additionally, desipramine administration in a dose of 15 mg/kg/day i.p (the present 
study used 10 mg/kg, i.p) was found to attain a plasma level at a range of 265-430 ng/ml following 
7-10 days of treatment in rats (Benmansour et al., 1999; Kaye et al., 1989).  Thus, based on previous 
studies, the doses of paroxetine and desipramine used in the present study, are likely to reach 
plasma concentrations similar to levels associated with therapeutic response in humans  
(Benmansour et al., 1999; Brimberg et al., 2007; Gundersen et al., 2013; Kozisek et al., 2007; Mathes 
and Spector, 2011).  At the end of the designated period rats were sacrificed according to Schedule 
one procedure (Home Office, Animal act, 1986), trunk blood was collected, and the brain was 
removed.  For biochemical analysis of brain tissue and in some cases plasma (see Chapters Three, 
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Four and Six) rats were killed one hour after the last injection.  For the gene expression study 
(Chapter Five) animals were sacrificed at 24 hour after the final injection, based on previous gene 
expression studies (Andriamampandry et al., 2002; Lee et al., 2010; Nakatani et al., 2004; Yamada 
et al., 2003).  Generally, on the day of the experiment, the overall body weights for the treated 
animals were not statistically different compared to the corresponding controls after acute 
treatment (p value = 0.277) (Table 2.1 and Figure 2.2) and this was also the case following chronic 
administration (p value = 0.370) (Student’s t-test) (Tables 2.2 and Figure 2.2).    
 
Table 2.1: The mean +/- SEM for body weights and corresponding brain sections weight in grams 
following acute administration for the control and treatment groups (n = 6 or 12 per group).  
Abbreviations: PFC, prefrontal cortex; HP, hippocampus and ST, striatum. 
 
 
                                                                    
 
                                           
 
 
Table 2.2: The mean +/- SEM for body weights and corresponding brain sections weight in grams 
















Control 304 ± 4 0.180 ± 0.009 0.222 ± 0.012 0.397 ± 0.026 











Control 270 ± 7 0.193 ± 0.011 0.218 ± 0.006 0.411 ± 0.026 





Figure 2.2: Animals body weight in grams for the whole control and treatment groups across the 
experiments. Data presented as mean ± SEM (p > 0.05) (Student’s t-test). 
 
2.1.3. Brain tissues dissection: 
On the day of the experiment, the animals were weighed, treated and killed according to a precise 
timetable, making sure that all animals were terminated at one hour after the injection or in the 
case of the gene expression study (Chapter Five) at 24 hours.  The whole brain was then removed, 
and brain regions were dissected out rapidly on ice into three targeted brain regions (Figure 2.3).  
The dissection was performed in correspondence with the Rat Brain Atlas (Paxinos and Watson, 
2006).  The brain was cut into four separate planes (see Figure 2.3), firstly the olfactory bulb was 
removed and then the prefrontal cortex was cut out with a scalpel. The striatal region was obtained 
by cutting a section posteriorly at the hypothalamus (Quansah, 2017), eventually, the hippocampus 
was acquired via sectioning anterior to the brain stem structures and both halves of the 
hippocampus were carefully released from the adherent cortical tissues. The brain samples were 
then snap frozen in isopentane on dry ice, weighed and stored at - 80°C until subsequent 




















Figure 2.3: (A) The dissection planes. (B) A representation of the three examined regions in the rat 
brain. (A) Prefrontal cortex; (B) striatum and (C) hippocampus, based on Paxinos and Watson rat 
brain atlas (Paxinos and Watson, 2006).  Abbreviations: PFC, Prefrontal cortex; PCx, parietal cortex; 
ST, striatum; NAc, nucleus accumbens; HP, hippocampus. 






















Figure 2.4: Brain sections weight in grams following acute administration for the control 
and treatment groups in all the achieved experiments.  Data presented as mean ± SEM (p > 0.05) 
(Student’s t-test). Abbreviations: PFC, the prefrontal cortex; HP, the hippocampus; ST, striatum. 
 
 
Figure 2.5: Brain sections weight in grams following chronic administration for all the control 
and treatment groups in all the accomplished experiments.  Data presented as mean ± SEM (p > 
0.05) (Student’s t-test). 
 
In addition, the overall brain sections weight within both control or treatment groups and following 
either acute or chronic administration were not statistically different (p > 0.05) (Student’s t-test) 






2.1.4. Drugs and chemicals: 
The drugs and chemicals used in the whole experimental work of the present study with their 
suppliers are summarized in the list below: 
• Acetonitrile was of LC-MS grade (Fisher Scientific, UK).  
• Carmofur was a gift from LKT Laboratories (Germany). 
• Ceramide and sphingosine standards were of LC-MS grade (Sigma-Aldrich, UK). 
• Chloroform was of LC-MS grade (Rathburn Chemicals Ltd, UK).  
• Desipramine hydrochloride was purchased from Sigma-Aldrich, USA.  
• Deuterium oxide (99.8%; Acros Organics) and deuterium oxide containing 3-(trimethylsilyl) 
propionic – 2, 2, 3, 3 – d4 acid (TSP) sodium salt (Acros Organics BVBA). 
• DNA ladder (Bioline, UK), 2% agarose was obtained from (ThermoFisher Scientific, UK).  
• Ethanol was of LC-MS grade (Fisher Scientific, UK).   
• iScript cDNA Synthesis Kit was purchased from Bio-rad, UK.  
• Methanol was of HPLC (Stratlab, UK) and LC-MS grades (Rathburn Chemicals Ltd, UK). 
• Monoamine neurotransmitters and their metabolite standards were obtained from Sigma-
Aldrich, UK.  
• My Taq red master mix (Bioline, UK). 
• Paroxetine hydrochloride hemihydrate was a gift from Glaxo Smith Kline (i.e. GSK). 
• Perchloric acid (Rathburn Chemicals Ltd, UK).   
•  RNeasy Mini Kit was purchased from Qiagen, UK.  
• SensiFAST SYBR HI-ROX was obtained from Bioline, UK. 
• Turbo DNAse-AM free kit (Ambion Inc, USA) and 96-well reaction plates were supplied by 
Thermo Fisher Scientific, UK.  




2.1.5. Data presentation and statistical analysis: 
The effect of acute and chronic antidepressant drugs as well as after acute carmofur administration 
were statistically analysed using Prism 5.0 Software (Graph Pad Prism).  Statistical analysis of the 
recorded two datasets (saline versus drug-treated) groups were performed by Student´s t-test (see 
Chapter Six and Chapter Four section 4.3.2).  On the other hand, multiple datasets were tested using 
either two-way analysis of variance (two-way ANOVA with Bonferroni post-hoc test) (see Chapter 
four section 4.3.1 and Chapter Six) or one-way analysis of variance (one-way ANOVA with Bonferroni 
t-test) (see Chapter Five) for multiple comparison.  All data were presented either as means or 
fraction of controls ± standard errors of the mean (SEM) for each group. Statistically significant 
difference was considered at a level of p < 0.05.  For analysis of NMR data see section 2.2.6.    
 
2.2. Proton nuclear magnetic resonance spectroscopy (¹H NMR 
spectroscopy):    
¹H NMR spectroscopy is a powerful analytical technique that has been widely employed in  number 
of applications including: chemical, clinical, biomedical and biological research, pharmaceutical 
production as well as in the food, medicine and chemical industry (Günther, 2013; Powers, 2009). 
This spectroscopic tool (Figure 2.6) has been extensively used to investigate the structural 
configuration and physical properties of certain molecules within a tissue sample.  In addition, it 
allows the determination of metabolic changes and also the identification of a wide range of 
metabolites in biological fluids in response to external conditions such as diet or various drug 
applications (Cloarec et al., 2005).  
 
2.2.1. Basic principles of NMR spectroscopy: 
The atomic nuclei are electrically charged units (carry a positive charge) and usually they possess a 
specific intrinsic property of spinning randomly around their axis in different directions (termed as 
nuclear spin, I). The tendency of a nucleus to spin (I) is totally dependent upon its internal structure, 
i.e. the number of protons and neutrons contained within the nucleus, if the total number is even, 
then the nucleus has no spin (zero spin) such as ¹6O or 12C, whereas other atoms are composed of 
odd number of protons and neutrons (odd mass number), hence they have a non-zero spin or (I) = 
½ or one of its multiples (3/2 or 5/2,…) and these elements include for example, hydrogen 1 (1H), 
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19F and 13C which are all particularly useful for the analysis by  NMR spectroscopy.  In particular, the 
proton or 1H is the most commonly used element in NMR studies with a high magnetic activity 
(García‐Álvarez et al., 2016; Günther, 2013).  Furthermore, irradiating the sample with a pulse of 
radiofrequency waves promotes transition of the hydrogen nuclei within the analysed sample from 
a lower energy level to a higher energy level which is accompanied by the subsequent absorption 
of energy (known as excitation of the nuclei).  Then, the excited nuclei may flip back to the initial 
lower energy state (termed as relaxation) and hence, emitting the absorbed energy as resonant 
signals that can be detected by the receiver of the utilized instrument, thus generating the NMR 






















2.2.2. Chemical shift: 
Throughout the NMR spectra, a series of resonant signals spread over a horizontal axis from zero 
parts per million (ppm) unit to ten ppm scale range (Figure 2.7).  Additionally, within each analysed 
sample a reference compound (trimethylsilylpropanoic acid, TSP) is used as a standard that gives a 
resonant signal (a reference signal) at the zero point of the chemical shift (Günther, 2013).  
Importantly, preparing a sample for the NMR analysis necessitates the use of specific solvents that 
do not contain 1H hydrogen atoms such as deuterium oxide (D₂O) to avoid introducing an interfering 
signal within the spectrum.  
 
 
                                                                                                                    Chemical shift (ppm)           Control (red + green), desipramine (red only) 
Figure 2.7: ¹H NMR spectra of hippocampal extracts obtained from control (red + green) and 
treated rats (red only) showing different metabolites identified following acute desipramine 
treatment. Abbreviations: Glu, glutamate; NAAG, N-acetylaspartylglutamate; Gln, glutamine; NAA, 
N-acetyl aspartate; Chol, choline; Pho ethanol, phosphoryl ethanolamine; Pho creatine, 
phosphocreatine; P cho, phosphoryl choline; ATP, adenosine triphosphate; Tau, taurine; Aspart, 







2.2.3. Sample preparation for NMR spectroscopic analysis: 
2.2.3.1. Preparation of brain samples: 
The preparation of brain samples for NMR spectroscopic analysis was based on previously published 
protocols (Adinehzadeh et al., 1999; Lan et al., 2009; Shi et al., 2007).  The frozen brain samples 
were thawed and homogenized in 1.5 ml cold acetonitrile and water (1:1 volume ratio) of HPLC-
grade from Fisher Scientific, UK using the Polytron PT3000 at 2600 rpm for 15 seconds.  The 
homogenates were then centrifuged in 2ml plastic centrifuge tubes at 1000 g for 5 minutes at 4oC 
(Sorvall Legend Micro 17R, Thermo Scientific, UK). This was followed by separation and evaporation 
of the supernatant to dryness under vacuum for two hours.  The sediments of the brain 
homogenates were then preserved and stored at - 80oC for further lipophilic extraction and analysis 
(see Chapter Four and Chapter Two, section 2.3). The dried supernatant residue was reconstituted 
with 550 µl of D2O containing 0.9 mM trimethylsilylpropanoic acid (TSP) (Sigma Aldrich, UK) and 50 
µl of 1M phosphate buffer (138 g NaH2PO4-H2O in 1 litre dH2O) at pH 7.0 and vortex- mixed for 10 
seconds.  The samples were then centrifuged at 1000 g for 10 minutes at 4oC.  Finally, the 
supernatants were placed into the NMR tubes (5 mm in diameter) (Norell, UK) for subsequent NMR 
analysis.  
 
2.2.3.2. Preparation of plasma samples: 
The preparation of plasma samples for NMR spectroscopic analysis was based on previously 
published protocols (Deprez et al., 2002; Shi et al., 2007; Zira et al., 2013).  Blood samples collected 
in heparin tubes (BD, USA) were centrifuged for 10 minutes at 1300 g for complete separation of 
the plasma from the whole blood.  Then 500 µl of separated serum was removed and transferred 
to the centrifuge tubes with the addition of 55 µl of D₂O (Fisher Scientific, UK). The samples were 
centrifuged again at 1000 g for 10 minutes at 4°C. Lastly, the supernatants were transferred to 5.0 







2.2.4. NMR spectroscopy and experimental conditions: 
1H NMR analysis was conducted with a Bruker Avance AM-400 spectrometer operating at a 
frequency of 399.94 MHz and a probe temperature of 298 K (25°C).  Scanning of the analysed 
samples was performed with the application of 128 scans, a relaxation delay of 3 seconds and a 
spectra width of 4800 Hz.   
 
2.2.5. Data collection and pre-processing: 
 
NMR spectra of all groups were interpreted and processed manually via ACD/NMR Processor 
Academic Edition (Ontario, Canada) software prior to statistical analysis using Metabo Analyst 3.0 
software (Xia et al., 2015; Xia and Wishart, 2002, 2016).  In addition, all areas including noise peaks, 
also the spectral regions representing the water signal at 4.60-5.10 ppm of the chemical shift were 
deleted from all the spectra before eventually starting data analysis.   
 
2.2.6. Statistical analysis of NMR data: 
Using the Metabo Analyst software (Xia et al., 2015), the normalised integral data were investigated 
by means of both Univariate and Multivariate analytical methods, and on the bases of the literature 
values (Gao et al., 2013; Govindaraju et al., 2000; Liu et al., 2014).  Multivariate statistical analysis 
was performed by both Principal Component Analysis (PCA) and the Partial Least Squares 
Discriminant Analysis (PLS-DA) to maximize the experimental groups’ separation and samples 
clustering and to identify those metabolites significantly affected by drug treatment using the 
variable importance in projection (VIP) scores.  Univariate statistical analysis was carried out using 
the Student´s t-test to identify the significant changes of these metabolites within each explored 
brain region (see Chapter Three).  Statistically significant changes were defined as those 
demonstrating a probability p < 0.05.  Moreover, fold changes were calculated to assess the results 
and to determine the direction of metabolite changes in treatment groups in comparison with the 






2.2.6.1. Multivariate analysis methods: 
Principal Component Analysis (PCA) is a statistical method used to provide a viewed summary of the 
clustering pattern for the analysed samples, hence allowing the detection of any abnormal point 
that represents an outlier value to be excluded from the overall study.  Further analysis was 
conducted by means of Partial Least Squares Discriminant Analysis (PLS-DA) which enables data 
discrimination and metabolic identification via performing the two-dimensional (2D) (Figure 2.8) 
and the three-dimensional (3D) scores plot (Figure 2.9. A), thus demonstrating the visualized 
graphical output for experimental groups separation. Identification of the underlying metabolites 
responsible for this separation pattern was implemented using the variable importance in 
projection (VIP) scores (investigating the first 25 selected spectral bins for the included metabolites 











Figure 2.8: PLS-DA 2D Scores Plot of control and treatment groups. 
46 
 
























Figure 2.9: PLS-DA (A) 3D Scores Plot of control and treatment groups. (B) Variables of importance 
in projection (VIP) scores. The coloured boxes on the right indicate the relative concentration of the 




2.3. Liquid chromatography–mass spectrometry (LC-MS): 
Liquid chromatography–mass spectrometry (LC-MS or HPLC-MS) (Figure 2.10) is a micro 
analytical tool that combines the separation capability of HPLC with the effective mass 
analysing specificity of mass spectrometry. It provides a sensitive and highly selective 
technique that is extensively utilized in a broad range of clinical, biological and chemical 
applications, allowing the simultaneous detection and quantification of various metabolites 
and biomolecules ranging from large organic compounds such as proteins and peptides to  
small pharmaceutical molecules (Kang, 2012; Pitt, 2009).  Additionally, LC-MS can successfully 
identify the structure and accurate molecular weight of the analyte in a sensitive, affordable 
and less time consuming approach compared to other analytical methods including HPLC-EC 
(Pitt, 2009).    
 
Figure 2.10: A schematic diagram of the basic components of the LC-MS (YassineMrabet, 
2017).  
 
2.3.1. Basic principles of LC-MS:  
Typically, the LC-MS system offers a coupling of two components, a high resolution HPLC 
separation and a sensitive mass spectrometric detection system, hence determining the 
structure of the analyte in a biological sample.  The liquid chromatographic extraction was 
achieved using a reversed phase column for molecular separation (polar mobile phase with 
non-polar stationary phase).  Furthermore, the separation capability of the desired molecule
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is mainly dependent upon its affinity to interact with the stationary phase, thus the analyte 
that expresses a higher lipophilic affinity requires a longer time to be eluted, whereas a 
molecule with a lower tendency to interact with the stationary phase shows a shorter eluting 
time (Kang, 2012; Parasuraman et al., 2014).  When the separated neutral compound within 
the current HPLC mobile phase reaches the mass spectrometry detector (Figure 2.10), it 
undergoes heating and subsequent vaporization. This is followed by ionization via 
electrospray ionization technique (ESI) which leads to the formation of positively charged 
particles or ions in a gaseous phase (molecular or protonated ions, M+). Subsequently, the 
molecular ions are guided and accelerated through the mass analyzer that represents the 
heart of the MS-system, promoting the separation and deflection of the ions path by the 
surrounding electromagnetic field according to their mass to charge (m/z) ratios (light ions 
show a high deflection capability, whereas heavy ions display a lower bending property 
(Parasuraman et al., 2014). Then, the emerging ions from the mass analyzer are directed 
toward the detector, generating an electrical signal which in turn is converted into a digital 
response that can detected and stored by the computer, thus measuring the relative 
abundance of the target ion species (counting the number of ions of a particular m/z value) 
(Kang, 2012).   
 
 
Figure 2.11: LC-MS spectrum showing sphingosine signal in the scan mode (m/z = 300.4) in 





Figure 2.12: LC-MS chromatogram of frontal cortical samples obtained from upper: control 
and middle: treated rats showing sphingosine peaks at a retention time of 4.213 and 4.242 
minutes respectively. Lower: sphingosine standard peak at a concentration of 10 mg/L and 
a retention time of 4.226 minute. 
 
2.3.2. Sample preparation and lipid extraction: 
The achieved drug treatment method was already described in section 2.1.2. The lipid 
extraction procedure used in the present study was based on the published methods (Bligh 
and Dyer, 1959; Merrill et al., 2005; Sullards et al., 2011).  After completing the aqueous 
extraction for the initial metabolic study using the NMR technique, the frozen tissue pellets 
were placed in Pyrex 13 x 100 mm borosilicate tubes with Teflon-lined caps.  Borosilicate 
tubes were used to minimize the lipid loss, because lipids may stick to some types of glass.  
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The brain samples were then homogenized at 1:3 wet weight per volume in cold phosphate 
buffered saline (PBS).  For the blood samples 100 µl from each blood sample was used for the 
lipid extraction procedure. Specific volumes (as described below) of chloroform/methanol 
mixture (1:2 v/v) then chloroform and water  were added to the tissue homogenates or the 
blood samples according to the relative ratios: 1 volume of the sample; 3.75 volume of 1:2 
CHClᴣ:MeOH; 1.25 volume CHClᴣ; 1.25 volume of dH₂O in a total volume of 7.25 volumes 
(Bligh and Dyer, 1959). The samples were sonicated for 30 seconds and incubated overnight 
in sealed Pyrex tubes at 48 °C in a water bath.  After cooling the samples, 150 µl of 1 MKOH 
in methanol (5.6 g of KOH in 100 ml of MeOH) were added.  Samples were then sonicated for 
30 seconds and incubated for 2 hours at 37°C (Sullards et al., 2011).  The tubes were cooled 
to room temperature and pH adjusted to 7 by the addition of 6 µl of glacial acetic acid 
followed by the addition of 1.25 volume each of chloroform and water and vortexing, then 
centrifugation to separate the samples into upper and lower phases. Then, the lower layer 
was carefully removed with Pasteur pipette leaving behind the protein in the interphase.  Re-
extraction of the upper layer was achieved by adding 1.25 volume of chloroform followed by 
vortexing, centrifugation and collection of the lower layer which was then pooled with the 
first lower phase and evaporated to dryness under a stream of nitrogen (without 
overheating).  Subsequently, the dried organic phase residues were reconstituted in 300 µl of 
the mobile phase, sonicated for 15 seconds and centrifuged for 10 minutes.  Finally, 50 µl of 
the clear supernatants were transferred into glass inserts placed inside 2 ml glass vials for LC-
MS analysis. 
 
2.3.3. LC-MS protocol: 
Chromatographic separation of sphingosine, a ceramide metabolite was successfully 
separated from the other lipid species using either: a) Thermo Scientific BDS HYPERSIL C18 
Reversed Phase column (4.6 x 150 mm, 5 µm) or b) ACE UltraCore 5 Super C18 Reversed Phase 
column (4.6 x 150 mm, 5 µm).  The mobile phase(s) A and B used for both columns contained: 
A) 60% methanol, water, acetic acid (58/41/0.1, v/v/v) and ammonium formate at 5 mM and 
B) 40% methanol, acetic acid (99/0.1, v/v) and ammonium formate at 5 mM, flow rate was 
set at 1 ml/min.  Using an on-line LC-MS detector, the mobile phase was flowing through the 
column by the use of an Agilent 1260 Infinity LC-system (Agilent Technologies) and the 
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optimal MS conditions were the following: nitrogen gas temperature was set at 350°C; the 
drying gas flow was 11 L/min; the fragmentor voltage was 100 V; with a nebulizer pressure of 
53 psig and the gain was 1 A.  Electrospray ionization (ESI) was achieved in the positive mode 
and selective ion monitoring (SIM) mode was set to a fragment ion of m/z 300.4 at a retention 
time of approximately 5.39 – 5.40 minutes in the samples investigated which was confirmed 
by the m/z value and the retention time of sphingosine standards (Figures 2.11 and 2.12).   
Because of the setup of the available LC-MS system, there was a subsequent failure of 
detecting a molecule with a mass exceeding 500 on the SIM mode (i.e. the C18 ceramide, m/z 
= 566.7), hence the required ceramide analysis was unachievable.  Thus, a separate HPLC-UV 
system was set up for the analysis of ceramide (see section 2.4).  In order to normalise the 
samples, the Bradford assay was carried out to determine the total protein concentration of 
individual samples (section 2.3.5). 
 
2.3.4. Calibrations for quantitative analysis of sphingosine: 
Standard curves were generated with each analysed group of samples to quantify sphingosine 
concentration in our samples.  Sphingosine standard was dissolved in methanol to produce a 
stock solution at 200 mg/L and stored at - 80˚C.  Immediately before the analysis of individual 
sample sets, 50 mg/L working stock and subsequent fresh serial dilutions were made up in 
methanol to provide concentrations ranging from 0.2 – 15 mg/L. Validation of the method 
was examined by observing the linearity of the standard curves.  Further, the standard curves 
and their linear coefficient of variation (R2) values for the different brain tissue and plasma 
groups are outlined below (Tables 2.3, 2.4 and Figures 2.13, 2.14).  
 
Table 2.3: Linear coefficient of variation (R²) of the analytical method for sphingosine 
standard curve measurement from brain samples in all treatment groups.          
 
 Group R² 
1 Acute paroxetine 0.995 
2 Acute desipramine 0.9989 
3 Chronic paroxetine 0.9951 




Table 2.4: Linear coefficient of variation (R²) of the analytical method for sphingosine 
standard curve measurement from plasma samples in all treatment groups. 
 
 Group R² 
1 Acute paroxetine 0.9956 
2 Acute desipramine 0.9956 
3 Chronic paroxetine 0.9986 











Figure 2.13: A standard (calibration) curve used for sphingosine concentration 











Figure 2.14: A standard (calibration) curve used for sphingosine concentration 


















2.3.5. Determination of total protein concentration in tissue samples: 
Total protein concentration of tissue samples was determined using the Bradford assay.  A 
dilution of 1 mg/ml of bovine serum albumin (BSA) in distilled H2O (dH2O) was prepared in 
order to generate a standard protein curve by preparing duplicates of serial concentrations 
from the initial BSA stock of 1 mg/ml at intervals of 0.1 mg/ml (Stoscheck, 1990). Tissue 
homogenates were prepared in dilutions of 1 to 8 (diluting 5 µl of the tissue homogenates in 
40 µl of dH2O) and were loaded in a 96-well plate (polystyrene multi-well plate, Fisher 
Scientific, UK).  Finally, 200 µl of the Bradford reagent (Sigma Aldrich, UK) was added to the 
wells during gentle mixing.  Samples were then incubated for 30 minutes at 37°C (Stoscheck, 
1990) allowing them to cool and finally placing the plate in a micro plate reader (Bio Tek, USA) 
which was set at a wave length of 595 nm to measure the total protein concentration (mg/ml) 
in the analysed samples.   
 
2.4. High-performance liquid chromatography with ultraviolet 
detection (HPLC-UV): 
High-performance liquid chromatography with UV detection (HPLC-UV) offers a reliable and 
a sensitive analytical technique that can be applied for the detection and quantification of UV 
absorbing organic compounds in biological samples.  This method was used in the present 
study (see Chapter Four) for the detection of ceramide in rat brain samples from animals 
treated with antidepressant drugs or saline.  Basically, following a derivatization reaction, 
brain samples were analysed for the content of ceramide using a reversed phase HPLC system 
with a UV detector set at a wave length of 230 nm (Figure2.15) (Cremesti and Fischl, 2000; 
Iwamori et al., 1979; Tepper and Blitterswijk, 2000). 
  
2.4.1. Basic principles of HPLC-UV:  
Samples (30 µl) to be analysed were manually injected by a Hamilton glass syringe into a 
Rheodyne injector equipped with a 50 µl injection loop, then transported within the 
continuously running stream of the polar mobile phase through the HPLC column (non-polar 
stationary phase) under high pressure to separate the analytes of the brain samples.  This set 
up allowed the non-polar molecules within the injected sample to move slowly through the 
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packed column, whereas the polar compounds travel rapidly through the column resulting in 
a chromatographic separation of the analytes within the investigated samples (Bird, 1989).  
Subsequently, as the sample exits the column and reaches the UV-detector, a beam of 
ultraviolet light is directed across a flow cell toward a sensor that measures the absorbance 
of UV-light passing through the sample within the flow cell at a specific wave length (Figure 
2.15), resulting in the amplification of the produced electrical signal that is recorded by the 
computer, thus generating a series of peaks in the recorded UV-spectrum (Bird, 1989).  For 







Figure 2.15: Detection principals of HPLC-UV (Esmaeilzadeh et al., 2016). 
  
Since the ceramide molecule lacks a chemical group that absorbs light (i.e. a chromophore 
such as the benzoyl group) identification of the ceramide by the HPLC with UV-detection was 
not initially possible.  To overcome this problem a derivatization method was developed 
which was based on a benzoylation reaction, using benzoyl chloride to form the ceramide 
benzoate, a compound that can be readily detected by UV absorption at a wave length of 230 
nm via the HPLC-UV system (Figure 2.16) (Cremesti and Fischl, 2000; Iwamori et al., 1979; 
Tepper and Blitterswijk, 2000).  
 
2.4.2. Sample preparation and benzoylation of ceramide: 
Lipid extraction was conducted via the previously mentioned procedure (see Chapter Two, 
section 2.3.2) based on the published methods by (Bligh and Dyer, 1959; Sullards et al., 2011).  
The totally extracted lipids were then benzoylated using 50 µl of benzoyl chloride and 500 µl 
of pyridine (1:9, v/v) at 70°C for 3 hours.  The benzoylation reaction was then stopped by the 
addition of 500 µl of water and 30 minutes incubation at room temperature. The pyridine 
content was then evaporated, and the dried lipid residue reconstituted with 1.5 ml of 5% 
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sodium bicarbonate.  After vortexing the samples and centrifugation for 5 minutes at 1000 
rpm, which allowed the partitioning of the extract into two distinct layers with the upper layer 
containing the ceramide content.  The ceramide content was then extracted twice with 2 ml 
of hexane and the clear upper layers were collected and pooled in clean Pyrex 13 x 100 mm 
borosilicate tubes with Teflon-lined caps.  Then, the hexane was washed with 500 µl of 5% 
sodium bicarbonate and thoroughly dried under a stream of nitrogen. Finally, the benzoylated 
ceramide was reconstituted with 200 µl of acetonitrile and 35 µl aliquots were injected into 














Figure 2.16: UV-HPLC chromatogram of hippocampal samples obtained from upper: control 
and middle: treated animals following chronic paroxetine administration showing ceramide 
peaks at a retention time of 5.51 and 5.57 minutes respectively. Lower: ceramide standard 
peak at a concentration of 40 mg/L and a retention time of 5.54 minutes. 
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2.4.3. HPLC-UV protocol: 
The identification and analysis were performed using a Perkin Elmer Series 200 HPLC system. 
The benzoylated ceramide was separated on an ACE UltraCore 5 Super C18 Reversed Phase 
column (4.6 x 150 mm, 5 µm) using 40% methanol and acetic acid (99/1, v/v) as a mobile 
phase A and 60% water with formic acid (99.9/0.1, v/v) as a mobile phase B at a flow rate of 
1 ml/min and an operating pressure of 1500-2000 psig (pounds per square inch, gage).  Both 
mobile phase mixtures were degassed before use by sonication.  The benzoylated ceramide 
content was detected using an UV absorbance detector set at 230 nm.  In order to adequately 
analyse ceramide concentration in individual brain samples, standard curves were generated 
before the analysis of each experimental group.  For this purpose, powdered ceramide was 
dissolved in methanol to produce a stock solution at a concentration of 1000 mg/L which was 
stored at - 80˚C. For the generation of standard curves, a 50 mg/L working stock and 
subsequent fresh serial dilutions were made in methanol to obtain concentrations ranging 
from 0.5 – 40 mg/L.  Validation of the method was assessed by the level of linearity of the 
standard curves (Figure 2.17).  The complete running time for the samples was set at 8 

































2.5. High-performance liquid chromatography with electrochemical 
detection (HPLC-ECD): 
HPLC with electrochemical detection (HPLC-ECD) is a sensitive and rapid analytical tool for the 
simultaneous measurements of monoamine neurotransmitters including catechol and indole 
amines and their corresponding acidic metabolites in brain tissue samples. It has been used 
successfully for the measurement of a variety of compounds that display electrochemical 
responses including oxidation or reduction reactions.  The method is further well established 
for the measurements of electroactive neurotransmitters and drugs in biological samples 
including: cultured cells, brain tissues, plasma, cerebrospinal fluid and dialysates from brain 
microdialysis sampling (Yang and Beal, 2011).   
 
2.5.1. Basic principles of HPLC-ECD:  
After manual injection of the sample, it will be carried by the polar mobile phase through the 
HPLC column (Waters Spherisorb reversed phase C18 column, 4.6 x 100 mm and particle size 
of 3 µm), which is packed with non-polar particles forming a non-polar stationary phase. 
Basically, the polar molecules within the introduced sample pass rapidly through the column 
(low attraction) whereas the non-polar compounds cross slowly (high attraction).  
Subsequently, the sample containing an electrochemically active substance exits the column 
and it enters the detector and passes through the electrochemical flow cell where a reaction 
(oxidation or reduction) takes place at the surface of the working electrode when an electrode 
potential is applied (+ 0.70 V in this study) (Yang and Beal, 2011). Additionally, the 
electrochemical cell has two other electrodes; the auxillary or the counter electrode (during 
oxidation, at the surface of the working electrode electrons are produced and subsequently 
moving towards the auxillary electrode which then helps to transmit an electrical current). 
The third electrode of the ECD set up encompasses the reference electrode which stabilises 
the applied potential (i.e. + 0.70 V) (Figure 2.18).  Then, the resultant electrical signal from 
the analyte is recorded by the computer as a corresponding peak, hence generating an ECD 






Figure 2.18: A schematic diagram of a flow cell within an HPLC-ECD system (Mason, 2015). 
 
The electrochemical reactions for monoamines are summarized below: 
1. 5-HT: In an acidic solution, the electrochemical oxidation of 5-HT results in the 
formation of 5,7-dihydroxytryptamine (5,7-DHT), then further oxidation occurs leading 
to another intermediate namely 4,5,7-trihydroxytryptamine and ultimately, the final 
oxidation product is 5-hydroxytryptamine-4,7-dione (Wrona et al., 1986). 
2. Dopamine: Increasing the cell potential results in oxidation of dopamine into 
dopamine-o-quinone which will be reduced back to dopamine when the potential is 
decreased (Ss et al., 2015). 
3. Noradrenaline: Oxidation of the neurotransmitter noradrenaline results in the 
production of its ortho-quinone form (noradrenaline-o-quinone) which can be reduced 







































Figure 2.19: (A) HPLC-ECD chromatogram showing 5-HT and 3, 4-dihydroxyphenylacetic acid 
(DOPAC) standard peaks at a concentration of 20 ng/ml and a retention time of 2.78 and 
3.50 minutes respectively. (B) HPLC-ECD chromatogram showing dopamine (DA) standard 
peak at a concentration of 50 ng/ml and a retention time of 1.912 minute. 
 
2.5.2. Carmofur treatment:  
A detailed description of carmofur administration is fully described in Chapter Six, section 
6.2.1.1, whereas the brain dissection and sample collection are described in detail in Chapter 
Two, sections 2.1.2 and 2.1.3. 
 
2.5.3. Sample preparation:  
Total tissue extraction method  was based on the previously described procedure by (Colado 
et al., 1997; Yang and Beal, 2011; Zhou et al., 2009). Removal of proteins (e.g. removal of 







by homogenization in cold 0.2 M perchloric acid (PCA, 1:3 weight per volume).  The Eppendorf 
tubes were then capped and vortexed immediately after adding the PCA to prevent gelling of 
the proteins in the samples.  This was followed by the disruption of the brain tissue using the 
Polytron PT3000 for 20 seconds at 1000 rpm. Subsequently, the samples were centrifuged for 
5 minutes at 10 000 g, 4°C and the clear supernatants were transferred into clean centrifuge 
tubes.  Finally, the collected supernatants were utilized for the measurement of 5-HT, DA, NA, 
5-HIAA and DOPAC levels using the highly sensitive HPLC-ECD system, whereas the sediments 
of the tissue homogenate were preserved at - 80°C for further lipophilic extraction and 

























































Figure 2.22: HPLC-ECD chromatogram of frontal cortical samples obtained (A) from a control 
animal and (B) from a carmofur treated animal showing 5-HT peak at a retention time of 















2.5.4. HPLC-ECD protocol:  
2.5.4.1. Mobile phase: 
The monoamine neurotransmitters and their metabolites were separated using the following 
mobile phase (Hajós-Korcsok et al., 2000; Pei et al., 1995; Zetterström et al., 1988): 
5-HT mobile phase:  
• 600 ml of 1M NaH2PO4. 2H2O (adjust pH at 3.0 by phosphoric acid) 
• 14.9 ml of 10% EDTA 
• 4550 ml H2O 
• 0.022 g sodium octanyl sulphonate 
• 590 ml of methanol  
• pH = 3.8 (adjust using sodium hydroxide) 
 
Dopamine mobile phase:  
• 600 ml of 1M NaH2PO4. 2H2O (adjust pH at 3.0 by phosphoric acid) 
• 14.9 ml of 10% EDTA 
• 3400 ml H2O 
• 0.322 g sodium octanyl sulphonate 
• 710 ml of methanol  
• pH = 3.8 (adjust using sodium hydroxide) 
 
Noradrenaline mobile phase:  
• 500 ml of 1M NaH2PO4. 2H2O (adjust pH at 3.0 by phosphoric acid) 
• 14.9 ml of 10% EDTA 
• 3900 ml H2O 
• 2.16 g sodium octanyl sulphonate 
• 600 ml of methanol  
• pH = 4.6 (adjust using sodium hydroxide) 
 
All of the above described mobile phases were degassed for 30 minutes and filtered through 
Whatman filter discs (Whatman, UK) prior to their usage on the HPLC-ECD system. 
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2.5.4.2. Sample analysis using HPLC-ECD: 
Following the manual injection of 50 µl aliquots into a Rheodyne injector (model 7725i) fitted 
with a 50 µl loop, monoamines and their metabolites were separated on a C18 Spherisorb 
column (4.6 x 100 mm and particle size of 3 µm; Waters Ltd, UK) which was connected to a 
pre-column equipped with a filter of pore size 0.5 µm (Waters, Ltd, UK).  Flow rate was set at 
1.2 ml/min with a Waters 1515 Isocratic HPLC pump.  Content of the samples were finally 
analysed using the on-line Waters 2465 Electrochemical Detector (Waters Ltd, UK) equipped 
with the ECD flow cell (Waters model 282065).  The optimal operating parameters were the 
following: the operating pressure, 2000 psig; column temperature, 30°C; injection volume, 50 
µl and the applied detection potential was set at + 0.70 V. Preparation of fresh serial dilutions 
of the individual monoamine and metabolite standards were done daily in 0.2 M PCA to 
obtain concentrations ranging from 10-500 ng/ml and were then loaded on the system to 
identify the representative peaks, their retention times and the area under each peak 
following a pronounced chromatographic separation.  Then, a standard calibration curve was 
plotted with each investigated group to calculate the concentration of the corresponding 
neurotransmitters and their metabolites in each analysed brain sample (Figures 2.20 and 
2.21). Validation of the method was assessed by observing the linearity of the standard 
curves. The complete assay was achieved within 10 minutes and 5-HT, DA, NA, 5-HIAA and 
DOPAC peaks were approximately eluted at the following retention times: 2.7, 1.9, 5.2, 4.7 
and 3.5 minutes respectively using Breeze 2 software (Waters Ltd, UK) (Figure 2.22). 
 
2.6. Real-time quantitative polymerase chain reaction assay (RT-
qPCR): 
Quantitative polymerase chain reaction (qPCR) is a valuable, highly sensitive and widely used 
molecular technique that facilitates studying and quantification of the gene expression level 
of specific genes through the generation of millions or billions of copies of a selected DNA 
sequence in a broad range of biological samples.  It has become an essential tool that is used 
in various applications and research fields including pathology, biology, forensic sciences, 
pharmacology and cancer studies.  This method allows a selective amplification (production 
of multiple copies or amplicons) of a particular DNA fragment which is complementary to the 
sequence of interest (Giri, 2015; Pestana et al., 2009).    
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2.6.1. Basic principles of RT-qPCR: 
2.6.1.1. Main components of PCR reaction:  
• The DNA template: a double stranded DNA (complementary DNA, cDNA) that is 
extracted from the sample. 
• The primers: short segments or pieces of single stranded DNA (20-30 base pairs in 
length) that are identical to certain parts of the target DNA sequence. The primers 
serve as a starting point for adding nucleotides that are required for constructing the 
new DNA strand.  
• Deoxynucleotides: DNA bases which are the substrates of the DNA including four 
bases: adenine (A), thymine (T), cytosine (C) and guanine (G) (Giri, 2015; Pestana et 
al., 2009). 
• DNA polymerase: a thermally stable enzyme that does not denature under high 
temperature (98°) and it exerts an essential role in adding the deoxynucleotide bases 
to the initial DNA template, thereby synthesizing a new DNA strand that is 
complementary to the DNA template strand (Giri, 2015). 
• Potassium or magnesium Buffers: These are required for providing the optimal 
reaction conditions (Staněk, 2013).  
 
2.6.1.2. Main steps of PCR:  
• Denaturation (step one): 
The reaction mixture containing the DNA template is heated to a high temperature 
approximately 94°C for 20-30 seconds which facilitates breaking the weak hydrogen 
bonds that hold the double DNA strands together.  Thus, splitting (denaturing) the double 
strands completely into two single stranded DNA (Giri, 2015; Pestana et al., 2009).  
  
• Annealing (step two): 
Lowering the temperature of the PCR reaction to a particular temperature (a primer-
specific temperature) usually between 50-60°C for 20-40 seconds and therefore, enabling 
the primers to be bound (annealed) to a specific site (the complementary sequence) on 
the single DNA template strand (Staněk, 2013). 
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• Extension or elongation (step three): 
Finally, raising the reaction temperature to 72-80°C for 2 minutes (usually 72°C) which is 
the optimal temperature that permits the DNA polymerase enzyme to start adding the 
deoxynucleotides to the attached primer at a rate of 1000 base pairs per minute.  Thereby, 
extending the primer using the target DNA sequence, thus constructing a new 
complementary copy of a double stranded DNA molecule containing one old strand 
attached to another new one (Giri, 2015). Within one PCR cycle, a single molecule of 
double stranded DNA template will be amplified into two double stranded DNA pieces 
(two copies) which undergo further amplification in the following cycles (Giri, 2015).  
Eventually, with using the PCR analysis enough copies of the gene of interest are obtained 
after repeating the PCR steps for 30-40 cycles (usually 35 cycles).  
 
2.6.1.3. Real time quantitative PCR assay (RT-qPCR) (melting curve 
analysis):                          
Quantification of the target gene is accomplished by real time quantitative PCR assay (RT-
qPCR) via melting curve assessment (measuring the fluorescence intensity against the 
temperature changes). In the qPCR, a fluorescent double stranded DNA binding dye is 
used to bind to a double stranded DNA molecule, therefore generating a single 
fluorescent peak by increasing the temperature (Figure 2.23. A). Using the programmed 
thermal cycler to run the qPCR after completing the amplification cycles, the temperature 
sets above the primer specific temperature (approximately 65°C). As the dye is 
incorporated with the double stranded DNA, the level of the measured fluorescence is 
significantly increased producing a fluorescent signal.  Subsequently, the temperature is 
raised and the double DNA strands are separated or denatured forming two single 
stranded DNA, the dye becomes dissociated resulting in a decrease in the detected 
fluorescence (Figure2.23) (Pryor and Wittwer, 2006).  
 
   

























Figure 2.23: (A) Fluorescent signals of a triplicate. (B) Melting curve from qPCR of the ASAH1 
gene. The figure shows the relation between the level of the detected fluorescence and the 
temperature, displaying a single amplicon peak, thus verifying one PCR product. 
 
2.6.2. Drug treatment: 
Details of the antidepressant drug treatment, brain regions dissection and samples collection 
were fully described in Chapter Five, section 5.2.1 as well as in Chapter Two, sections 2.1.2. 
and 2.1.3. 
 
2.6.3. Total RNA extraction: 
Total RNA was extracted from all collected brain samples using RNeasy Mini Kit following the 
previously published method by Logmann  (Logmann et al., 1987).  Samples were treated with 
10 µl of β-mercaptoethanol and 1 ml of Buffer RLT (lysis buffer). Twenty milligrams of each 
frozen sample were separated and homogenized in 350 µl of lysis buffer followed by careful 
removal of the supernatant.  Then, 350 µl of 70% ethanol was added to the lysate and mixed 
by pipetting without centrifugation. The whole sample (700 µl) was transferred into an 




000 g.  After changing the collection tube, 700 µl of Buffer RW1 (washing buffer) was added 
to the sample in a spin column and centrifuged for 1 minute at 10 000 g and the flow through 
was then discarded.  This was followed by the addition of 500 µl of buffer RPE (washing buffer) 
to the sample, centrifuged for 1 minute at 10 000 g and the flow through was discarded.  Then, 
500 µl of the same buffer solution were added followed by centrifugation for 2 minutes at 10 
000 g.  The collection tubes were changed, and further centrifugation was carried out for 1 
minute at 10 000 g to dry the membrane.  Under strict sterilization, new collection tubes were 
placed under the RNeasy spin columns and 30 µl of RNase-free water were added directly to 
the spin columns containing the RNA samples and centrifuged for 2 minutes at 10 000 g.  
Repeated centrifugation for another 2 minutes was performed to obtain approximately 30 µg 
of highly refined RNA samples which were transferred into new tubes and stored in - 80°C for 
subsequent analysis. 
  
2.6.4. Turbo DNA digestion: 
DNA digestion in all the samples was performed following the manufacturer´s instructions to 
eliminate any DNA contamination by DNAse treatment using the Turbo DNAse-AM free kit.  
All RNA samples were treated with 3 µl of Turbo DNAse buffer and 1 µl of Turbo DNAse.  Then, 
samples were incubated for 30 minutes at 37°C on a hot block and 3 µl of DNAse inactivation 
reagent was added to each sample followed by incubation at room temperature for 5 minutes 
with intermittent mixing. Samples were centrifuged for 1.5 minutes at 10 000 g and the 
supernatants were transferred into new tubes.  Finally, RNA concentration in all the samples 
was evaluated and recorded using a Nanodrop spectrophotometer (Thermo Scientific 
Nanodrop Lite spectrophotometer, UK).     
 
2.6.5. Complementary DNA (cDNA) synthesis: 
The cDNA was synthesized in all samples using an iScript cDNA Synthesis Kit (Bio-rad, UK) 
according to the manufacturer’s guidelines.  In brief, 1 µg of clean, total RNA was used as a 
template to generate the cDNA in a 20 µl reaction mixture in each sample (4 µl of 5x iScript 
Reaction Mix, 1 µl of iScript Reverse Transcriptase, 15 µl of RNA and Nuclease-free water) and 
all the preparations were done on ice. Then, samples were incubated in a programmable 
thermal cycler (PTC-200 Peltier Thermal Cycler) and the conditions for thermocycling 
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reactions were priming for 5 minutes at 25°C, reverse transcription for 20 minutes at 46°C 
and reverse transcription inactivation for 1 minute at 95°C. Finally, the prepared cDNA 
samples were maintained in - 20°C for subsequent PCR amplification. 
 
2.6.6. PCR Amplification and gel electrophoresis:  
In order to assess the integrity of the RNA samples (absence of DNA contamination), the purity 
of the synthesized cDNA samples as well as testing the utilised primers condition, PCR 
amplification was subsequently performed using primer pairs supplied by IDT (Integrated 
DNA Technologies, Belgium). The genes of interest which were investigated in this study 
included the  ASAH1 gene (encodes acid ceramidase enzyme), the SMPD1 gene (encodes acid 
sphingomyelinase enzyme) and two reference genes namely: beta-actin (β-actin) and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) both of which were selected based on 
previously published studies (Bonefeld et al., 2008; Swijsen et al., 2012).  The selected primers 
were designed via Primer3Plus (http://primer3plus.com/cgi-bin/dev/primer3plus.cgi) using 
the following reaction conditions: annealing temperature of 57-63°C with an optimal 
temperature of 60°C, guanine-cytosine content (GC content) of 20-80 % (an ideal GC content 
of 50 %), a primer size of 18-27 base pairs (bp) with an optimal primer length of 20 bp and a 
maximal product size of 200 bp. The amplicon secondary structures were evaluated using the 
Mfold Web Server (http://unafold.rna.albany.edu/?q=mfold) without any interfering 
secondary structures at both binding sites of each primer. The primer sequences for the 










Table 2.5: The utilized primers sequence and the relevant optimized conditions for each. 
 Primer name  









1 ASAH1 F: ACCGTGGACAGAAGATTGCA 151 55 50 
R: AGTTCTCAACACAGGTGCCT 50 
2 SMPD1 F: CTCTGGAAACCCTGGCTTGAT 162 59 52.4 
R: TGCTGGGTCTGTCTTGTTCAG 52.4 
3 GAPDH F: TCACCACCATGGAGAAGGC 168 53 45 
R: GCTAAGCAGTTGGTGGTGCA 55 
4 β-actin F: TGTCACCAACTGGGACGATA 165 55 50 
R: GGGGTGTTGAAGGTCTCAAA  50 
 
A reaction mixture (My Taq Red Master Mix) (Bioline, UK) contained 5 µl of My Taq Red Mix 
reagent, 0.2 µl of the forward primer, 0.2 µl of the reverse primer, 1 µl of each cDNA (or 1 µl 
of RNA or 1 µl of nuclease free water) and 4.1 µl of RNase-free water was made up to a total 
volume of 10.5 µl.  The reaction mixtures were subjected to thermocycling conditions for 35 
cycles which included an initial denaturation at a temperature of 95°C for 15 seconds, 
followed by annealing for 15 seconds at the primer specific temperature (see Table 2.5) and 
a final extension (elongation) for 10 seconds at 72°C.  The PCR amplifications were performed 
using Lab tech. com Thermal Cycler (G-Storm).  Consequently, 5 µl of the PCR products (the 
analysed samples, RNA, the negative control or the blank and the DNA ladder) were loaded 
and separated on a 2 % agarose gel after running the set for 30 minutes at 90 V (Figure 2.24) 















Figure 2.24: PCR products visualisation by agarose gel electrophoresis. The first lane 
represents the ladder or the standard marker, then the PCR products of the negative control 
and the RNA (no visible bands) followed by the cDNA of the target genes: ASAH1 and SMPD1 
genes. 
 
2.6.7. Real-time quantitative PCR (RT-qPCR):  
The real-time qPCR analysis was performed using the Real-time PCR Machine (Applied Bio 
System, UK) using Step One Plus Real-Time PCR system.  Each reaction mixture contained 5 µl 
of SensiFAST reagent (SensiFAST SYBR HI-ROX), 0.2 µl of the forward primer, 0.2 µl of the 
reverse primer, 0.5 µl of the cDNA of each sample and 4.1 µl of RNase-free water to a total 
volume of 10 µl and triplicates were used for each sample.  Real-time PCR amplification 
conditions were the following: Holding stage (95°C for 2 minutes), cycling stage (40 cycles at 
95°C for 10 seconds and 30 seconds at each primer specific temperature) and melt curve stage 
(95°C for 15 seconds, 60°C for 1 minute and 95°C for 15 seconds). Analysis of the generated 
melting curve was accomplished following the amplification of each primer and standard 
curves were plotted using 10-fold serial dilutions of the PCR products of the utilized primer 
pairs (Figure 2.25).  Levels of the gene expression in all regional brain samples were evaluated 
relative to the reference genes: GAPDH and β-actin (normalizing factors). In addition, 
quantification of the target genes was performed by the qBASE+ relative quantification 
software (Qbase, UK) via 2¯ΔΔCT for data processing and by using the Ct values generated from 
each RT-qPCR experiment, then results were entered into Graph Pad Prism and one-way 














































Figure 2.25: A standard curve for the β-actin gene. The CT-value represents the number of 






















Analysis of rat brain metabolic profile following acute and chronic 




Depression is a common and serious psychiatric condition that requires an effective medical 
treatment. Despite the extensive research efforts into the mechanism of action by 
antidepressant drugs, which indeed have resulted in some progress (Bai et al., 2015; Leonard, 
2000; Taylor et al., 2005), to the best of our knowledge the molecular mechanism underlying 
the drugs therapeutic actions still remain to be fully understood. Recently, NMR-based 
metabonomic studies as well as structural imaging studies utilizing MRI technique (Brigitta, 
2002; Lan et al., 2009; Strakowski et al., 2005; Tsang et al., 2005) have been applied to 
investigate brain metabolic alterations following drug treatment of depression.  However, 
further biochemical information related to the efficacy of antidepressant drugs is still 
essential to elucidate the drug-induced metabolic consequences of both short and long-term 
administration of the current antidepressant medications. 1H NMR spectroscopy has been 
increasingly utilized to explore such metabolic profiling in tissues as well as biological fluids 
which allows a higher sensitivity and a greater accuracy of biochemical detection and 
quantification compared to the magnetic resonance spectroscopy technique (MRS) (Tsang et 
al., 2005).  Additionally, the NMR methodology has been widely used in many studies to 
investigate the biochemical changes of psychiatric diseases and their drug treatments 
particularly bipolar disorders (Lan et al., 2009) and schizophrenia (Holmes et al., 2006).  In this 
respect, further brain research performed on schizophrenic patients compared to controls 
utilizing the non-invasive MRS technique identified metabolic reduction in the level of N-
acetyl aspartate (NAA, a biomarker of neuronal integrity) (Ohrmann et al., 2007) and elevated 
lactate level (Halim et al., 2008). Furthermore, another biochemical study conducted on 
depressed patients in comparison with normal controls utilizing the proton MRS approach 
identified changes in various metabolites including glutamate, glutamine and γ-amino butyric 
acid (GABA) within specific brain regions: the prefrontal cortex, amygdala and hippocampus 
(Yüksel and Öngür, 2010).  In addition, a metabolic screening analysis using NMR spectroscopy 
was conducted on postmortem brain samples from patients diagnosed with bipolar disorder 
identified numerous biomolecules within the prefrontal cortex that might be related to the 
pathogenesis of the disease including metabolites and amino acids such as glutamate, GABA 
and myo-inositol as well as creatine (Lan et al., 2009; Smith et al., 2014; Strakowski et al., 
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2005). To date, however, these studies have not revealed any consistent pattern of brain 
metabolic changes related to depressive illness or antidepressant drug administration.  
  
3.1.1. Aim: 
In this study, 1HNMR spectroscopy was employed to investigate the postulated differential 
effects of both acute and chronic administration of two antidepressant drugs (paroxetine and 
desipramine) in rats on aqueous metabolite levels in plasma and brain regions implicated in 
the pathogenesis of depression including the prefrontal cortex, hippocampus and the 
striatum.  In particular, the study examined drug and region-specific alterations in a wide 
range of brain metabolites.  Moreover, the study specifically aimed to evaluate the possibility 
of differential changes following acute and chronic treatment which may give further insight 
into the therapeutic mode of action of the currently available antidepressant agents.  
 
3.2. Material and methods: 
3.2.1. Drug administration and brain dissection: 
 
A full description of animal housing conditions, drug treatments, brain dissection and sample 
collection is described in Chapter Two, section 2.1. To examine the effects of acute drug 
administration, 48 male Sprague-Dawley rats were separated into two sets and each set into 
two groups comprising 12 animals per group and were housed in groups of 4 animals per 
cage.  Within the first set, the first group (control) received a single i.p. injection of saline (1 
ml/kg) and the second group (paroxetine) received a single i.p. injection of paroxetine (5 
mg/kg). The second set of experiments also consisted of a drug group (n = 12) and a saline 
group.  The drug group received desipramine (10 mg/kg, i.p).  All rats were sacrificed one hour 
after injection via schedule one procedure (Home Office, Animal act, 1986) and blood samples 
were collected immediately after lesion of the jugular vein. The whole brain was dissected 
out rapidly on ice into three specific brain regions in correspondence with the Rat Brain Atlas 
(Paxinos and Watson, 2006): the prefrontal cortex, hippocampus and striatal region.  The 
brain samples were rapidly frozen using isopentane on dry ice, weighed and stored at - 80°C 
until subsequent preparation for NMR analysis 
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To examine the effects of chronic drug administration, forty-eight male Sprague-Dawley rats 
were divided into control and drug treated groups (12 rats per group).  The first group (control 
group) received a single i.p. injection of saline (1 ml/kg/day) for 15 days. The desipramine 
group received a single i.p. injection of desipramine (10 mg/kg/day) for 15 days. The 
paroxetine group received a single i.p injection of paroxetine (5 mg/kg/day) for the same 
period.  Then, at the end of the treatment, rats were sacrificed one hour after the last 
injection.  Brains were dissected out, weighed and plasma samples were collected.  All 
samples were stored at - 80°C until needed for 1HNMR analysis.   
 
3.2.2. NMR spectroscopy and sample preparation: 
A detailed description of 1H NMR analysis and procedures for sample preparation was shown 
in Chapter Two, sections 2.1 and 2.2 respectively.  
                                                   
3.3. Data collection and statistical analysis: 
 
NMR spectra of all groups were processed using Metabo Analsyt 3.0 software (Xia et al., 
2015).  Multivariate statistical analysis was performed by partial least squares discriminant 
analysis (PLS-DA) to maximize the experimental groups’ separation (determining whether the 
control and treatment groups are clearly different).  In addition, it allows the identification of 
the variables that contribute to this actual groups separation (specifying the metabolites or 
biomarkers significantly affected by drug treatment) using the variable importance in 
projection (VIP) scores.  Univariate statistical analysis was carried out using the Student t- test 
to identify significant changes of these metabolites within each brain region. Statistically 
significant changes were defined as those demonstrating a probability p < 0.05.  In addition, 
fold changes were calculated to assess the results and to determine the direction of 
metabolite changes in treatment groups in comparison with the relevant control groups. 
 
3.4. Results: 
3.4.1. 1H NMR spectra of rat brain extract: 
The 1H NMR spectra acquired from analysing the aqueous brain extracts of drug and saline 
treated rats within a spectral region of 0.8-4.5 ppm displayed resonances of a large number 




Figure 3.1: 1H NMR spectra of a frontal cortical extract obtained from control rat showing different metabolites. Abbreviations: Glu, glutamate;          
NAAG, N-acetylaspartylglutamate; Gln, glutamine; NAA, N-acetyl aspartate; Chol, choline; GABA, Gamma amino butyric acid; PCholi, Phpshporyl 








Figure 3.2: ¹H NMR spectra of hippocampal tissue extracts obtained from control (A) and treated rats (B) showing different metabolites 
significantly changed identified within the hippocampus following acute desipramine treatment. Abbreviations: Glu, glutamate; NAAG, N-
acetylaspartylglutamate; Gln, glutamine; NAA, N-acetyl aspartate; Chol, choline; Pho ethanol, phosphoryl ethanolamine; Pho creatine, 
phosphocreatine; P cho, phosphoryl choline; ATP, adenosine triphosphate; Tau, taurine; Aspart, aspartate; Myo-inos, myo-inositol; BCAA, 
branched chain amino acid.
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3.4.2. Acute paroxetine and desipramine treatment: 
 
3.4.2.1. Metabolic changes in the prefrontal cortex following acute drug 
administration: 
Acute treatment with paroxetine significantly decreased a number of metabolites within the 
prefrontal cortex (Table 3.1 and Figure 3.1). The PLS-DA scores plot in Figures 3.3 and 3.4 
shows the separation between the treatment and control groups.  In contrast, data analysis 
following acute desipramine treatment exhibited no significant differences in any metabolite 
within the prefrontal cortex (data not shown). 
 
Table 3.1: Metabolites significantly changed identified within the prefrontal cortex following     
acute paroxetine treatment (Student t-test). Abbreviations: d, doublet; t, triplet and m, 
multiplet. 
 
 Metabolites Chemical shift (ppm) Multiplicity P-value Fold changes 
1 Valine 0.83 - 1.00 d 0.019 -1.39 
2 Leucine 0.97 - 1.01 t 0.021 -1.45 
3 ATP 4.15 - 4.23 m 0.043 -1.30 
4 Glutamate 2.33 - 2.39 m 0.043 -1.26 




















3.4.2.2. Metabolic changes in the hippocampus following acute drug 
administration: 
Both acute paroxetine and desipramine administration induced a significant reduction in the 
level of several metabolites identified within the hippocampus.  However, acute desipramine 
treatment was associated with a higher number of significantly changed metabolites 
compared with the acute paroxetine treatment group (see Figure 3.2).                          
 
A. Acute paroxetine treatment: 
Identification of the significant metabolic changes within the hippocampus after acute 
paroxetine treatment showed significantly decreased levels of 4 metabolites (Table 3.2 and 
Figure 3.2).  The PLS-DA scores plot in Figures 3.5 and 3.6 shows the separation between the 
treatment and control groups. 
 
Table 3.2: Metabolites significantly changed identified within the hippocampal tissue   
following acute paroxetine treatment (Student t-test). Abbreviations: d, doublet; t, triplet and 
dd, doublet of doublet. 
 
 Metabolites Chemical shift (ppm) Multiplicity P-value Fold changes 
1 Serine 3.84 - 3.87 dd 0.027 -1.18 
2 D-Glucose(α) 3.81 - 3.84 dd 0.042 -1.18 
3 Valine 3.58 - 3.59 d 0.044 -1.19 
4 Myo-inositol 3.60 - 3.66 t 0.044 -1.19 





















B. Acute desipramine treatment: 
Acute desipramine administration induced a significant decrease in 9 metabolites within 
hippocampal tissue extract as displayed in Figures 3.2, 3.9 and Table 3.3.  The PLS-DA method 
showed a clear separation between the drug treatment group and control groups following 
acute desipramine treatment as demonstrated in Figures 3.7 and 3.8. 
 
Table 3.3: Metabolites significantly changed within the hippocampal tissue following acute 
desipramine treatment (Student t-test). Abbreviations: d, doublet; t, triplet; dd, doublet of 
doublet; m, multiplet; qu, quartet and s, singlet. 
 
 Metabolites Chemical 
Shift (ppm) 
Multiplicity P-value Fold       
changes 
  2.52 - 2.57 dd 0.002 -1.33 
1 N-Acetylaspartylglutamate 2.18 - 2.23 m 0.005 -1.33 
  2.68 - 2.73 dd 0.009 -1.31 
2 Glutamine 2.43 - 2.47 m 0.004 -1.33 
  2.11 - 2.18 m 0.024 -1.27 
3 N-Acetyl aspartate 2.47 - 2.51 dd 0.004 -1.33 
4 Lactate 1.31 - 1.35 d 0.012 -1.36 
  4.08 - 4.15 qu 0.012 -1.35 
  3.60 - 3.66 t 0.014 -1.30 
5 Myo-inositol 3.51 - 3.56 dd 0.015 -1.30 
  3.26 - 3.29 t 0.050 -1.28 
6 Scyllo-inositol 3.30 - 3.31 s 0.015 -1.36 
7 Glutamate 3.73 - 3.77 dd 0.022 -1.26 
  2.33 - 2.38 m 0.041 -1.28 
8 Phosphoryl ethanolamine 3.22 - 3.26 m 0.031 -1.29 
9 Choline 3.46 - 3.51 m 0.044 -1.92 
10 Creatine / Phosphocreatine 3.03 - 3.05 s 0.054 -1.26 















Figure 3.9: Variables of importance in projection (VIP) scores for the significantly changed 
metabolites in the PLS-DA of control and acute desipramine treatment groups in the 
hippocampus. The panel to the right indicates the direction of metabolite changes in both 
groups. Abbreviations: NAA, N-acetyl aspartate; Glu, glutamate; Gln, glutamine; NAAG,  
N-acetylaspartylglutamate; P ethan, phosphoryl ethanolamine; myo-inos, myo-inositol. 
 
3.4.2.3. Metabolic changes in the striatal region following acute drug 
administration: 
Analysis of data obtained from the rat striatal region showed different effects following acute 
paroxetine and desipramine treatment.  Thus, acute paroxetine administration did not result 
in any significant changes in this particular brain region whereas, acute desipramine 
treatment revealed the highest number of significant metabolic changes in this region. 
Interestingly, these changes were overall opposite compared to those seen in the prefrontal 
cortex and the hippocampus, thus in the striatum desipramine generally caused an up-
regulation of a range of metabolites as compared to its effect in the two other brain regions 
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examined, where the drug in contrast reduced the levels of a number of metabolites (Figures 
3.1, 3.12 and Table 3.4).  The PLS-DA scores plot in Figures 3.10 and 3.11 shows the separation 
between the treatment and control groups. 
 
Table 3.4: Metabolites significantly changed identified within the striatal tissue following 
acute desipramine treatment (Student t-test). Abbreviations: d, doublet; t, triplet; dd, doublet 
of doublet; m, multiplet and s, singlet. 
 
 Metabolites Chemical 
shift (ppm) 
Multiplicity P-value Fold 
changes 
1 N-Acetylaspartylglutamate 4.17 - 4.21 dd 0.008 +1.40 
  2. 07 - 2.08 s 0.016 +1.29 
  4.15 - 4.23 m 0.008 +1.40 
2 ATP 4.30 - 4.37 m 0.014 +1.38 
  4.37 - 4.42 m 0.016 +1.30 
  4.27 - 4.30 m 0.012 +1.38 
3 Phosphoryl choline 3.21 - 3.22 s 0.016 +1.34 
  3.66 - 3.70 m 0.020 +1.28 
4 Taurine 3.41 - 3.45 t 0.016 +1.30 
  3.24 - 3.26 t 0.016 +1.34 
5 Phosphoryl ethanolamine 3.97 - 4.05 m 0.016 +1.30 
  3.22 - 3.24 m 0.016 +1.34 
  2.04 - 2.10 m 0.016 +1.29 
6 Glutamate 2.33 - 2.38 m 0.030 +1.24 
  3.74 - 3.77 dd 0.056 +1.24 
7 Valine 0.84 - 1.00 d 0.031 +1.32 
  3.58 - 3.59 d 0.025 +1.27 
  2.48 - 2.47 m 0.019 +1.27 
8 Glutamine 2.11 - 2.18 m 0.022 +1.26 
  3.77 - 3.79 t 0.056 +1.24 
9 Aspartate 3.88 - 3.92 dd 0.020 +1.26 
10 Creatine  3.92 - 3.94 s 0.020 +1.26 
 Phosphocreatine 3.03 - 3 .05 s 0.020 +1.26 
  3.60 - 3.66 t 0.020 +1.28 
11 Myo-inositol 4.05 - 4.08 t 0.021 +1.28 
  3.26 - 3.29 t 0.023 +1.27 
  3.51 - 3.56 dd 0.029 +1.26 





Figure 3.10: PLS-DA 2D Scores Plot of control and acute desipramine treatment groups in 




Figure 3.11: PLS-DA 3D Scores Plot of control and acute desipramine treatment groups in 





Figure 3.12: Variables of importance in projection (VIP) scores for the significantly changed 
metabolites in the PLS-DA of control and acute desipramine treatment groups in the striatal 
region. The panel to the right indicates the direction of metabolite changes in both groups. 
Abbreviations: P ethan, phosphoryl ethanolamine; Glu, glutamate; NAAG, N-acetyl 
aspartylglutamate; P chol, phosphoryl choline; Gln, glutamine; ATP; adenosine triphosphate; 
myo-inos, myo-inositol; scyllo-ino, scyllo-inositol.    
 
                  
3.4.2.4. Metabolic changes in the plasma following acute drug administration: 
The plasma samples of the two acute treatment groups varied in number for technical reasons 
(i.e. difficulties with blood sampling). The acute paroxetine group contained 12 plasma 
samples; 6 controls and 6 treatment samples whereas acute desipramine treatment group 
included 24 samples; 12 controls and 12 treatment samples.  Spectral analysis of the plasma 
samples obtained from the acute desipramine group did not show any significant variation 
between the control and the treatment animals (data not shown), whereas the acute 
paroxetine group showed a significant decrease of some metabolites as indicated in Table 
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3.5.  The PLS-DA scores plot in Figure 3.13 and Figure 3.14 displays the separation between 
the paroxetine treatment and control groups. 
 
Table 3.5: Metabolites significantly changed identified within the plasma following acute 
paroxetine treatment (Student t-test). Abbreviations: d, doublet; and s, singlet. 
 
 Metabolites Chemical 
Shift (ppm) 
Multiplicity P-value Fold changes 
1 Serine 4.23 - 4.40 d 0.016 -1.63 
2 α-Hydroxyisovalerate 4.17 - 4.24 d 0.024 -1.45 
3 Succinate 2.64 - 2.66 s 0.031 -1.56 
4 Creatine 3.08 - 3.09 s 0.043 -1.85 
 
 







Figure 3.14: PLS-DA 3D Scores Plot of control and acute paroxetine treatment groups in the 
plasma.  
 
3.4.3. Chronic paroxetine and desipramine treatment: 
3.4.3.1. Metabolic changes following chronic paroxetine administration: 
A. Metabolic changes in brain regions: 
Analysis of chronic paroxetine data revealed a significant reduction in the level of succinate 
(Student t-test, p = 0.04) with a trend to decrease in myo-inositol level within the 
hippocampus (p values for the myo-inositol peaks = 0.067, 0.073, 0.096 respectively) (Table 













Table 3.6: Metabolites significantly and non-significantly changed identified within the  
hippocampal tissue following chronic paroxetine treatment (Student t-test). Abbreviations: t, 
triplet; dd, doublet of doublet; and s, singlet. 
 





3.51 - 3.56 dd 0.067 -1.58 
3.60 - 3.66 t 0.073 -1.58 
4.05 - 4.08 t 0.096 -1.56 
2 Succinate 2.40 - 2.42 s 0.040 -1.85 
 
B. Metabolic changes in the plasma: 
Spectral analysis of the plasma samples obtained from the chronic paroxetine group did not 
show any significant variation between the control and the treatment animals (data not 
shown).  
 
3.4.3.2. Metabolic changes following chronic desipramine administration: 
A. Metabolic changes in brain regions: 
Comprehensive analysis of chronic desipramine data displayed no statistically significant 
changes in any metabolite between control and desipramine treatment rats within any of the 
three brain regions (data not outlined). 
 
B. Metabolic changes in the plasma: 
Spectral analysis of the plasma samples obtained from the chronic desipramine group showed 
a significant increase in the level of creatinine only (Student t-test p value = 0.030) with a 
trend to an increase in serine level (p value = 0.077).  The PLS-DA scores plot in Figure 3.15 




















Along with the theories attempting to elucidate the pathogenesis of depression and its 
available therapy, the neurochemical alterations of various important brain biomolecules that 
may be associated with depression and the relevant treatment remain to be determined.  
Recent studies have investigated the metabolic effects of antidepressant drug treatment 
using different technologies. Thus, a previous clinical imaging study using MRI (magnetic 
resonance imaging) scans revealed a decreased metabolic activity within the dorsolateral 
prefrontal cortex, as well as an increased metabolic activity within the ventrolateral prefrontal 
cortex, the orbitofrontal cortex and the inferior orbital gyrus in depressed subjects. These 
changes were normalized following successful paroxetine treatment  (Brody et al., 1999).  In 
line with this study, a magnetic resonance spectroscopy (MRS) study in depressed patients 
implied that there were regional abnormalities of several brain metabolites some of which 
were also changed by antidepressant drugs in the current study including: choline, glutamate, 
glutamine and NAA levels in the brain of the affected subjects (Yildiz-Yesiloglu and Ankerst, 
2006). In this regard, a recent post mortem study using NMR spectroscopy identified a 
number of metabolic alterations involving glutamate, GABA, myo-inositol and creatine that 
may be associated with psychological disorders (Lan et al., 2009). 
 
In order to better understand the mechanism of action by antidepressant drugs, the present 
study investigated the metabolic effects of two different antidepressant drugs in three 
separate brain regions (the prefrontal cortex, hippocampus and the striatum) implicated in 
the mechanism of action by antidepressant drugs.  This was done following either acute 
(single injection) or chronic (once daily for 15 days) treatment regimes.  Metabolic changes 
were also recorded in the corresponding plasma samples.  For this purpose, we used 1H NMR 
spectroscopy to investigate for the first time the effect of antidepressant drugs on brain 
metabolites in rat brain regions thought to be associated with depression. Two 
antidepressant drugs from different classes were utilized in the study: paroxetine and 
desipramine. Paroxetine is an SSRI that blocks extracellular 5-HT uptake by inhibiting its 
neuronal transporter (SERT).  The other drug, desipramine is a TCA which inhibits the neuronal 
noradrenaline transporter (NET) and to a much lesser extent also SERT. By preventing the 
uptake of these monoamines, these drugs cause an increase in the concentration of 5-HT and 
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NA within the synaptic cleft. An effect likely to contribute to the drugs well known 
antidepressant action (David et al., 2003; Hyman and Nestler, 1996). 
 
The present study found that acute administration of paroxetine and desipramine induced 
significant metabolic changes, which frequently depended on duration of treatment and were 
often both brain region and drug specific. These differential results probably reflect the fact 
that desipramine and paroxetine primarily block different types of transporters, NET and SERT 
and therefore preferentially increase extracellular levels of NA and 5-HT respectively, thereby 
stimulating receptors with differential distribution and actions in the different brain regions 
investigated.  In contrast following chronic administration, very few metabolic effects were 
detected. 
 
The brief function of the main metabolites identified as being significantly modified by the 
antidepressant drugs of brain regions and in plasma samples are summarized below in section 
3.7.1 (see Figures 3.1 and 3.2). 
 
3.5.1. List of antidepressant-induced changes of metabolites identified in 1H 
NMR spectra:  
• Adenosine triphosphate (ATP): ATP is the principle source of energy production 
(Erecińska and Silver, 1989). 
• Aspartate: This amino acid acts as an excitatory amino acid neurotransmitter in the 
brain and also enhances the immune response by facilitating immunoglobulin and 
antibody production (Klunk et al., 1996). 
• Choline: Choline is an essential substrate of phospholipids and is involved in the 
synthesis of the neurotransmitter acetylcholine (Pouwels and Frahm, 1998). 
• Creatine and phosphocreatine: These compounds participate in cerebral energy 
production. They are required for the synthesis and metabolism of ATP in the brain 
(Crespo et al., 2008; Smith et al., 2014). 
• D-Glucose: Glucose is the main source of energy (Gruetter et al., 1996). 
• Glutamate: Glutamate is the main excitatory neurotransmitter in the brain and the 
major source of GABA (Van Zijl and Barker, 1997). 
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• Glutamine: Glutamine is a precursor to glutamate and hence also a source for the 
inhibitory amino acid GABA (Pouwels and Frahm, 1998). 
• Lactate: Lactate is an important substrate in cerebral energy metabolism. It is 
produced by the anaerobic breakdown of glucose (Fillenz, 2005; Van Zijl and Barker, 
1997). 
• Leucine: Leucine is a branched amino acid which plays an important role in insulin 
release (Garlick, 2005). 
• Myo-inositol: Myo-inositol is an essential osmolyte which can be used as an indicator 
of  intracellular osmolarity (Brand et al., 1993; Tsang et al., 2006).  
• N-acetyl aspartate (NAA): NAA is the source of NAAG and exhibits the same function 
of NAAG in transferring the metabolic water to the extracellular space to maintain the 
neuronal integrity that is necessary for the neuronal activity (Baslow, 2003). 
• N-acetylaspartylglutamate (NAAG): NAAG is synthesized from N-acetyl aspartate 
(NAA) and glutamate in neurons. This substance participates in the maintenance of 
normal neuronal osmolarity by releasing the free metabolic water to the extracellular 
compartment opposite the concentration gradient of water and thereby, maintaining 
a normal neuronal structure  (Baslow and Guilfoyle, 2006). It achieves an important 
role in the excitatory neurotransmission to astrocytes. Therefore, liberates a 
considerable amount of energy needed for the neuronal neurotransmission and it is 
also a precursor of glutamate (Pouwels and Frahm, 1997). 
• Phosphoryl ethanolamine: This compound originates from the alcohol part of the 
phosphoglyceride ethanolamine (Govindaraju et al., 2000). 
• Scyllo-inositol: A form of inositol which is found  in a lower concentration compared 
to that of myo-inositol in a ratio of 12:1 (Michaelis et al., 1993). 
• Serine: Serine is  an important amino acid required for several vital functions including 
a precursor for myelin sheath, maintenance of normal glucose level, normal muscle 
growth and NMDA  receptor neurotransmission (Panatier et al., 2006). 
• Succinate: This metabolite exerts an essential role in generating ATP in the 
mitochondria (Mills and O’Neill, 2014). 
• Taurine: This amino acid functions as an inhibitory neurotransmitter in the CNS and a 
cell membrane stabilizer by increasing the level of the brain threshold in epilepsy.   
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Taurine is also involved in regulation of cellular osmolarity (Hardy and Norwood, 
1998). 
• Valine : Valine is a branched chain amino acids essential for protein synthesis and 
energy production (Siegel et al., 1989). 
 
3.5.2. Metabolic alteration in the prefrontal cortex following acute 
antidepressant drug administration: 
Compared to the corresponding saline treated control group, acute paroxetine treatment 
resulted in a significant reduction in 4 metabolites: valine, leucine, ATP, and glutamate.  In 
contrast, the acute desipramine treatment group did not exhibit any significant metabolic 
difference within this particular brain region.  ATP is the main source of energy within the 
cells and glutamate apart from acting as the main excitatory amino neurotransmitter and the 
metabolic precursor of GABA in the brain, also plays an indirect role in the process of glycolysis 
in the brain (Schousboe et al., 2007). This observation suggests that acute paroxetine 
medication but not desipramine targets amino acid metabolism and the cerebral pathway of 
glucose metabolism. Further, reduced level of valine and ATP indicates that paroxetine 
acutely may decrease energy production within the prefrontal cortex.  Moreover, previous 
clinical studies reported a pronounced hypoglycaemia with an enhanced insulin release 
following both acute and chronic paroxetine treatment in both diabetic patients as well as 
normoglycemic control subjects (Derijks et al., 2008; Han et al., 2016).  In this regard, a recent 
experimental study revealed a similar finding which indicated that acute paroxetine 
administration at a dose of 5 mg/kg resulted in hypoglycaemia with an increased insulin 
release in mice (Kadioglu et al., 2011). Thus, the drug-induced hypoglycaemia following acute 
paroxetine treatment is possibly reflecting the initial metabolic alteration, in particular the 
recorded reduced leucine level in the prefrontal cortex.  
 
3.5.3. Metabolic alteration in the hippocampus following acute antidepressant 
drug administration: 
The hippocampal data analysis after acute paroxetine treatment showed a statistically 
significant reduction in 4 metabolites as compared to the controls, including: serine, D-
glucose, valine and myo-inositol. Acute desipramine induced significant down-regulation 
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within the hippocampus of NAAG, glutamine, NAA, lactate, myo-inositol, scyllo-inositol, 
glutamate, phosphoryl ethanolamine and choline. Taken together, this suggests that the 
hippocampus is affected by the two drugs in a similar way to the effect detected in the 
prefrontal cortex following acute paroxetine treatment. 
 
3.5.4. Metabolic alteration in the striatal region following acute 
antidepressant drug administration: 
Analysing the striatal data after acute treatment with the two antidepressant drugs displayed 
a strikingly drug dependent metabolic effect within this brain region. Thus, while acute 
paroxetine treatment did not reveal any significant effects within the striatal brain region.  On 
the contrary, acute desipramine administration exhibited the highest number of significant 
metabolite changes within this brain region.  Interestingly, the desipramine induced effects 
of brain metabolites in the striatum were in contrast, to those seen in the other two brain 
regions (i.e. decreases) increased in the striatum.  An important finding that was consistent 
with a previous 1H NMR study following chronic methylphenidate treatment in rats (Quansah, 
2017). Detected increases were indeed recorded for up to twelve different functionally 
important brain metabolites and included: NAAG, ATP, phosphoryl choline, taurine, 
phosphoryl ethanolamine, glutamate, aspartate, creatine and phosphocreatine, myo-inositol 
and scyllo-inositol.  
 
3.5.5. Metabolic alteration in the plasma following acute antidepressant drug 
administration: 
Spectral analysis of plasma samples obtained from the acute desipramine group did not reveal 
any significant variation compared to the control group, whereas, analysing the data of the 
acute paroxetine group showed a significant reduction of serine, α-hydroxyisovalerate, 







3.5.6. Metabolic changes specific for acute desipramine administration: 
3.5.6.1. N-acetyl aspartate (NAA) and N-acetylaspartylglutamate (NAAG): 
 
NAAG and NAA are important amino acids present in high concentration in the brain. Both 
exert an essential role in maintaining normal neuronal structure, activity, plasticity and energy 
production (Baslow and Guilfoyle, 2006). Acute desipramine treatment resulted in a 
significant reduction of both NAAG and NAA in the hippocampus and in contrast, a significant 
increase in aspartate, a precursor of NAA and NAAG levels in the rat striatal brain region.  
These observed changes suggest that acute desipramine may exert an initial region-specific 
effect on neuronal viability and energy production. Interestingly, a recent MRS study on 
bipolar patients found that these patients showed a regional abnormality of NAA brain levels 
(Yildiz-Yesiloglu and Ankerst, 2006). Further, a previous metabolomic study utilized gas 
chromatography-mass spectrometry showed a down-regulation of NAA and glutamate in the 
hippocampus of stressed mice following sub-chronic treatment with imipramine and 
fluoxetine for 14 days (Zhao et al., 2015). In addition, a previous MRS study reported that 
depressed patients who received chronic lithium treatment had increased NAA brain levels 
compared to control subjects (Moore et al., 2000).  In comparison, another study showed no 
significant changes in NAA level following chronic lithium treatment, similarly a previous rat 
brain study also failed to show effects on NAA levels following chronic lithium administration 
(Brambilla et al., 2004; Lan et al., 2009; O’Donnell et al., 2003). 
 
3.5.6.2. Glutamate and glutamine: 
Acute desipramine treatment also significantly decreased levels of the main excitatory amino 
acid glutamate and its precursor glutamine in the hippocampus.  In contrast, in the striatal 
region their levels were increased while in the prefrontal cortex no significant changes were 
recorded. Glutamine is stored in the glial cells and taken up by neurons where it is converted 
to glutamate. The rate of this glutamate-glutamine cycle between cell types in the brain is 
indicative of glutamatergic neurotransmission (Van Zijl and Barker, 1997).  Thus, the observed 
change in glutamate and glutamine levels may indicate that acute desipramine produces a 
change in brain glutamatergic activity and that this effect varies in different parts of the brain 
(decreases in the hippocampus while increases in the striatum).  In this respect a number of 
functional magnetic resonance imaging studies showed alterations in neural activity in 
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depressed patients, although the reported results were inconsistent (Chang et al., 2004; 
Strakowski et al., 2005; Yüksel and Öngür, 2010).  
  
3.5.6.3. Myo-inositol, scyllo-inositol and taurine: 
Acute desipramine treatment resulted in a significant reduction of both myo-inositol and 
scyllo-inositol levels in the hippocampus and in contrast a significant increase in their levels 
were detected in the striatal region.  Myo-inositol is an important intracellular osmolyte in 
the CNS that contributes to maintaining an osmotic balance in the cell by regulating its 
transport across the plasma membrane (Haris et al., 2011). Furthermore, myo-inositol 
constitutes an important precursor of the cell membrane inositol containing phospholipids 
and myelin sheath and also a key marker for glial integrity as it is present in a higher 
concentration in glia cells compared to neurons (Brand et al., 1993; Chiappelli et al., 2015; 
Tsang et al., 2006).  This essential metabolite is synthesized via the enzymatic action of inositol 
monophosphatase enzyme which is inhibited by lithium, a mood stabilising drug used in 
bipolar disorder treatment (Ohnishi et al., 2014; Rango et al., 2008).  Moreover, previous brain 
imaging studies of patients with depressive disorder reported a reduction in myo-inositol level 
in comparison with healthy controls (Chiappelli et al., 2015; Rango et al., 2008).  In addition, 
taurine, an amino acid which is also involved in the intracellular osmo-regulatory function 
(Brand et al., 1993; Fisher et al., 2002; Hardy and Norwood, 1998) was similarly to myo-
inositol increased in the striatal region by acute desipramine treatment. The observed 
findings therefore suggest that acute desipramine administration initially alters tissue osmo-
regulation and hence may acutely modulate glial cell volume and structure.  Possible related 
to the finding of the present study includes a previous study demonstrating changes in myo-
inositol levels in the frontal cortex of depressed patients compared to normal controls, and 
that such effect was partly reversed by chronic lithium treatment (O’Donnell et al., 2003).  
Also a significant reduction of myo-inositol level was reported in the striatum and 
hippocampus of the rat following lithium treatment (Lan et al., 2009).  
 
3.5.6.4. Phosphoryl ethanolamine, choline and phosphoryl choline:  
All three of these metabolites are known to be important for the synthesis of membrane 
phospholipids.  Interestingly, alterations in membrane lipid metabolism has been reported in 
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the brain of patients suffering from bipolar disorder (Frey et al., 2007). In this study, the 
observed significant changes (Tables 3.3 and 3.4) of these metabolite levels suggest that 
desipramine may transiently exert a region-specific regulatory role on neuronal membrane 
phospholipids.   
 
3.5.6.5. Energy metabolism: 
Many studies indicate that brain energy metabolism is altered in depressive disorder 
(Pieczenik and Neustadt, 2007; Stork and Renshaw, 2005). In the current study, several 
metabolites involved in cerebral energy metabolic pathways were found to be significantly 
altered following acute desipramine treatment including: lactate, ATP, creatine and 
phosphocreatine. The observed findings therefore, suggest that acute but not chronic 
desipramine treatment may target pathways related to cerebral energy production.   
 
3.5.7. Metabolic changes specific to acute paroxetine administration: 
Acute paroxetine treatment significantly reduced valine and glucose levels in the 
hippocampus. In comparison, within the prefrontal cortex there was only a trend by 
paroxetine to decrease glucose level.  However, in the hippocampus, paroxetine significantly 
reduced ATP, glutamate and valine levels.  These metabolites are all known to play roles in 
various pathways related to energy metabolism and indeed recent studies showed that 
glutamatergic neurotransmission is of particular importance in this respect (Schousboe et al., 
2007; Stork and Renshaw, 2005).  Importantly, the glutamate-glutamine cycle is an energy 
demanding process, hence it is closely linked to cerebral glucose oxidation and energy 
production (Schousboe et al., 2007).  In this context, abnormalities of energy metabolic 
pathways have recently been identified in depressed patients (Pieczenik and Neustadt, 2007; 
Stork and Renshaw, 2005). Additionally, in line with our results, a previous in vivo study 
conducted on rat revealed that acute citalopram administration induced a significant 
reduction of glutamate in the prefrontal cortex following a single intraperitoneal injection at 
a dose of 20 mg/kg, hence acute SSRI treatment may affect glutamatergic neurotransmission 






Acute paroxetine treatment resulted in significant decrease of myo-inositol and serine levels 
in the rat hippocampus but not in the prefrontal cortex or the striatum which may initially 
represent a region-specific alteration in tissue osmo-regulatory function within the brain.  
 
3.5.8. Metabolic changes in the brain regions and plasma following chronic 
administration of paroxetine: 
In the present study, while acute paroxetine treatment significantly decreased the level of a 
number of metabolites in the prefrontal cortex and hippocampus, chronic paroxetine 
administration clearly revealed fewer metabolic changes in one brain region (see Table 3.6).  
Thus, in the hippocampus only a significant reduction of succinate was recorded and a trend 
to decrease myo-inositol level compared to the controls. Further, chronic paroxetine 
treatment failed to alter metabolite levels in the prefrontal cortex and the striatum as well as 
in plasma samples which may suggest the occurrence of neuroadaptive changes to the acute 
metabolic responses seen after short-term paroxetine treatment.  Succinate exerts a crucial 
role in the generation of adenosine triphosphate (ATP) which represents the main source of 
energy in the mitochondria (Mills and O’Neill, 2014).  Together with the finding of the present 
study that acute paroxetine changes levels of some metabolites including valine, glucose and 
ATP which likewise succinate are related to energy metabolism, it is likely that metabolic 
pathways involved in the generation of energy are targeted by paroxetine. Further, it is 
possible that this drug effect is related to its therapeutic action.  In support of this, a recent 
animal study demonstrated that chronic paroxetine treatment normalizes the increase of 
hippocampal energy metabolism in a stress model of depression in rats (Khedr et al., 2015).  
Additionally, chronic paroxetine administration resulted in a non-significant hippocampal 
reduction in myo-inositol level which is an important marker for glial integrity (Tsang et al., 
2006).  This effect may reflect the possible role of paroxetine in modulating the tissue osmo-





3.5.9. Metabolic changes in the brain regions and plasma following chronic 
administration of desipramine: 
Chronic desipramine treatment, in contrast to its acute administration which revealed a 
number of changes of water soluble brain metabolite levels (see Tables 3.3 and 3.4), failed to 
show any significant differences between chronically treated rats and their corresponding 
controls within the explored brain regions.  In addition, spectral analysis of the plasma 
samples obtained from the chronic desipramine group showed a significant increase in the 
level of creatinine only.   
 
Our results with the TCA desipramine and the SSRI paroxetine are in contrast to a previous 
study, investigating the metabolic profile following chronic administration of a different TCA 
namely imipramine and the SSRI fluoxetine.  Similar to this study, Zhao et al, treated rats for 
two weeks although in contrast to the present study they reported significant down 
regulation of: leucine, valine, glutamic acid, aspartic acid, glycine, NAA, and lysine within the 
hippocampus by both drugs while fluoxetine also significantly reduced myo-inositol levels  
(Zhao et al., 2015).  The discrepancy between our study and the study by Zhao et al, might be 
explained by the fact that we used normal rats while their study was conducted on ‘’stressed’’ 
rats which in itself could have caused neuroadaptive changes resulting in a modified response 
to chronic antidepressant drug administration (Herman, 2013).  In addition, a recent brain 
imaging study utilizing the MRI technique indicated a widespread activation throughout 
specific brain regions including the cerebral cortex and the hippocampus after acute 
citalopram administration in rats. However, localization of the reported changes was 
observed following chronic treatment which may suggest the development of neuroadaptive 
responses (Sekar et al., 2011).  In this respect, a recent experimental study conducted on the 
frontal cortex of freely moving mice utilising the in vivo microdialysis technique revealed that 
a single antidepressant drug administration (paroxetine, citalopram or venlafaxine at three 
different doses: 1, 4 and 8 mg/kg, i.p) induced a pronounced increase in the extracellular 
levels of 5-HT and NA in the cortical dialysates.  An effect that would be expected to occur by  




While acute antidepressant drug administrations caused widespread changes of several brain 
metabolites in the present study, the lack of response by chronic treatment could possibly 
reflect the onset of a neuroadaptive effect by the drug following chronic administration.  In 
parallel with this observation, a previous animal study recorded that chronic desipramine 
treatment has been indicated to promote adaptive changes in specific brain regions, 
especially in the hippocampus of rats (Sacchetti et al., 2001).  Such adaptive response in the 
noradrenergic neurons, have been shown to encompass down-regulation of the presynaptic 
inhibitory α2 autoreceptors and the postsynaptic β-adrenergic receptors following chronic 
administration of antidepressant drugs including the TCAs (Hyman and Nestler, 1996; 
Sacchetti et al., 2001; Schultz et al., 1981; Sulser et al., 1978; Taylor et al., 2005).  Thus, 
initially, acute antidepressant treatment (TCA) increases the synaptic levels of noradrenaline 
by blocking its transporter function which will cause hyper-stimulation of presynaptic α2 
autoreceptors as well as postsynaptic β-adrenergic receptors.  Subsequently, this response 
will result in phosphorylation of the stimulated receptors through activation of specific 
synaptic enzymes, namely the G protein-coupled receptor kinases leading to desensitization 
of these receptors (Lefkowitz, 1993). In addition, acute SSRI administration increases the 
synaptic level of 5-HT via blocking the serotonin transporter, which in turn activates the 
presynaptic inhibitory receptors (i.e. the somatodendritic 5-HT1A autoreceptors) resulting in 
a decreased serotonergic neurotransmission at the level of the raphe nuclei, the origin of the 
5-HT neurons.  Accordingly, these 5-HT1A autoreceptors also become desensitised and hence 
contributing to the subsequently elevated 5-HT level. This enhancement of 5-HT 
neurotransmission  is attributed to the completely recovered firing activity of the serotonergic 
neurons as a consequence of long-term drug exposure (2-3 weeks of treatment) (Blier and de 











The current study was aimed at the detection of drug-induced alterations of water soluble 
metabolites using 1H NMR following the administration of two antidepressant drugs by either 
acute or chronic treatment. The findings of the study show that both acute paroxetine and 
desipramine treatment influence the brain levels of a number of metabolites involved in 
important mechanisms of the brain including: energy consumption, neurotransmission and 
neuronal integrity. The study investigated the effect of two antidepressant drugs in three 
separate brain regions relevant to depression and its treatment namely: prefrontal cortex, 
hippocampus and the striatum.  Overall, the recorded changes of metabolite levels following 
an acute injection varied, depending on both brain regions and drug type.  However, these 
observed drug-associated metabolic responses were not maintained after chronic treatment 
which may suggest the occurrence of neuroadaptive changes following repeated drug 
administrations.  Further studies are needed to better understand if these acute effects of 
paroxetine and desipramine on functionally important brain metabolites are part of a chain 
of events resulting in the therapeutic effect or even the undesirable adverse effects seen after 

























LC-MS and HPLC-UV analysis of sphingosine and ceramide content in rat 































The main structural components of all biological membranes are proteins, lipids and small 
amounts of carbohydrates. In mammalian cells, the plasma membrane lipids are 
predominantly composed of phospholipids and cholesterol (Fahy et al., 2005).  Phospholipids 
are divided into two major families: glycerophospholipids with the glycerol backbone and 
sphingophospholipids which contain the sphingoid base backbone.  Sphingophospholipids (or 
sphingolipids) are bioactive compounds that contain sphingoid bases (SBs) which are di- or 
trihydroxy long chain alkanes of 14 to 22 carbon atoms linked to longer chain fatty acids 
(Figure 4.1) (Gault et al., 2010). Sphingoid bases encompass 60 different species where 
sphingosine, phytosphingosine or sphinganine are the main distinctive SBs.  The wide array 
of sphingolipids results from the possible variation in the sphingoid base type, position and 
number of the double bonds, hydroxyl groups and the length of the fatty acid chains (Gault 
et al., 2010; Kolter and Sandhoff, 1999). Ceramide belongs to a class of hydrophobic 
sphingolipid molecules that represent a central core in sphingolipid biosynthetic pathways as 
well as an important precursor of other simple sphingolipid species including sphingosine and 
sphingosine-1-phosphate (Gault et al., 2010). A growing body of evidence indicates an  
important role of these highly bioactive molecules in a wide range of vital cellular functions 
including cell signaling and synaptic neurotransmission (see Chapter One, section 1.10.1) 
(Dinoff et al., 2017; Gracia-Garcia et al., 2011; Müller et al., 2015; Schneider et al., 2017). 
Additionally, ceramide may contribute to functions related to membrane permeability by 
interacting with specific ion channels (see Chapter One, section 1.10.3) (Gulbins et al., 1997; 
Lepple-Wienhues et al., 1999; Tsui-Pierchala et al., 2002).  In addition, it has been shown that 
ceramide could be involved in the regulation of growth arrest (Dinoff et al., 2017) as well as 
apoptosis or programmed cell death that occurs specifically in the mitochondria (see Chapter 























Figure 4.1: Chemical structure of sphingolipids. (A) Sphingosine. (B) Ceramide (N-
acylsphingosine). (C) Sphingomyelin (ceramide phosphocholine) (Fahy et al., 2005).  
 
4.1.1. Sphingolipid biosynthesis: 
Ceramide or N-acyl sphingosine is the essential building block of the sphingolipids and can be 
generated through three main pathways (Gault et al., 2010) as illustrated in Figure 4.2 and 
outlined below: 
4.1.1.1. Lysosomal sphingomyelin hydrolysis: 
Sphingomyelin constitutes a major and complex sphingolipid component of the cellular 
plasma membrane in the brain.  The degradation of sphingomyelin (utilised as a substrate) 
into ceramide and phosphorylcholine particularly within the membrane lipid rafts is catalysed 
via the activity of the acid sphingomyelinase enzyme (also known as sphingomyelin 
phosphodiesterase which is encoded by the SMPD1 gene), a process that is enhanced in 
response to stress (i.e. food deprivation for 24 hour) (Grassmé et al., 2015; Gulbins et al., 
2015; Kornhuber et al., 2014).  Interestingly, it was found that this pathway represents the 







4.1.1.2. The de novo pathway: 
The de novo biosynthesis of ceramide is initiated by the condensation of the amino acid serine 
and the fatty acid palmitate to form 3-ketodiydrosphingosine (3-ketosphinganine) through 
the action of the rate-limiting enzyme serine palmitoyltransferase in the cytoplasm of the 
endoplasmic reticulum (the main site for lipid biosynthesis) (Hanada, 2003).  Subsequently, 3-
ketosphinganine is reduced to sphinganine (diydrosphingosine) via the enzyme 3-
ketosphinganine reductase (3-ketodihydrosphingosine reductase). Then, sphinganine is 
acylated by the enzyme dihyro ceramide synthase to produce dihydroceramide (Pewzner-
Jung et al., 2006).  Eventually, the last reaction in ceramide production is catalysed by the 
action of the enzyme dihydroceramide desaturase to generate ceramide (Rother et al., 1992).  
Subsequently, a cytoplasmic transfer protein namely the ceramide transporter (CERT) 
mediates the transport of ceramide from the endoplasmic reticulum to the Golgi apparatus 
where ceramide undergoes further conversion to liberate other complex sphingolipids such 
as sphingomyelin (Hanada, 2006).  
 
4.1.1.3. The salvage pathway: 
This pathway includes the lysosomal hydrolysis of complex sphingolipids such as: 
glucosylceramide (formed by adding a glucose molecule to ceramide)  and sphingomyelin 
which results eventually in the production of sphingosine (the major product of ceramide 
catabolism) (Gault et al., 2010; Tafesse et al., 2006). The sphingosine released from the 
lysosome is then reused through recycling or re-acylation to serve as a substrate for further 
regeneration of ceramide in the endoplasmic reticulum via the action of the ceramide 




Figure 4.2: The biosynthetic pathways of sphingolipids (Kornhuber et al., 2014). 
 
4.1.2. Biological functions of sphingosine: 
Sphingosine (the main metabolite of ceramide) is a simple sphingolipid molecule produced 
within the plasma membrane, lysosomes, endoplasmic reticulum and the Golgi complex by 
degradation of ceramide through the action of the enzyme acid ceramidase (Gault et al., 2010; 
Sun et al., 2008).  Sphingosine has been reported to be implicated in the process of apoptosis 
(see Chapter One, section 1.10.2.1) (Cuvillier, 2003; Suzuki et al., 2004) as well as in the 
pathogenesis of a neurodegenerative disease termed Niemann-Pick disease type C1 (NPC1)  
(te Vruchte et al., 2004).  This disease is an inherited lysosomal storage disease characterized 
by accumulation of various lipids such as sphingosine, sphingomyelin and cholesterol with a 
concomitant reduction in the calcium concentration within the lysosomes compared to 
normal cells (Höglinger et al., 2015; Lloyd-Evans et al., 2008; te Vruchte et al., 2004).  A recent 
study conducted on both human and mouse cultured fibroblast cells with sphingosine 
incubation observed that an acute increase of sphingosine levels was immediately followed 
by an enhanced release of lysosomal calcium compared to cells not incubated with 
sphingosine (Höglinger et al., 2015). This intracellular response was found to trigger 
autophagy (a controlled destruction of proteins and other cellular components) (Höglinger et 
al., 2015).   
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Furthermore, the increased calcium level was shown to promote a translocation of the 
transcription factor EB (TFEB) to the cellular nucleus and consequently activating genes that 
are involved in the process of autophagy (Höglinger et al., 2015; Medina et al., 2015).  
Additionally, it was reported that two proteins located on the surface of the lysosomes, two-
pore channel 1 and 2 (TPC1) and (TPC2), were activated by the action of the sphingosine.  
Subsequently, they may act as channels to allow the release of calcium ions from the 
lysosome, thus mediating a reduced lysosomal calcium concentration following a significantly 
increased sphingosine level within these organelles which is a known feature in Niemann-Pick 
disease type C1 patients  (Höglinger et al., 2015; Lloyd-Evans et al., 2008).  
 
In the current study, initially it was planned to employ liquid chromatography coupled with 
mass spectrometry (LC-MS) approach to explore the effect of acute and chronic 
antidepressant drug treatment on ceramide content in lipid samples extracted from rat brain.  
However, the limitations of the operating LC-MS system available failed to detect molecules 
with a mass exceeding 500.  Since ceramide has a molecular weight of 567, it was not possible 
to use this technique for the direct quantification of ceramide content.  Instead, sphingosine 
which represents the major metabolic product of ceramide as well as its precursor in the 
salvage pathway of ceramide synthesis (see Figure 4.2) was measured using the LC-MS 
technique.  Sphingosine has a molecular mass of 300 and hence could be directly quantified 
using the equipment available within the School of Pharmacy.  Subsequently, measurements 
of ceramide content in hippocampal brain samples following antidepressant drug treatment 
was successfully undertaken via the development of an already published method (Couch et 
al., 1997; Iwamori et al., 1979).  Thus, ceramide analysis was achieved by means of chemical 
derivatisation of the extracted ceramide followed by high-performance liquid 
chromatography with ultraviolet detection technique (HPLC-UV). Additional studies were 








4.1.3. Ceramide, biological functions and depression: 
Recently, the major lipid components of the cell membrane: sphingolipids, particularly 
ceramide species have been focussed on for their implication in depression (see Chapter One, 
section 1.8) (Dinoff et al., 2017; Gulbins et al., 2013, 2015).  In the cell membranes, these 
bioactive hydrophobic molecules aggregate in organized membrane compartments termed 
lipid rafts which may consequently, merge to form larger ceramide-rich platforms. These 
membrane platforms permit re-organisation and clustering of numerous proteins and 
signaling molecules including receptors (i.e. G-protein coupled receptors, GPCRs) and 
thereby, altering neuronal firing and signal transduction (see Chapter One, section 1.9) (Dinoff 
et al., 2017; Gulbins et al., 2013, 2015; Schneider et al., 2017).  In this respect, these ceramide-
rich platforms play important role in various biological functions such as cell signaling and 
monoamine neurotransmission, also affecting membrane permeability by regulating ion 
channels, in particular the calcium channels as well as the potassium channels (i.e. Kv 1.3) 
(see Chapter One, section 1.10) (Dinoff et al., 2017; Müller et al., 2015; Schneider et al., 2017; 
Tsui-Pierchala et al., 2002). In addition, ceramide exerts an essential role in vital cellular 
mechanisms such as growth arrest and apoptosis (see Chapter One, section 1.10.3) (Pettus et 
al., 2002; Ruvolo, 2003).  Furthermore, recent studies indicate that lipid rafts are the main 
site for the activation of the enzyme acid sphingomyelinase (ASM) which in turn results in the 
enhancement of ceramide generation and the subsequent formation of the membrane 
ceramide-rich platforms (Gulbins et al., 2015; Schneider et al., 2017). Growing evidence 
suggests that many antidepressant drugs induce inhibition of ASM by promoting a proteolytic 
degradation of this enzyme (Dinoff et al., 2017; Gulbins et al., 2013, 2015).  Consistent with 
these emerging findings, a previous animal study reported that administration of the 
antidepressant drugs: amitriptyline and fluoxetine at therapeutic plasma concentrations 
inhibited the activity of the enzyme ASM resulting in reduced ceramide concentrations in the 
hippocampus.  This was coincided with a reduction of depression-like behaviours in a mouse 
model of depression (Gulbins et al., 2013). Overall, more studies are required to fully 







With the recent findings in hindsight that sphingolipids could be implicated in depression and 
its treatment, the present study was aimed at investigating the effect of acute and chronic 
antidepressant drug treatment on brain levels of two of the bioactive lipid molecules in the 
sphingolipid pathway namely: ceramide and its major metabolite sphingosine in the rat.  The 
experiments were designed to test the hypothesis that chronic antidepressant drug 
treatment lowers the brain level of the sphingolipid molecules, specifically ceramide and 
sphingosine.  In order to assess this, the below experiments were performed: 
•  By using the LC-MS technique, levels of sphingosine were determined in regional 
brain extracts and plasma samples from groups of rats treated with acute or chronic 
antidepressant drugs namely, the SSRI paroxetine or the TCA desipramine. 
• The effects of antidepressant drug treatment on sphingosine level in cultured mouse 
macrophages cells was investigated via the LC-MS. 
• An HPLC-UV method was developed for the measurements of ceramide in 
hippocampal brain extracts from rats treated chronically with the SSRI paroxetine. 
 
4.2. Materials and method: 
4.2.1. Sphingosine analysis by liquid chromatography coupled with mass 
spectrometry (LC-MS): 
4.2.1.1. Sphingosine analysis in cultured mouse macrophages: 
The preparation of the cultured cells for the sphingosine analysis using the LC-MS technique 
was based on previously published protocols (Couch et al., 1997; Elojeimy et al., 2006; Shaner 
et al., 2009).  Mouse macrophages cell line (RAW 264.7), a common type of the monocyte-
derived cell line was used in this limited preliminary study to test the effect of two 
antidepressant drugs (desipramine and paroxetine) treatment at a concentration of 10 µM 
on sphingosine content after 30 minutes or 60 minutes incubation periods and prior to a 
detailed animal study.  The cells were cultured (at 5 x 105 cells/ml) and were grown in RPMI 
culture medium (Fisher Scientific, UK), which was supplemented with 200 µg/ml streptomycin 
and 200 units/ml penicillin.  The frozen cells were collected from the liquid nitrogen, then the 
stored vial was thawed in a warm water bath. In a sterilized cell culture hood, the cell 
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suspension was transferred from the vial for incubation in a humidified incubator under 
controlled conditions: 95% relative humidity, 5% CO₂ and a temperature of 37˚C.  
Subsequently, the cultured cells were split and regularly examined under the microscope 
every day for any sign of contamination.  The investigated antidepressant drugs: desipramine 
and paroxetine were added to the cultured cells at a concentration of 10 µM (Elojeimy et al., 
2006) and were incubated for 30 minutes or 60 minutes under the same conditions.   
Following the specified incubation periods, the cells were washed several times with an ice-
cold phosphate buffered saline (PBS) and centrifuged at 500 g for 5 minutes at room 
temperature.  The supernatants were then removed, and the residues were stored at - 80˚C 
for a subsequent lipid extraction and LC-MS analysis.  The frozen cell pellets were thawed and 
re-suspended in 500 µl of cold PBS, then lipids were extracted using the described method in 
Chapter Two, section 2.3.2. 
 
4.2.1.2. Sample preparation and lipid extraction: 
Full details of animal housing conditions, drug administration, brain dissection and samples 
collection are described in Chapter Two, section 2.1, whereas the sample preparation and the 
subsequent lipid extraction procedure is described in detail in Chapter Two, section 2.3.2.  For 
both acute and chronic treatment studies, male Sprague-Dawley rats (266-301 g body weight) 
were separated into four groups, each comprising 12 animals.  Rats were housed four animals 
per cage. Two antidepressant drugs were utilized in this study: paroxetine, a selective 
serotonin reuptake inhibitor (SSRI) was administered at 5 mg/kg intraperitoneally (i.p). The 
other drug: desipramine, a tricyclic antidepressant (TCA) was administered at 10 mg/kg i.p.  
The control animals received i.p saline 0.9 % (1ml/kg). In the acute study, treatment was 
administered once only, and the rats were sacrificed 1 hour later. In the chronic study, 
treatment was repeated once daily at 10 a.m. for 15 consecutive days and the rats were 
sacrificed 1 hour after the final injection. Consequently, blood samples were collected 
immediately after lesion of the jugular vein and the whole brain was dissected out rapidly on 
ice into three specific brain regions: prefrontal cortex, hippocampus and the striatal region.  
The brain samples were rapidly frozen using isopentane cooled with dry ice, weighed and 
then stored with the blood samples at - 80°C for subsequent lipid analysis.  Lipid extraction 
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was based on a previously published method (Bligh and Dyer, 1959; Merrill et al., 2005; 
Sullards et al., 2011) and was fully described in Chapter Two, section 2.3.2. 
 
4.2.1.3. LC-MS protocol: 
The liquid chromatographic separation conditions, the optimal MS conditions, type of 
columns and the mobile phases used in the performed LC-MS analysis are described in detail 
in Chapter Two, section 2.3.3. Because of the restriction of the operating LC-MS, it was 
impossible to detect and analyse C18 ceramide (molecular mass = 566.7 g/mol) on the 
selective ion monitoring mode (SIM) with the available equipment.  However, LC-MS analysis 
of the main ceramide metabolite, sphingosine (m/z 300.4) was achievable.  Thus, detection 
and quantification of sphingosine content was carried out in the extracted lipid samples which 
was confirmed by the m/z value (mass-to-charge ratio) and the retention time of sphingosine 
standards (Figure 4.3). The Bradford assay was used to determine the total protein 
concentration in each sample and subsequently, was used as a normalizing parameter to 
quantify the sphingosine concentration in the investigated samples (see Chapter Two, section 
2.3.5).   
 
Figure 4.3: Lower: Sphingosine standard peak at a concentration of 40 mg / L and a retention 
time of 5.361 minute. Upper: LC-MS chromatogram of hippocampal tissue obtained from a 
rat following chronic desipramine treatment; showing sphingosine peak at a retention time 
of 5.388 minute. 
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4.2.1.4. Data presentation and statistical analysis: 
Datasets generated from the LC-MS study of the sphingosine were analysed statistically either 
by two-way analysis of variance (two-way ANOVA with Bonferroni post-hoc test) or via one-
way analysis of variance (one-way ANOVA followed by Bonferroni post-hoc test) for multiple 
comparison. On the other hand, statistical analysis of the HPLC-UV ceramide data was 
established by means of the Student’s t-test, data obtained from both sphingosine and 
ceramide study were tested using Prism 5.0 Software (Graph Pad Prism Software, version 5).  
Values were presented as means ± standard errors of the mean (SEM) for each group and 
they were expressed as mg sphingosine or ceramide/mg protein in all the analysed samples 
(using the area under the peak for each integrated signal).  Statistically significant difference 
was considered at a level of p < 0.05.     
 
4.2.1.5. Calibrations for quantitative analysis of sphingosine: 
Determination of sphingosine concentration after generating a standard curve was 
performed with each analysed group of samples, together with the used standards, chemicals 
and solvents in the sphingosine assay are fully described in Chapter Two, section 2.3.5 and 
section 2.3.6.  
  
4.2.2. Ceramide analysis by high-performance liquid chromatography with 
ultraviolet detection (HPLC-UV): 
Direct quantitation of ceramide via high-performance liquid chromatography with ultraviolet 
detection method (HPLC-UV) was not feasible due to the lack of a UV-absorbing chemical 
group at a specific wave length region within the ceramide molecule. Therefore, a 
benzoylation reaction was performed to allow a quantitative analysis of the resultant 
ceramide benzoates at 230 nm using the HPLC-UV technique (Figure 4.4).  This method was 
successful albeit time consuming and required the use of carcinogenic chemicals such as 
pyridine and benzoyl chloride and, hence experiments had to be performed in a fume 







4.2.2.1. Sample preparation and benzoylation of ceramide: 
The procedure for ceramide quantification following a benzoylation reaction using HPLC-UV  
used in this study relied on a number of previously published method (Couch et al., 1997; 
Iwamori et al., 1979; Ogawa et al., 2010; Tepper and Blitterswijk, 2000). For a full description 
of the performed method involving preparation of samples, the ceramide benzoylation steps, 
HPLC protocol, the generated standard curves and the utilized reagents and chemicals see 
Chapter Two, section 2.4.2, section 2.4.3 and section 2.4.4 respectively. 
 
 
Figure 4.4: Lower: UV-HPLC chromatogram of a hippocampal sample obtained from a 
control animal showing the ceramide peak at a retention time of 5.47. Upper: ceramide 









4.3.1. LC-MS analysis of sphingosine in rat brain and plasma following acute 
and chronic antidepressant drug administration: 
4.3.1.1. Regional differences in the basal sphingosine level among the control 
groups in rat brain: 
Prior to the evaluation of the sphingosine level in rat brain and plasma samples following 
short and long-term antidepressant drug treatment, a reliable assessment of the basal 
sphingosine level was performed among all the acute as well as the related chronic control 
groups by means of the LC-MS technique. Statistical analysis using one-way analysis of 
variance (one-way ANOVA) with Bonferroni t-test for multiple comparison showed that the 
expression of this sphingolipid molecule follows a region-specific manner.  The present study 
found that there was a clear distinction in the basal level of sphingosine in the brain regions 
examined (PFC, HP and ST).  Accordingly, acute control data analysis indicated that there was 
a significantly lower basal sphingosine content in the striatum compared to its recorded level 
in the other two brain regions (the PFC and HP) (p = 0.001, F (2,68) = 7.243) (Figure 4.5).  
 
Figure 4.5: Basal sphingosine content (mg/mg protein) in the three investigated brain 
regions in the acute control groups.  All values represent mean ± SEM (n = 24).  Abbreviations: 
PFC, prefrontal cortex; HP, hippocampus and ST, striatum. * P < 0.05 and ** p < 0.01 (one-







Also, a similar expression level was observed by analysing the chronic control groups (p = 
0008, F (2,67) = 7.890) (Figure 4.6). 
 
Figure 4.6: Basal sphingosine content (mg/mg protein) in the three investigated brain 
regions in the chronic control groups. All values represent mean ± SEM (n = 24). 
Abbreviations: PFC, prefrontal cortex; HP, hippocampus and ST, striatum. * P < 0.05 and ** p 
< 0.01 (one-way ANOVA with Bonferroni t-test). 
 
Additionally, to exclude the possible stressful effect of the repeated animals handling as well 
as their daily injections on the analysed sphingosine level, a subsequent comparison of the 
acute saline-treated rats with the corresponding chronic control animals was established 
using two-way ANOVA followed by Bonferroni t-test.  Consequently, no significant alteration 
in basal sphingosine level was detected between the overall acute and the relevant chronic 
saline-injected controls (p = 0.70) (Figure 4.7).  
 
 
Figure 4.7: A comparison of the basal sphingosine content (mg/mg protein) in the three 
investigated brain regions following both acute and chronic saline administration.  All values 
represent mean ± SEM (n = 24).  Abbreviations: PFC, prefrontal cortex; HP, hippocampus and 





4.3.1.2. Effect of acute and chronic paroxetine treatment on sphingosine level 
in rat brain:  
In the present study, for the two antidepressant drugs tested, two-way analysis of variance 
(two-way ANOVA) was performed for each analysed treatment group to test for the effects 
of treatment (paroxetine or desipramine versus saline) and brain region (the prefrontal 
cortex, hippocampus and striatal regions). Two-way ANOVA indicated a clearly significant 
effect of brain region on sphingosine level following acute paroxetine treatment (p < 0.0001, 
F (2,64) = 12.78) without a statistically significant interaction effect between the two assessed 
variables (i.e. no brain region versus treatment interaction).  The highly significant effect of 
brain region detected is possibly related to the observation that the striatum had a 
significantly lower sphingosine level compared to the other two brain regions including the 
prefrontal cortex and hippocampus and this was seen following acute administration of 
paroxetine as well as desipramine in both acute treatment groups (see Chapter Four, section 
4.3.1.1).  Subsequently, the Bonferroni post hoc analysis did not show any statistically 
significant changes in the level of sphingosine within any of the three investigated brain 
regions after acute treatment with paroxetine (Figure 4.8 and Table 4.1) compared to the 











Figure 4.8: Sphingosine content (mg/mg protein) in brain of rats following acute paroxetine       
treatment.  All values represent mean ± SEM (n = 12).  Abbreviations: PFC, prefrontal cortex; 
HP, hippocampus and ST, striatum.  
 
Similar to the effect observed with the acute paroxetine administration data, two-way ANOVA 





(p < 0.0001, F (2,65) = 18.42) (Figure 4.9).  In contrast to acute treatment of paroxetine, post-
hoc analysis using the Bonferroni t-test indicated a significant paroxetine induced decrease in 
sphingosine content in both the prefrontal cortex (p < 0.001) (Figures 4.9, 4.12 and 4.13) and 
hippocampus (p < 0.001) (Figures 4.9 and 4.14). This was however, not seen in the striatum, 
where chronic paroxetine treatment failed to significantly reduce sphingosine levels 











Figure 4.9: Sphingosine content (mg/mg protein) in brain of rats following chronic 
paroxetine treatment.  All values represent mean ± SEM (n = 12). Abbreviations: PFC, 
prefrontal cortex; HP, hippocampus and ST, striatum. *** P < 0.001 for both the PFC and HP 
but not significant for the striatum (two-way ANOVA with Bonferroni t-test). 
 
To compare the effects of acute and chronic paroxetine administration, two-way ANOVA was 
undertaken within each brain region.  In prefrontal cortex there was a highly significant 
interaction between treatment and duration (p < 0.001, F (1,42) = 10.94) and the Bonferroni 
t-test indicated a significant reduction in sphingosine level after chronic but not acute 






Figure 4.10: Sphingosine content (mg/mg protein) in the prefrontal cortex following acute 
and chronic paroxetine treatment.  All values represent fraction of controls ± SEM (n = 12). 
Abbreviations: PFC, prefrontal cortex; HP, hippocampus and ST, striatum. *** P < 0.001 for 
the chronic paroxetine group (two-way ANOVA with Bonferroni t-test). 
 
In the hippocampus, the interaction effect between treatment and duration did not quite 
reach statistical significance (p = 0.086, F (1,44) = 3.095) and although, qualitatively similar 
changes were seen as in PFC, these were not statistically significant according to the 
Bonferroni test (Figure 4.11 and Table 4.1).   
 
 
Figure 4.11: Sphingosine content (mg/mg protein) in the hippocampus following acute and     
chronic paroxetine treatment.  All values represent fraction of controls ± SEM (n = 12). 







Figure 4.12: LC-MS chromatogram of frontal cortical samples obtained from upper: control 
and middle: treated rat following chronic paroxetine administration showing sphingosine 
peak at a retention time of 4.199 and 4.242 minute respectively. Lower: LC-MS 
chromatogram showing sphingosine standard peak at a concentration of 10 mg/L and a 








Figure 4.13: LC-MS chromatogram of frontal cortical samples obtained from upper: control 
and middle: treated rat following chronic paroxetine administration showing sphingosine 
peak at a retention time of 4.216 and 4.224 minute respectively.  Lower: LC-MS 
chromatogram showing sphingosine standard peak at a concentration of 10 mg/L and a 








Figure 4.14: LC-MS chromatogram of hippocampal samples obtained from upper: control 
and middle: treated rat following chronic paroxetine administration showing sphingosine 
peak at a retention time of 4.204 and 4.222 minute respectively. Lower: LC-MS 
chromatogram showing sphingosine standard peak at a concentration of 10 mg/L and a 






4.3.1.3. Effect of acute and chronic desipramine treatment on sphingosine 
level in rat brain:  
Acute desipramine administration revealed a clearly significant effect of brain region (p = 
0.001, F (2,62) = 7.718), whereas no significant effect of treatment or interaction effect (brain 
region x treatment) was observed.  A subsequent Bonferroni post hoc analysis did not show 
any statistical significance in the sphingosine level in any of the three brain regions explored 
of the drug treated rats compared to their saline treated controls (Figure 4.15 and Table 4.2).  
 
 
Figure 4.15: Sphingosine content (mg/mg protein) in brain of rats following acute 
desipramine treatment. All values represent mean ± SEM (n = 12). Abbreviations: PFC, 
prefrontal cortex; HP, hippocampus and ST, striatum. 
 
Two-way ANOVA following chronic desipramine administration indicated a significant effect 
of brain region (p < 0.05, F (2,62) = 4.445) (Figure 4.11) but post-hoc analysis did not indicate 
significant changes in any of the three brain regions.  However, there was a non-significant 












Figure 4.16: Sphingosine content (mg/mg protein) in brain of rats following chronic 
desipramine treatment. All values represent mean ± SEM (n = 12). Abbreviations: PFC, 
prefrontal cortex; HP, hippocampus and ST, striatum. 
 
Consistent with the reported finding after chronic paroxetine administration, treatment with 
desipramine in prefrontal cortex indicated a significant interaction between treatment and 
duration (p < 0.05, F (1,40) = 4.798) and Bonferroni post hoc analysis revealed that chronic 
but not acute desipramine treatment significantly decreased sphingosine content (Figure 4.17 
and Table 4.2).  Within both the hippocampus and striatal region, no significant changes were 
recorded following either acute or chronic desipramine compared with the relevant controls 
(Figure 4.16 and Table 4.2). 
 
Figure 4.17: Sphingosine content (mg/mg protein) in the prefrontal cortex following acute 
and chronic desipramine treatment.  All values represent fraction of controls ± SEM (n = 12). 
Abbreviations: PFC, prefrontal cortex; HP, hippocampus and ST, striatum. * P < 0.05 for the 





4.3.1.4. Effect of acute and chronic antidepressant drug treatment on plasma 
level of sphingosine:  
Analysis of the generated plasma data is detailed below: the two-way ANOVA indicates no 
significant interaction effect comparing acute versus chronic desipramine treatment in 
plasma.  However, the subsequent Bonferroni t-test showed a significant difference (p < 0.05) 
between control and treatment groups following acute desipramine treatment but not after 
chronic administration (Figure 4.18).  In contrast, similar qualitative changes were seen in the 
plasma following paroxetine treatment, although the two-way ANOVA revealed no significant 
interaction effect comparing acute versus chronic paroxetine treatment. The post hoc 
analysis displayed a trend toward a reduced sphingosine level in plasma after acute 
paroxetine administration without any detected significant difference following its chronic 
treatment (Figure 4.19).  
 
Figure 4.18: Sphingosine content (mg/mg protein) in plasma of rats following acute and 
chronic desipramine treatment. All values represent fraction of controls ± SEM (acute 
desipramine n = 8) (chronic desipramine n = 12). * P < 0.05 for the acute desipramine group 
(two-way ANOVA with Bonferroni t-test). 
 
 
Figure 4.19: Sphingosine content (mg/mg protein) in plasma of rats following acute and 
chronic paroxetine treatment. All values represent fraction of controls ± SEM (acute 





Table 4.1: Summary of effects of acute and chronic paroxetine (5 mg/kg) on sphingosine in 










Acute     
Control 15.59 ± 1.218 15.38 ± 2.934 6.604 ± 0.681 1.849 ± 0.496 
Paroxetine 17.03 ± 2.211 16.89 ± 3.440 6.515 ± 0.574 1.056 ± 0.119 
Chronic     
Control 20.15 ± 0.857 17.25 ± 2.378 7.351 ± 1.872 2.055 ± 0.274 
Paroxetine 9.721 ± 1.327 ***    8.708 ± 1.563 *** 4.389 ± 0.661 1.765 ± 0.145 
 
Values indicate sphingosine content (mg sphingosine/mg protein) as mean ± SEM (n=12).    
*** P < 0.001 (two-way ANOVA with Bonferroni t-test).  Abbreviations: PFC, prefrontal cortex; 
HP, hippocampus and ST, striatum. 
 











Acute     
Control 19.53 ± 2.023 29.68 ± 5.395 13.29 ± 1.672 2.036 ± 0.517 
Desipramine 25.04 ± 3.787 30.31 ± 8.527 11.44 ± 1.228   0.914 ± 0.160 * 
Chronic     
Control 31.50 ± 8.759 27.49 ± 6.225 8.242 ± 1.955 1.858 ± 0.167 
Desipramine 13.45 ± 2.397 21.18 ± 4.605 11.14 ± 3.607 1.590 ± 0.173 
 
Values indicate sphingosine content (mg sphingosine/mg protein) as mean ± SEM (n=12).  
* P < 0.05 (two-way ANOVA with Bonferroni t-test).  Abbreviations: PFC, prefrontal cortex; 







4.3.1.5. Effect of antidepressant drug treatment on sphingosine level in 
cultured mouse macrophages: 
This initial study was established to examine whether the utilized antidepressant drugs induce 
an alteration of the main ceramide metabolite: sphingosine content in whole cell lysates from 
cultured mouse macrophages (RAW 264.7 cells) using LC-MS. Our data showed that 
treatment of the cultured cells with desipramine or paroxetine at a concentration of 10 µM 
for different incubation periods (either 30 minutes or 60 minutes) did not induce any 
detectable alteration of the sphingosine content compared to the corresponding control cells 
following the same treatment (Figure 4.20).  Protein measurement of the cell homogenate 
aliquots was undertaken for normalization and determination of the sphingosine 
concentration in the analysed cell samples was achieved after generating a standard curve. 
 
 
Figure 4.20:  Effect of desipramine and paroxetine treatment (10 µM) in RAW 264.7 cells on 
sphingosine content (mg/mg protein) after one-hour incubation.  All values represent mean 












4.3.2. Analysis of ceramide in rat brain following chronic paroxetine 
administration by the HPLC-UV: 
As indicated previously, a reliable detection and quantification of the ceramide content in the 
extracted lipid content from brain extracts following chronic antidepressant drug treatment 
was possible via a developed method, using high-performance liquid chromatography with 
ultraviolet detection technique (HPLC-UV). This analysis was undertaken using the same 
samples from the hippocampus of rats chronically treated with saline or paroxetine which 
had previously been assayed for sphingosine content.  In order to evaluate if changes of the 
ceramide metabolite (sphingosine) reflected changes of its precursor (ceramide), we 
measured ceramide levels from the hippocampus after chronic paroxetine using this method. 
Student’s t-test was performed to determine statistical differences between the analysed 
group means representing both the treatment group and the corresponding saline treated 
animals.  Consistent with the reported sphingosine data in the hippocampus following chronic 
paroxetine administration (Figures 4.9 and 4.23), this treatment protocol also resulted in a 
highly significant reduction of ceramide levels in this brain region compared to the saline 
injected controls (p < 0.0001) (Figures 4.21, 4.22 and Table 4.3).  
 
Figure 4.21: Ceramide content (mg/mg protein) in the rat hippocampus following chronic 









Table 4.3: Effect of chronic paroxetine treatment (5 mg/kg/day) for 15 days on ceramide  
content (mg/mg protein) in rat hippocampus.  All values represent mean ± SEM (n = 12);  
*** p < 0.001 (Student’s t-test).                                                 
 
 Ceramide content 
(mg/mg protein) 
Control 33.45 ± 4.360 
Chronic paroxetine  8.25 ± 1.534 
 
Figure 4.22: Ceramide content (mg/mg protein) in the rat hippocampus comparing control 













Figure 4.23: Sphingosine content (mg/mg protein) in the rat hippocampus comparing 
control versus chronic paroxetine-treated animals (n = 12); *** p < 0.001 (two-way ANOVA 



























































In order to investigate the association between the ceramide content and its major 
metabolite, sphingosine data from the same hippocampal brain samples were analysed by 
linear regression analysis. Such analysis indicated that there was a highly significant 
correlation between ceramide and sphingosine in both control groups (p < 0.0001, F (1,10) = 
522.4, R2 = 0.981) (Figure 4.24) and treatment groups (p < 0.0001, F (1,10) = 275, R2 = 0.965) 
(Figure 4.25) in the hippocampus of saline as well as paroxetine-treated rats (Figure 4.26). 
Figure 4.24: Linear regression analysis of ceramide (mg/mg protein) and sphingosine 
content (mg/mg protein) in the rat hippocampus of the control groups following chronic 
saline treatment.  All values represent mean (n = 12). 
Figure 4.25: Linear regression analysis of ceramide (mg/mg protein) and sphingosine 
content (mg/mg protein) in the rat hippocampus of the treatment groups following chronic 



































































Figure 4.26: Linear regression analysis of ceramide (mg/mg protein) and sphingosine 
content (mg/mg protein) in the rat hippocampus of both control and treatment groups 
following chronic paroxetine administration.  All values represent mean (n = 24). 
 
Furthermore, the overall regression analysis of hippocampal ceramide and sphingosine data 
revealed that there was a statistically significant relationship between the two molecules of 
interest (p < 0.0001, F (1,22) = 155.1, R2 = 0.876) in paroxetine treated samples and their 
corresponding controls (Figure 4.27).  
 
Figure 4.27: Linear regression analysis of ceramide (mg/mg protein) and sphingosine 
content (mg/mg protein) in the rat hippocampus of all control and treatment data following 
































Taken together, these experiments show that sphingosine is generally a good index of its 
parent sphingolipid ceramide. 
  
4.4. Discussion: 
4.4.1. Principal findings: 
Recent studies have indicated a role of sphingolipids in depression.  Therefore, the current 
study was conducted to investigate the effect of acute and chronic treatment of two 
antidepressant drugs: the SSRI paroxetine and the TCA desipramine on brain sphingolipid 
levels in treated rats and their corresponding saline injected controls.  For this purpose, levels 
of sphingosine and its precursor, ceramide were measured in brain regions implicated in 
depression.  These two sphingolipid molecules were reliably measured in brain structures that 
have been reported to be involved in the symptoms of depression: the prefrontal cortex, 
hippocampus and striatum (Holmes, 2008; Sheline, 2011) using LC-MS and HPLC-UV 
techniques for the measurements of sphingosine and ceramide respectively. The results 
revealed that chronic antidepressant drug administration induced a pronounced reduction of 
sphingosine content in two of the brain regions investigated (a region-specific effect) namely, 
the prefrontal cortex and hippocampus (a similar trend for a reduced sphingosine level in the 
hippocampus after chronic desipramine administration was also detected) (see Figures 4.9 
and 4.16).  Thus, the observed changes in sphingosine content were stronger in the prefrontal 
cortex, whereas the striatum failed to display any significant changes. Interestingly, the 
marked decrease in sphingosine level was recorded only following chronic and not after the 
acute treatment.    
  
In contrast, acute treatment with desipramine and paroxetine exhibited no statistically 
significant changes in the level of sphingosine in any of the three brain regions examined (see 
Figures 4.8 and 4.15).  On the other hand, the obtained plasma data showed a significant 
reduction after acute desipramine and a trend to a reduced sphingosine level after acute 
paroxetine treatment.  In contrast both drugs failed to significantly alter plasma levels after 
chronic administration of both drugs (see Figures 4.18 and 4.19). Additionally, an initial cell 





alteration in the sphingosine content in cultured cells following treatment with 
antidepressant drugs compared to the corresponding control cells.  Consistent with the 
sphingosine data, using the HPLC-UV, the hippocampal ceramide level indicated a significant 
reduction in the treated animals compared to their corresponding saline injected controls 
(Figure 4.20) with a significant correlation between hippocampal ceramide and sphingosine 
levels following chronic paroxetine treatment (see Figures 4.24, 4.25, 4.26 and 4.27 
respectively).  
 
4.4.2. Chronic antidepressant induced alteration of sphingolipids:   
In the present study, mass spectrometry as well as HPLC-UV data showed that chronic 
antidepressant drug treatment resulted in a significant reduction of sphingosine levels in the 
hippocampus and the prefrontal cortex but not in the striatum.  In addition, there was a 
concomitantly pronounced decrease in hippocampal ceramide content in paroxetine-treated 
rats compared to their corresponding saline-injected controls. The study also clearly 
demonstrated that in the hippocampal samples, levels of sphingosine were significantly 
correlated with its parent lipid ceramide in both control and treated animals. Therefore, 
sphingosine levels appear to be a reliable index of ceramide in rat brain extracts.  
Interestingly, the observed findings from our study were consistent with a previous study 
reporting a similar reduction of hippocampal ceramide level following long-term 
antidepressant drug therapy (Gulbins et al., 2013).  Several preclinical studies indicate that 
chronic stress to rodents, results in enhanced depression-related behaviours when using 
animal models of depression (Bai et al., 2017; Gulbins et al., 2013, 2015; Kornhuber et al., 
2014; Schneider et al., 2017).  In this respect, a recent animal study revealed that exposure to 
chronic unpredicted stress for four weeks via applying a randomized daily exposure for one 
hour to one of the following stressful conditions: vibration, overcrowding, exposing the 
animal to a cold water at 18°C or a hot air stream resulted in increased ceramide level in the 
prefrontal cortex and hippocampus.  Likewise, indicating an increased synthesis of ceramide, 
a decrease in the content of the precursor to ceramide namely sphingomyelin was recorded 
in these brain regions of the same chronically stressed rats compared to their relevant 
controls (Oliveira et al., 2016).  This previously reported effect could be explained by an 





pathways of ceramide synthesis such as the de novo and the salvage pathways (see pages 3 
and 4 in the introduction) could also contribute to these chronic stress induced enhancements 
of ceramide (Gault et al., 2010; Oliveira et al., 2016).  In accordance with a recent study 
(Gulbins et al., 2013), the present findings from our lipid measurements suggest that the 
detected sphingolipids alteration following chronic antidepressant drug treatment in the 
prefrontal cortex and hippocampus may be related to a dysregulation of the main sphingolipid 
metabolizing enzymes, in particular acid sphingomyelinase (ASM) in both brain regions (for 
detailed information see the relevant Chapter Five).  Furthermore, a number of animal and 
human studies indicated that these particular brain regions which are implicated in the 
pathogenesis of depression may undergo a structural as well as functional impairment 
following exposure to chronic stress (reduction in cortical and hippocampal volume, altered 
transmission, impaired synaptic plasticity of the hippocampus) (Bai et al., 2017; Oliveira et al., 
2016; Sousa and Almeida, 2012). Indeed, these brain regions are reported to have 
neurophysiological abnormalities in depressed patients as indicated by previous post-mortem 
and neuroimaging studies (Drevets, 2000; Lee et al., 2009).  As being the focus of many recent 
studies and in support of our data, it was mentioned that the stress induced increase of 
ceramide level can be reversed or normalized by the potential use of antidepressant drugs 
such as fluoxetine, paroxetine, desipramine and maprotiline (Dinoff et al., 2017; Gulbins et 
al., 2013, 2015, Kornhuber et al., 2008, 2011, 2014). Consistent with our findings, a previous 
animal study demonstrated that chronic administration of fluoxetine and amitriptyline at 
similar doses to those which achieve therapeutic plasma concentrations in depressed patients 
resulted in a reduced activity of acid sphingomyelinase and decreased ceramide 
concentration in the hippocampus of “depressed” mice (Gulbins et al., 2013). Further, this 
coincided with an increase of neuronal maturation and proliferation (i.e. neurogenesis) 
compared to the corresponding controls. In addition, a reduction of depression-like 
behaviours was noted (reduced sucrose preference and neglect of the animal coats) (Gulbins 
et al., 2013). Taken together, these studies indicate a relationship between antidepressant 
induced reduction of ceramide and a reduction in signs of depression in animals. In this 
regard, the same study also revealed that non-stressed mice over-expressing acid 
sphingomyelinase or had a deficiency of the acid ceramidase enzyme or where injected with 
C16 ceramide into the hippocampus showed a decrease in neurogenesis which coincided with 





normalized by antidepressant drug treatment (Gulbins et al., 2013). Hence, the recorded 
findings in the current study are in line with previously reported work on ceramide and its 
implication in depression as well as its pharmacological treatment.  Overall, the present study 
is unique, since it performed regional measurements of sphingosine following both acute and 
chronic administration of paroxetine and desipramine.  In this respect, the current study also 
detected marked regional differences in the effect of both drugs.  Thus, effects were generally 
more pronounced in brain regions strongly associated with symptoms and treatment of 
depression i.e. the prefrontal cortex and the hippocampus compared to the striatum (Drevets 
et al., 2008; Lee et al., 2013; McEwen and Morrison, 2013).  In summary, the generated data 
from the present study appear to support and extend the knowledge of the recently emerged 
lipid hypothesis of depression and its drug treatment (see Chapter One, section 1.3.3).   
   
4.5. Conclusion: 
The current study showed that chronic antidepressant drug treatment induced a clear 
reduction of sphingosine level in the prefrontal cortex and hippocampus of the rat.  In this 
respect, chronic administration of the SSRI paroxetine appeared to be more effective 
compared to chronic treatment of the TCA desipramine.  In contrast, no significant changes 
were recorded in the level of sphingosine within any of the three-investigated brain regions 
following acute treatment. Strikingly, chronic paroxetine administration also induced a highly 
significant reduction of ceramide level in the hippocampus of paroxetine treated rats 
compared to the corresponding saline injected controls.  Furthermore, regression analysis of 
hippocampal ceramide and sphingosine data revealed that there was a statistically significant 
correlation between the two sphingolipid molecules after chronic paroxetine or saline 
treatment.  Therefore, indicating that brain sphingosine levels serve as reliable index of its 
precursor sphingolipid ceramide.  In this regard, here the reported reduction of sphingolipids 
following chronic antidepressant drug treatment could be due to a dysregulation of the main 
sphingolipid-metabolizing enzymes particularly acid sphingomyelinase.  Thus, in Chapter Five, 
we have extended this study by looking into the possibility that this enzyme and/or acid 
ceramidase are indeed implicated in the effects seen in the current chapter.  This was 
achieved by measuring mRNA levels for these two enzymes by using the RT-PCR technique.  





drugs, our results show that long-term treatment with antidepressant drugs may be required 
to induce reductions of the brain ceramide content as well as its main metabolite sphingosine 









































Effects of antidepressant drug treatment on gene expression for two key 
enzymes of the rat brain sphingolipid pathway using real-time quantitative 

























Ceramide is an important biomolecule of the sphingolipid family and has a central role for the 
normal function of biological cell membranes.  Also, it is a main sphingolipid precursor which 
undergoes synthesis and metabolism to generate other simple (e.g. sphingosine) or complex 
sphingolipids (e.g. sphingomyelin) through actions of the key metabolizing enzymes: acid 
sphingomyelinase (ASM) and acid ceramidase (AC) respectively (see Figure 5.2) (Dinoff et al., 
2017; Gangoiti et al., 2010).  Recently, it has been suggested that membrane sphingolipids 
possibly via changes in the expression of ASM and AC play a role in the pathogenesis of 
depression and the therapeutic effect of antidepressant drugs (Canals et al., 2011; Müller et 
al., 2015; Osherovich, 2013).  Ceramide is involved in cell growth arrest and apoptosis 
(Hannun and Obeid, 2008).  In comparison, the ceramide metabolite sphingosine (which is 
formed by the enzyme AC) when phosphorylated into sphingosine-1-phosphate mediates 
cellular growth and proliferation (Futerman and Hannun, 2004). The balance between these 
different sphingolipids which often regulate opposing biological functions is critical in 
maintaining a proper dynamic, regarding the balance between cellular growth and death and 
thereby, determining cellular fate (Cuvillier et al., 2001; Spiegel, 1999).  In addition, it has 
been reported that activation of the enzyme ASM with the resultant accumulation of 
ceramide has been linked to several brain disorders including Alzheimer's disease and major 
depressive disorder (He et al., 2010; Kornhuber et al., 2005, 2011).  In this context, a previous 
clinical study conducted on depressed patients recorded an increase of ASM activity during 
episodes of depressive symptoms compared to corresponding healthy controls (Kornhuber et 
al., 2005). Moreover, a number of recent studies identified several antidepressant drugs as 
functional inhibitors of ASM activity such as the TCA drugs: desipramine, imipramine, 
amitriptyline and nortriptyline; the tetracyclic antidepressant drug maprotiline (Canals et al., 
2011; Kornhuber et al., 2010) as well as the SSRIs: fluoxetine, paroxetine and sertraline 
(Kornhuber et al., 2008, 2011).  Further and in line with these previously reported findings, 
another study indicated that administration of the antidepressant drugs, fluoxetine and 
amitriptyline at doses similar to those which achieve therapeutic plasma concentrations in 
patients with depression resulted in a decline in hippocampal ceramide concentration.  An 
effect which coincided with a reduction of ASM activity and a prevention of depression-like 





previous genetic and pharmacological studies showed that genetic deficiency of AC or over 
expression of ASM enzymes in mice induced depression-related behavioural effects such as a 
pronounced reduction in sucrose preference, a notable delay in the novelty-suppressed 
feeding test, a delayed forced swim test and a marked neglect of the animal coats. 
Interestingly these enhanced effects in models of depression coincided with increased levels 
of hippocampal ceramide compared to the corresponding controls.  Further, and in support 
of a role for ceramide in depressive behaviours, ceramide levels were normalized following 
chronic antidepressant drug treatment (Gulbins et al., 2013, 2015).  
 
5.1.1. The main sphingolipid metabolizing enzymes: 
Ceramide undergoes generation or degradation via action of the enzymes outlined below and 
as illustrated in Figure 5.2:    
5.1.1.1. Acid sphingomyelinase (ASM):  
Sphingomyelin phosphodiesterase 1 (SMPD1) is the gene that encodes the acid 
sphingomyelinase (ASM) glycoprotein, a water-soluble lysosomal hydrolase that is active in 
its membrane-bound form to catalyse the hydrolysis of sphingomyelin into ceramide and 
phosphorylcholine at an acidic pH (the optimum pH for the peak enzyme activity is 5.0) (Figure 
5.2) (Canals et al., 2011; Linke et al., 2001).  The enzyme ASM is present in different cellular 
locations: lysosomes, mitochondria and on the outer surface of the  plasma membrane as 
well as the extracellular space (Grassme et al., 2001; Gulbins et al., 2015).   
 
5.1.1.2. Functional inhibition of acid sphingomyelinase (ASM):  
By using both in vivo as well as in cell culture models, a class of drugs have recently been 
identified which all share an important property regarding the function of ASM.  This diverse 
group includes many drugs i.e. various antidepressant drugs (e.g. paroxetine, fluoxetine, 
desipramine and amitriptyline), amlodipine (a calcium-channel blocker), clomiphene (an 
ovulatory stimulant), promethazine (a phenothiazine with antipsychotic and antihistamine 
actions), mebeverine (an anticholinergic), loperamide (an anti-diarrhoeal) and promazine (an 
antipsychotic) (Kornhuber et al., 2008, 2010, 2011).  These compounds are often described as 





group and a hydrophobic (a lipophilic) domain (Funk and Krise, 2012; Kornhuber et al., 2010).  
Also, most of these small molecules are weak bases with a molecular weight lower than 500 
and are likely to cross the blood-brain barrier (BBB) (Kornhuber et al., 2010, 2011).  Thus, they 
have the ability to accumulate inside the acidic lysosomal apparatus of the neurons and 
therefore, they can potentially induce an indirect or a functional inhibition of the enzyme ASM 
without directly inhibiting the activity of the enzyme (Kornhuber et al., 2009, 2010, 2011).  
Hence, this group of drugs are referred to as “functional inhibitors of ASM” (Figure 5.1).  As a 
consequence of this action, it could be speculated that this type of drugs (e.g. paroxetine and 
desipramine) dependent on the validity of the “ceramide hypothesis of depression” could 
contribute to their usefulness in the treatment of this condition (Kornhuber et al., 2010, 
2011). Inside the acidic lysosomal compartment a pH of 4.8 is maintained by an energy 
dependent proton pump and the inner surface of the lysosomal membrane is shown to be 
negatively charged, whereas the enzyme (i.e. ASM) carries a positive charge (Kölzer et al., 
2004; Kornhuber et al., 2009, 2014).  Therefore, ASM is electrostatically attached to the inner 
phase of the lysosomal membrane, thereby it will be protected from its inactivation by the 
low pH in the acidic lysosomal lumen as well as from proteolytic degradation via the lysosomal 
proteases (Bohley and Seglen, 1992; Kölzer et al., 2004; Kornhuber et al., 2010, 2011).  
Potential functional inhibitors of ASM such as the two amphiphilic antidepressant drugs 
paroxetine and desipramine used in the present study have been shown to pass through the 
lysosomal membrane in their neutral or uncharged forms by a process of passive diffusion 
(Kornhuber et al., 2009, 2014).  Thus, due to the amphiphilic nature of the drug (i.e. the TCA 
desipramine) inside the lysosome, desipramine becomes positively charged and hence, loses 
its ability to pass through the lysosomal membrane, which is mainly permeable to uncharged 
molecules (Kornhuber et al., 2010). Subsequently, the intra-lysosomal concentration of the 
drug becomes high (intra-lysosomal accumulation of the positively charged or protonated 
drug form) and thereby, resulting in a displacement of the positively charged ASM from its 
binding place within the inner lysosomal membrane(Beckmann et al., 2014; Kornhuber et al., 
2010, 2014). The resultant detachment of the ASM enzyme from the intra-lysosomal 
membrane promotes its subsequent inactivation by the low pH and/or by a proteolytic 
breakdown.  This process is outlined in Figure 5.1 and could be achieved by one of the two 
antidepressant drugs investigated in the present study as an example of a functional inhibitor 





Possibly of clinical relevance, it has also been reported that a functional inhibition of ASM by 
fluoxetine and amitriptyline was seen at a plasma concentration within the therapeutic range 
for the clinical treatment of depression (Gulbins et al., 2013; Kornhuber et al., 2014).   
 
 
Figure 5.1: Mechanism of action of the functional inhibitors of ASM (Beckmann et al., 2014). 
The amphiphilic tricyclic compound (i.e. desipramine) accumulates in its charged form inside 
the acidic lysosomes, thus displacing ASM from the inner lysosomal membrane leading to 
inactivation or proteolysis of the enzyme in the acidic lysosomal lumen.  This mechanism is 
known as functional inhibition of ASM. 
 
5.1.1.3. Acid ceramidase (AC):  
The N-acylsphingosine amidohydrolase 1 (ASAH1) gene encodes the acid ceramidase (AC) 
enzyme, a lysosomal protein that hydrolyzes ceramide into sphingosine and free fatty acid at 
an optimum pH of 4.5 (Figure 5.2) (Canals et al., 2011; Kornhuber et al., 2010).  It was reported 
that AC activity has shown to be stimulated by various cellular stressors such as exposure to 
UV radiation or chemotherapy (Canals et al., 2011; Linke et al., 2001).  In support of the effect 
of antidepressant drugs on the AC enzyme, a previous study demonstrated that the TCA 
desipramine induced a down-regulation of the AC activity in cultured cancer cell lines, an 
effect that is accompanied by its inhibitory effect on the enzyme acid sphingomyelinase (dual 
effect of desipramine on both ASM and AC) (Elojeimy et al., 2006).  In this context, recent 
studies recorded that activity of the enzyme AC appears to be lower compared to the ASM 
activity as determined in postmortem  brain tissues from patients with Alzheimer's disease 
and normal controls (He et al., 2010; Kornhuber et al., 2010).  Furthermore, previous studies 





(inherited deficiency of AC, resulting in lysosomal accumulation of ceramide in the brain and 
several other body organs including: kidney, lungs, around the joints and in the subcutaneous 
tissues) (Canals et al., 2011; Ehlert et al., 2007; Koch et al., 1996).  On the other hand, it has 
been shown that up-regulation of the AC enzyme is associated with tumour progression and 
enhanced resistance of tumour cells to anticancer treatment including both radiotherapy and 
chemotherapeutic treatments (Saied and Arenz, 2014).   
 
Figure 5.2: Metabolic pathways of sphingolipids including the main metabolizing enzymes. 
A-SMase, acid sphingomyelinase; A-CDase, acid ceramidase; CerSs, ceramide synthases; C1P, 
ceramide-1-phosphate; CK, ceramide kinase; C1PP, ceramide-1-phosphate phosphatase; KDS, 
3-keto-dihydrosphingosine reductase; DES, dihydroceramide desaturase; SMSs, 
sphingomyelin synthases; SphKs, sphingosine kinases; SPP, sphingosine-1-phosphate 




In chapter Four, this project showed that two different types of antidepressant drugs namely, 
the SSRI paroxetine and the TCA desipramine significantly reduced levels of ceramide and its 
main metabolite sphingosine in rat brain regions following chronic but not acute 
administration.  To better understand the mechanism of action behind this effect, the current 
study was designed to investigate the effect of these two antidepressant drugs on gene 





the experiments of the current chapter aimed to test the hypothesis that chronic 
antidepressant drug treatment reduces the gene expression level for SMPD1 and ASAH1 the 
genes encoding, the ASM and AC enzyme proteins respectively.  This study was established in 
the same brain regions explored in Chapter Four (the prefrontal cortex, hippocampus and 
striatum).  Specifically, the present study examined the following: 
• By using the real-time quantitative polymerase chain reaction technique (RT-qPCR), 
the expression levels of the SMPD1 and ASAH1 genes were recorded in brain samples 
from rats chronically treated (once daily injections for 15 days) with antidepressant 
drugs (desipramine or paroxetine) or the corresponding vehicle controls.  
• To investigate the occurrence of any brain region-specific effect by chronic 
antidepressant drug treatments on the gene expression of SMPD1 and ASAH1.   
 
5.2. Materials and method: 
5.2.1. Drug treatment: 
Full details of the antidepressant drug treatment were previously described in Chapter Two, 
section 2.6.4.  Briefly, to investigate the effect of chronic antidepressant drug administration 
on the gene expression level for the key sphingolipid-metabolizing enzymes (ASM and AC), 18 
male Sprague-Dawley rats (body weights ranging from 122-142 g at the start of the 
experiment) were separated into three groups (6 animals/group/cage).  All rats were weighed 
throughout the injection period and the first group (control group) received a single saline 
injection 0.9% (1 ml/kg/day, i.p), the second group (paroxetine group) received a single 
paroxetine injection (5 mg/kg/day, i.p), whereas the third group (desipramine group) received 
a single desipramine injection (10 mg/kg/day, i.p).  All animals were injected once daily at 10 
am for 15 days.  Based on previously published studies investigating biochemical/molecular 
long-term effects of antidepressant drugs, rats were sacrificed 24 hour after the final injection 
(Andriamampandry et al., 2002; Bock et al., 2013; Gąska et al., 2012; Lee et al., 2010; Nakatani 
et al., 2004; Yamada et al., 2003).  Then, the whole brain was removed and brain regions 
including the prefrontal cortex (PFC), hippocampus (HP) and the striatum (ST) were rapidly 
dissected out on ice as before.  The regional brain samples were then quickly snap-frozen in 
isopentane on dry ice, brain samples were then weighed and stored at - 80°C until subsequent 





5.2.2. Measurement of the mRNA of genes encoding the sphingolipid-
regulating enzymes, ASM and AC after chronic antidepressant drug treatment: 
In this chapter, the real-time quantitative polymerase chain reaction (RT-qPCR) assay was 
employed to quantify changes in mRNA levels of SMPD1 and ASHA1, genes encoding the ASM 
and AC enzymes respectively (see Chapter Two, Figure 2.24).  This was performed in regional 
brain samples from rats treated chronically with either paroxetine, desipramine or the 
corresponding vehicle (saline) once daily for 15 days. The primers used were designed and 
selected as previously described (Chapter Two, section 2.6.8) and the procedures of RNA 
extraction, DNA digestion, complementary DNA (cDNA) synthesis and the RT-qPCR process 
have been described in detail in Chapter Two, sections 2.6.5-2.6.9 respectively.    
 
5.2.3. Data presentation and statistical analysis: 
The SMPD1 and ASAH1 mRNA levels were measured following chronic antidepressant drug 
treatment (paroxetine and desipramine) in the three examined brain regions (PFC, HP and 
ST).  The recorded values indicate the normalised expression levels of the mRNA of the two 
analysed genes of interest: SMPD1 and ASAH1 and were expressed as fraction of controls ± 
standard errors of the mean (SEM) for all regional brain samples (treated and controls). 
Additionally, the generated data were evaluated and normalised relative to two reference 
genes: beta-actin (β-actin) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) which 
were selected based on published studies investigating effects in rodent brain tissue 
(Bonefeld et al., 2008; Swijsen et al., 2012). Statistical analysis was performed by one-way 
analysis of variance (one-way ANOVA followed by Bonferroni t-test) using Prism 5.0 Software 
(Graph Pad Software) and statistically significant difference was set at a level of p < 0.05.  
 
5.3. Results: 
5.3.1. Effect of chronic antidepressant drug administration on the mRNA levels 
for the reference gene (β-actin): 
The reference genes utilized in this study were selected and adopted on the bases of 
previously published studies (Bonefeld et al., 2008; Swijsen et al., 2012), taking into account 





assay conditions.  From these previous studies two different reference genes (housekeeping 
genes) were chosen and tested for normalisation of the generated data namely, β-actin 
(ACTB) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Figures 5.3 and 5.4).  Based 
on these initial experiments, the β-actin gene (ACTB) showed the most stable expression and 
therefore, used for the further normalisation of our data.     
 
Figure 5.3: Visualisation of the β-actin PCR products by 2% agarose gel electrophoresis.  The 
first lane represents a ladder (a standard marker), then a negative control which is followed 
by the PCR products of the housekeeping gene (β-actin). 
 
 
Figure 5.4: Visualisation of the GAPDH PCR products by 2% agarose gel electrophoresis.  The 
first lane represents a ladder (a standard marker), then a negative control and the RNA 
product of this gene (no visible band) followed by the PCR products of the housekeeping gene 
(GAPDH). 
 
Statistical analysis using one-way analysis of variance (one-way ANOVA) revealed no 
significant alteration in the average expression level of β-actin in the three investigated brain 
regions following either chronic paroxetine or desipramine treatment in comparison with the 
relevant saline-injected controls. Thus, indicating a stable expression level of the reference 









Figure 5.5: A comparison of the average expression levels of β-actin (ACTB) in the prefrontal 
cortex following both chronic saline (control) and drug treatment (desipramine and 
paroxetine).  All values represent fraction of controls ± SEM (n = 6). 
 
 
Figure 5.6: A comparison of the average expression levels of β-actin (ACTB) in the 
hippocampus following both chronic saline (control) and drug treatment (desipramine and 







Figure 5.7: A comparison of the average expression levels of β-actin (ACTB) in the striatum 
following both chronic saline (control) and drug treatment (desipramine and paroxetine).  
All values represent fraction of controls ± SEM (n = 6). 
 
5.3.2. Effect of chronic antidepressant drug administration on SMPD1 mRNA 
levels: 
5.3.2.1. Effect of chronic paroxetine treatment on SMPD1 mRNA levels: 
The expression of the SMPD1 gene which encodes the ASM enzyme was measured following 
long-term paroxetine treatment (once daily for 15 days) in rat brain regions (prefrontal cortex, 
hippocampus and striatum) using RT-qPCR method. The Bonferroni t-test indicated a 
significant reduction of SMPD1 mRNA levels in the hippocampus of the chronic paroxetine-
treated rats compared to their corresponding saline-injected controls (p = 0.015, F (2,17) = 
5.610) (Figure 5.8 and Table 5.1).    
 
Figure 5.8: Normalised expression level of the SMPD1 gene in the hippocampus following 
chronic desipramine and paroxetine treatment (β-actin normalisation). All values represent 





In the prefrontal cortex, similar qualitative changes were observed following chronic 
paroxetine treatment, however and according to the Bonferroni t-test, this reduction failed 
to reach significance (p = 0.116) (Figure 6.9 and Table 6.1).  In the striatum, paroxetine also 
had a tendency to decrease levels of the SMPD1 gene, however likewise in the prefrontal 
cortex, this effect remained non-significant here too (p = 0.322) (Figure 5.10 and Table 5.1).   
 
 
Figure 5.9: Normalised expression level of the SMPD1 gene in the prefrontal cortex 
following chronic desipramine and paroxetine treatment (β-actin normalisation).  All values 
represent fraction of controls ± SEM (n = 6). 
 
 
Figure 5.10: Normalised expression level of the SMPD1 gene in the striatum following 
chronic desipramine and paroxetine treatment (β-actin normalisation).  All values represent 






5.3.2.2. Effect of chronic desipramine treatment on the SMPD1 mRNA level: 
Consistent with the recorded findings after chronic paroxetine administration, in the 
hippocampus, treatment with desipramine similarly showed a significant reduction of SMPD1 
mRNA levels in the drug-treated samples compared to the relevant controls as revealed by 
the Bonferroni t-test (p < 0.05, F (2,17) = 5.610) (Figure 5.8 and Table 5.1). Also, in the 
prefrontal cortex, there was a non-significant trend towards a reduced expression level of the 
SMPD1 gene (Figure 5.9 and Table 5.1). Further likewise with paroxetine in the striatum 
desipramine failed to significantly reduce expression levels of SMPD1 (Figure 5.10 and Table 
5.1). 
 
5.3.3. Effect of antidepressant drug administration on the ASAH1 mRNA level: 
5.3.3.1. Effect of chronic paroxetine treatment on the ASAH1 mRNA level: 
Measurement of the expression level of the ASAH1 gene which encodes the acid ceramidase 
(AC) enzyme was successfully established after chronic paroxetine treatment (once daily 
injections for 15 days) in the three investigated rat brain regions by means of the RT-qPCR 
technique.  With regards to the SSRI paroxetine, it was found that in two of the three analysed 
brain regions, namely the prefrontal cortex and hippocampus, chronic paroxetine treatment 
induced a non-significant trend to reduce ASAH1 mRNA levels (Figures 5.12, 5.11 and Table 
5.1).  However, in the striatum, samples from paroxetine treated rats had very similar levels 
of ASAH1 mRNA as compared to their corresponding control samples (Figure 5.13 and Table 
5.1).  
 
5.3.3.2. Effect of chronic desipramine treatment on ASAH1 mRNA levels: 
In comparison, to the effect by the SSRI paroxetine which failed to significantly alter ASAH1 
mRNA levels, chronic administration of the TCA desipramine (once daily for 15 days) 
significantly reduced the expression of the ASAH gene in the hippocampus. Thus, the 
Bonferroni t-test revealed a significantly reduced ASAH1 mRNA level in comparison with the 









Figure 5.11: Normalised expression level of the ASAH1 gene in the hippocampus following 
chronic desipramine and paroxetine treatment (β-actin normalisation).  All values represent 
fraction of controls ± SEM (n = 6). * P < 0.05 (one-way ANOVA with Bonferroni t-test).  
 
In addition, similar qualitative changes were observed in the prefrontal cortex, although they 
were not statistically significant (p = 0.126) (Figure 5.12 and Table 5.1).  Likewise, to 
paroxetine in the striatum, samples from desipramine treated rats had marginally similar 
levels to samples collected from the corresponding saline injected control group (Figure 5.13 
and Table 5.1). 
 
 
Figure 5.12: Normalised expression level of the ASAH1 gene in the prefrontal cortex 
following chronic desipramine and paroxetine treatment (β-actin normalisation).  All values 






Figure 5.13: Normalised expression level of the ASAH1 gene in the striatum following 
chronic desipramine and paroxetine treatment (β-actin normalisation).  All values represent 
fraction of controls ± SEM (n = 6). 
 
Table 5.1: Normalised expression level of the target genes in rat brain following chronic 
desipramine and paroxetine treatment (β-actin normalisation) using real-time qPCR 















Control 2.005 ± 0.910  4.572 ± 1.279 1.403 ± 0.486 
Desipramine 0.459 ± 0.168 1.226 ± 0.638 * 0.920 ± 0.454 
Paroxetine 0.520 ± 0.113  1.959 ± 0.504 1.525 ± 0.288 
 
SMPD1 
Control 7.012 ± 3.774  6.388 ± 2.326   1.060 ± 0.414 
Desipramine 0.488 ± 0.310 0.578 ± 0.353 * 0.597 ± 0.148 
Paroxetine 0.843 ± 0.372 1.025 ± 0.239 * 0.515 ± 0.139 
 
Values indicate the normalised expression level of the target genes: ASAH1 and SMPD1 as 









5.4.1. Principal findings: 
Clinical and pharmacological research have shown that high expression levels of AC in 
different cancer cells (i.e. melanoma, head and neck cancers, prostate and colon cancers) 
render these tumour cells to be more resistant to the pharmacological induction of apoptosis 
compared to normal cells (Pizzirani et al., 2013; Zeidan et al., 2008). This is likely to be 
associated with the enhanced tumour resistance to radiotherapy or chemotherapy, thus 
resulting in an increased risk of cancer relapse and progression (Pizzirani et al., 2013; Saied 
and Arenz, 2014). Indeed, small-molecules were recently identified as chemosensitizing 
compounds (i.e. carmofur) which promote death of cancer cells via AC inhibition (Canals et 
al., 2011; Pizzirani et al., 2013).  Additionally, extensive work in another field of research has 
focussed on the regulation of ceramide synthesis and metabolism by the lipid-metabolizing 
enzymes acid sphingomyelinase (encoded by the SMPD1 gene) and acid ceramidase (encoded 
by the ASAH1 gene) respectively (Canals et al., 2011; Gulbins et al., 2013, 2015; Kornhuber et 
al., 2011).  However, growing body of evidence also suggests that these two enzymes have 
potential roles in depression and its therapeutic interventions (Dinoff et al., 2017; Gulbins et 
al., 2013; Kornhuber et al., 2008, 2009; Jernigan et al., 2015).  In Chapter Four, it was shown 
that two different antidepressant drugs: paroxetine and desipramine decreased levels of 
sphingolipids in brain areas related to the symptoms of depression. In this chapter, we 
therefore, sought to find a possible link between this action and two of the key target 
sphingolipid-processing enzymes.  For this purpose, we used the polymerase chain reaction 
technique for the detection and quantification of the two target genes, SMPD1 and ASAH1. 
These two genes encode the ceramide synthesising enzyme acid sphingomyelinase and the 
ceramide metabolising enzyme acid ceramidase (breaks down ceramide to sphingosine) 
respectively.  Using this technique, we reliably measured mRNA levels for SMPD1 and ASAH1 
in rat brain regions (PFC, HP and ST) after chronic paroxetine and desipramine administration 
once daily for 15 days as well as from the corresponding controls receiving saline injection for 
the same period of time.  To the best of our knowledge, this is the first study which examines 
these two genes or the corresponding proteins (i.e. AC or ASM) in regional brain samples from 
rats following antidepressant drug treatment. Interestingly expression levels for both SMPD1 





lower in the striatum (Table 5.1).  In support of a lower activity of these genes in the striatum, 
this brain region also showed the lowest sphingosine levels (Chapter Four, Tables 4.1 and 4.2).  
Importantly, results from this chapter revealed that chronic paroxetine as well as desipramine 
treatment induced a significant reduction of SMPD1 mRNA levels in the hippocampus of the 
drug-treated rats compared to their corresponding saline-injected controls (Figure 5.8).  
Similarly, administration of both drugs resulted in a reduction of SMPD1 mRNA levels in the 
prefrontal cortex, this reduction however, in contrast to what was seen in the hippocampus, 
turned out to be a non-significant (Figure 5.9). In the striatum, both drugs failed to 
significantly alter the expression of the SMPD1 gene and generally the percentage reduction 
was smaller in this part of the brain (Figure 5.10).  In addition, statistical analysis showed a 
significantly reduced expression level of the ASAH1 gene in the hippocampus after long-term 
desipramine administration (Figure 5.11), whereas a non-significant trend toward a reduced 
expression level of this target gene was observed following paroxetine treatment in the same 
specified brain region. Also, a similar trend was recorded in the ASAH1 mRNA level in the 
prefrontal cortex (Figure 5.12) without any detectable alteration in the expression level of 
this gene in the striatum after chronic treatment with both antidepressant drugs (Figure 5.13).   
 
5.4.2. Effect of antidepressant drug administration on the expression of the 
SMPD1 gene: 
In the present study, the generated data showed that chronic administration of paroxetine 
and desipramine resulted in a significant reduction of the SMPD1 mRNA levels, in the 
hippocampus and a similar non-significant trend was also recorded in the prefrontal cortex, 
but not in the striatum of the drug-treated animals in comparison with the relevant controls.  
In correspondence with these findings, our previously stated results in Chapter Four indicating 
that a similar antidepressant induced reduction of the targeted sphingolipids (sphingosine 
and ceramide) was observed only following chronic and not acute treatment (see Figures 4.9, 
4.16 and 4.21 respectively).  In connection with the possible role of ceramide in depression 
and its treatment, recent studies have explored the consequences of enhanced ceramide 
synthesis. This was established using a genetically modified mice strain that over expresses 
the ceramide synthesising enzyme ASM, which should theoretically lead to higher levels of 





genetically modified mice with increased ASM activity showed higher hippocampal ceramide 
levels compared to normal mice. Moreover, such elevated ceramide levels coincided with 
enhanced depression-like behaviours in these mice compared to genetically non-modified 
mice. These animal models of depression included: suppression of feeding and sucrose 
preference as well as various behavioural tests such as the forced swim test and the coat test 
(Gulbins et al., 2013).  In support of the role of elevated ceramide levels in depression; the 
depression like behaviours in the mice with elevated expression of the gene (i.e. the SMPD1 
gene) encoding the ASM enzyme were significantly attenuated following administration of 
the SSRI fluoxetine or the TCA amitriptyline when administered in the drinking water at a 
concentration of 80 mg/L and 180 mg/L respectively. Drinking water containing the 
antidepressant drugs were made up fresh every 48 hours and treatment continued for 35 
days (Gulbins et al., 2013). In this context, previous studies have reported that many 
antidepressant drugs act as functional inhibitors of acid sphingomyelinase activity as they all 
share a property of inhibiting this enzyme (see section 5.1.1.2) including various SSRIs (i.e. 
paroxetine) and all of the TCAs (i.e. desipramine) (Dinoff et al., 2017; Kornhuber et al., 2008, 
2010, 2014).  Thus, it was indicated that inside the acidic lysosomal compartment of the 
neurone, a slow intra-lysosomal accumulation of the antidepressant drug is developed.  
Accordingly, the charged or the protonated form of the compound become accumulated and 
trapped inside the lysosome via a continuous proton pump across the lysosomal membrane, 
this process is known as acid trapping or lysosomotropism (Kornhuber et al., 2009, 2011, 
2014), see also Figure 5.1. Consequently, this increased drug concentration inside the 
lysosome induces a detachment and subsequent inactivation of ASM activity in the acidic 
lysosomal lumen (Kornhuber et al., 2009, 2014).  Interestingly, it was found that this 
functional inhibition of ASM action develops slowly and takes 2-3 weeks to occur until the 
antidepressant drug accumulates in adequate amount in the brain tissues particularly inside 
the neuronal lysosomes (Dinoff et al., 2017; Kornhuber et al., 2009).  Hence, the time required 
for the ASM inhibition is consistent with the time needed for the onset of the therapeutic 
action of the antidepressant drugs (Kornhuber et al., 1995, 2009, 2014), thus suggesting 
further evidence for the implication of ceramide in depression and the mechanism of 





5.4.3. Effect of antidepressant drug administration on the expression of the 
ASAH1 gene: 
The present experimental dataset demonstrated that chronic desipramine administration 
induced a significant reduction of the ASAH1 gene which encodes the acid ceramidase enzyme 
specifically in the hippocampus.  On the other hand, long-term paroxetine treatment showed 
only a non-significant trend towards a reduced expression level of the target gene in the same 
brain region of the drug-treated rats compared to their corresponding controls.  Of specific 
interest, a previous cell culture study which used Chinese hamster ovary cells found that both 
ASM and AC enzymes are under a parallel regulation and a detected over-expression of the 
AC was also associated with an enhanced ASM level.  Hence, suggesting that the expression 
level of these two enzymes are correlated.  Although, the specific activity and abundance 
inside the lysosomes of the ASM and AC enzymes are still unknown, the specific activity of the 
ASM in the total human brain tissue was shown to be higher compared to that of AC (100-
fold more) (He et al., 1999, 2003; Kornhuber et al., 2010).  Accordingly, recent post mortem 
human studies on brain tissues of patients with Alzheimer's disease showed an increased 
expression of both ASM and AC enzymes. Also, there was a concomitant elevation of both 
ceramide and its metabolite sphingosine, while levels of the ceramide precursor 
sphingomyelin were found to be reduced in these patient brain samples compared to the 
normal controls (He et al., 2010).  However, it was suggested that the TCA desipramine 
induces a non-selective functional or indirect inhibition of both lysosomal ASM as well as AC 
enzymes to the same extent (dual effect) (Arenz, 2010; Elojeimy et al., 2006; Kornhuber et al., 
2010).  In contrast, the SSRIs (e.g. paroxetine and fluoxetine) were shown to preferentially 
inhibit ASM activity over AC (Kornhuber et al., 2010).  The results of the present study are in 
line with this finding, thus desipramine significantly inhibited hippocampal gene expression 
for both enzymes while paroxetine only showed significant reductions for the gene encoding 
ASM but not for the one encoding AC (Table 5.1). Furthermore, it was reported that the 
desipramine-induced inhibition of the AC enzyme was mediated by cathepsins B and L 
degradation (lysosomal proteases that are implicated in the intra-lysosomal proteolysis) 
(Elojeimy et al., 2006; Saied and Arenz, 2014).  To the best of our knowledge, the current 
study is the first to investigate the effect of antidepressant drugs on the expression levels of 





and AC respectively in brain regions implicated in depression. However, further research 
should be undertaken to improve our understanding of the mechanism underlies this action.  
 
5.5. Conclusion: 
The present study revealed that chronic antidepressant drug administration resulted in a 
significant reduction of the SMPD1 mRNA level in the hippocampus of the drug-treated rats 
compared to the corresponding saline-injected controls. Similarly, administration of both 
paroxetine and desipramine induced a non-significant trend to a reduction of the SMPD1 
mRNA level in the prefrontal cortex but not in the striatum.  Additionally, our data showed a 
significantly reduced expression level of the ASAH1 gene specifically in the hippocampus after 
chronic desipramine administration, whereas a non-significant trend toward a reduced 
expression level of this gene was observed following paroxetine treatment in the same brain 
region.  Also, a similar trend was recorded in the ASAH1 mRNA level in the prefrontal cortex 
without any detected alteration in the striatum after chronic treatment with both 
antidepressant drugs.  In this experimental set, the recorded reduction in the expression level 
of the target genes particularly in the rat hippocampus could be related to a functional or 
indirect inhibition of the corresponding lysosomal protein.  However, and with respect to the 
ASAH1 gene, there was a more pronounced effect following chronic desipramine 
administration (a drug-specific effect) indicating a similar and a non-selective inhibition of 
both enzymes in the hippocampus after desipramine treatment.  In summary, our findings 
show that long-term antidepressant drug treatment in the rat may induce a notable down-
regulation of two hippocampal genes encoding two key enzymes of the brain sphingolipid 
pathways.  Future studies should further proceed on investigating the functional inhibitors of 
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According to the monoamine hypothesis of depression, a reduction of the monoamine 
neurotransmitters including noradrenaline (NA), 5-HT and dopamine (DA) underlies the 
symptoms of depression (Schildkraut, 1965). Subsequently, extensive clinical and biochemical 
research regarding the cause of depression have focussed on central monoaminergic 
transmission.  This  particularly emphasising the brain 5-HT system as a critical target for the 
cause and treatment of depression (aan het Rot et al., 2009; Brigitta, 2002; Charnay and Leger, 
2010; Hirschfeld, 2000).  Additionally, a pharmacologically induced deficiency in brain levels 
of the monoamine neurotransmitters (i.e. achieved by tryptophan depletion) was shown to 
induce a mood lowering state in both depressed patients as well as in healthy controls 
(Krishnan and Nestler, 2008; Oosterhof, 2016). In this respect, studies conducted on 
depressed patients reported a reduced neural activity in multiple brain regions innervated by 
5-HT neurons including the prefrontal cortex, hippocampus, thalamus and amygdala which 
are all associated with depressive symptoms (Oosterhof, 2016; Pandya et al., 2012; Price and 
Drevets, 2010). Further evidence for the involvement of 5-HT are studies demonstrating 
relapse of the disease state following depletion of the 5-HT precursor tryptophan (Bremner 
et al., 1997; Merens et al., 2008; Nemeroff, 2002; Oosterhof, 2016) to patients undergoing 
remission following antidepressant drug treatment. The indole monoamine 5-HT undergoes 
metabolism by the monoamine oxidase enzyme (MAO) which is found in two subtypes: MAO-
A and MAO-B albeit both are present in 5-HT neurons, but the latter constituting the 
predominant form. 5-HT is likewise NA preferentially metabolized by MAO-A, while DA is 
mainly metabolized by MAO-B (Oosterhof, 2016; Shih and Thompson, 1999). Following 
metabolism, 5-hydroxyindoleacetic acid (5-HIAA) is produced as the major 5-HT metabolite 
and then excreted into the cerebrospinal fluid (CSF), where it can be identified as a marker of 
5-HT metabolism and neurotransmission (Oosterhof, 2016). Previous clinical and post 
mortem studies of depressed patients as well as CSF sampling from suicide attempters have 
revealed a significantly lower CSF content of 5-HIAA in these patient groups as compared to 
levels found in healthy controls, indicating reduced 5-HT metabolism/neurotransmission in 
depressed subjects (Åsberg et al., 1984; Oosterhof, 2016; Placidi et al., 2001; Roy et al., 1989). 
Further, another important finding that supports abnormalities in 5-HT neurotransmission in 





the pre-synaptic inhibitory 5-HT1A receptors.  It was observed that the binding activity of 
these autoreceptors which are located on serotonergic neurons in the dorsal raphe nucleus 
of the midbrain is significantly increased in depression (Stockmeier et al., 1998).  In contrast, 
the binding activity of the post-synaptic 5-HT1A receptors was found to be decreased, 
particularly in the prefrontal cortex of depressed patients, suggesting a reduced serotonergic 
transmission in these affected subjects (Oosterhof, 2016; Stockmeier et al., 1998).  
 
Sphingolipids together with cholesterol constitute the major lipid components of the cell 
membranes in the brain.  These lipids interact to form specific compartments in the neuronal 
cell membranes known as lipid rafts which are considered to be the main sites for the 
activation of the acid sphingomyelinase enzyme which catalyzes the degradation of 
sphingomyelin into ceramide and phosphorylcholine. Subsequently, the generation of  
ceramide results in the formation of ceramide-rich platforms in the brain cell membranes (see 
Chapter One, sections 1.9 and 1.10) (Dinoff et al., 2017; Müller et al., 2015; Schneider et al., 
2017).  Interestingly, these platforms allow clustering and binding of receptors including G-
protein coupled receptors (GPCRs) such as the 5-HT1A autoreceptors.  Thus, modulation of 
ceramide levels may affect neurochemical mechanisms including cell signaling related to 5-
HT neurotransmission (see Chapter One, section 1.10.1) (Cremesti et al., 2002; Kolesnick et 
al., 2000; Singh et al., 2012).  Importantly, it was found that this lipid-protein interaction of 
the cell membrane appeared to be essential in maintaining the function as well as the ligand 
binding activity of the 5-HT1A receptors (Singh et al., 2012).  
 
Carmofur (1-hexacarbamoyl-5-fluorouracil) is a fluorinated pyrimidine that is converted in the 
body to 5-fluorouracil (a compound that inhibit DNA synthesis by inhibiting the thymidylate 
synthetase enzyme).  Carmofur has been widely used clinically since the early eighties as an 
effective antineoplastic agent (Koyama et al., 1980).  It was reported that this compound 
exerts a potent adjuvant chemotherapeutic effect with a low toxicity via mediating a 
synergistic action with other antitumoral agents to inhibit viability, proliferation and growth 
of cancer cells.   In addition, it may facilitate death of cancer cells (induction of apoptosis), in 
particular when combined with other chemotherapeutic drugs (Sakamoto et al., 2005, 2006).  





acid ceramidase activity leading to increased intracellular ceramide levels, an effect 
associated to the drug’s anti-proliferative activity (Mahdy et al., 2009; Pizzirani et al., 2013; 
Realini et al., 2013).  Acid ceramidase (AC) is a lysosomal polypeptide composed of 395 amino 
acids that operates optimally at a pH 4.5 to catalyze the hydrolysis of ceramide into 
sphingosine and fatty acid (Saied and Arenz, 2014; Shtraizent et al., 2008). Given that 
carmofur inhibits AC, a recent study reported that injections of carmofur (10 and 30 mg/kg 
i.p) to mice resulted in a significant increase of tissue ceramide levels (cerebral cortex and 
lung) with a concomitant reduction of sphingosine content compared to the corresponding 
controls (Realini et al., 2013).  In this regard, a related study revealed that the anti-
proliferative effect of carmofur is also dependent on its potent inhibitory activity of the acid 
ceramidase enzyme and not on the capability to inhibit DNA synthesis via the generation of 
5-fluorouracil (Pizzirani et al., 2013). Despite the accumulated evidence suggesting that a 
dysregulation of the central ceramide biosynthesis could be related to depression (Dinoff et 
al., 2017; Müller et al., 2015; Schneider et al., 2017), to the best of our knowledge, definitive 
evidence regarding the link between brain ceramide and monoamine levels is still deficient.  
In Chapter Four of this thesis, we showed that antidepressant drugs indeed reduced brain 
levels of sphingolipids. In this chapter, we attempted to elucidate a link between ceramide 
levels and monoamine levels by investigating the action of the AC inhibitor carmofur on 
monoamine levels in brain regions implicated in depression.  
 
6.1.1. Aim: 
The principal aim of the present study was to investigate the effect of acute carmofur 
administration to rats on the levels of the principal monoamine neurotransmitters including: 
5-HT, DA and NA as well as some of their metabolites namely, 5-HIAA and DOPAC in brain 
regions implicated in depression.  Further, the central effect of carmofur treatment was 
evaluated by measuring levels of ceramide and its major metabolite (sphingosine) in rat brain 
regions by means of HPLC-UV and LC-MS techniques respectively (see Chapter Four).  
Specifically, the effects of acute carmofur administration or the corresponding vehicle were 
assessed on: 
• Monoamine and metabolite levels in tissue samples from rat prefrontal cortex, 





• Ceramide levels in tissue samples from the prefrontal cortex, hippocampus and 
striatum using HPLC-UV. 
• Brain sphingosine content in the same samples as above using LC-MS. 
 
6.2. Materials and method: 
6.2.1. Analysis of monoamine and metabolite levels following acute carmofur 
treatment by HPLC-ECD: 
6.2.1.1. Carmofur treatment and sample collection: 
The present study was performed to examine the effects of acute carmofur administration on 
the following monoamine neurotransmitters: 5-HT, DA as well as NA.  In addition, levels of 5-
HIAA and DOPAC, metabolites of 5-HT and dopamine respectively were measured in the three 
investigated brain regions (prefrontal cortex, PFC; hippocampus, HP and striatum, ST) from 
rats treated with carmofur or the corresponding vehicle.  For this experimental set, 12 male 
Sprague-Dawley rats were separated into two groups (6 animals/ group/cage): The first group 
(control group, n = 6) received a single i.p injection (1 ml/kg) of the vehicle that carmofur was 
dissolved in, which consisted of 70% saline, 15% Tween-80 and 15% polyethylene glycol 
(Realini et al., 2013). The second group (carmofur group, n = 6) received a single i.p injection 
of carmofur (20 mg/kg).  The rats were sacrificed one hour after the injection via the schedule 
one method and the whole brain was removed.  Then, brain regions were rapidly dissected 
out on ice and snap frozen using isopentane on dry ice, weighed and stored at - 80°C to avoid 
enzymatic degradation until subsequent analysis by the HPLC-ECD system.   
 
6.2.1.2. Sample preparation:  
The sample preparation method and the HPLC protocol including all the mobile phases and 
the stationary phase used in these experiments are fully described in Chapter Two, sections 
2.5.3 and 2.5.4.  Following homogenization of tissues in cold 0.2 M perchloric acid (PCA) (0.1 
ml per mg of tissue), the samples were centrifuged for 5 minutes and the collected clear 
supernatants were utilized for the measurement of 5-HT, DA, NA, 5-HIAA and DOPAC using 
the HPLC-ECD system. Then, the remaining sediments of the tissue homogenates were 
preserved at - 80°C for subsequent lipophilic extraction and further sphingosine and ceramide 





6.2.1.3. Calibration and determination of monoamine concentrations: 
Fresh serial dilutions of individual monoamines and their acidic metabolite standards were 
prepared in 0.2 M PCA to obtain concentrations ranging from 10-500 ng/ml.  The individual 
standards were prepared immediately before the analysis and were loaded on the column to 
identify the representative peaks of individual compounds. In brief, following 
chromatographic separation; retention times and the area under each peak were determined 
using Breeze 2 software (for details see Chapter Two, section 2.5.4.2).  Standard calibration 
curves were plotted separately for each investigated group, this was done in order to 
calculate the concentration of the monoamines and their metabolites in each analysed brain 
sample (Figures 2.20 and 2.21). Validation of the method was examined by assessing the 
linearity of the generated standard curves and their linear coefficient of variation (R2) values 
(see Chapter Two, sections 2.5.3 and 2.5.4).    
 
6.2.1.4. Data presentation and statistical analysis: 
Data from the monoaminergic HPLC study was analysed statistically by Student’s t-test using 
Prism 5.0 Software (Graph Pad Prism Software) to determine the difference between the 
control and treatment groups. Values were expressed as ng/g tissue wet weight for each 
analysed brain sample. Datasets obtained from the sphingosine and ceramide analysis using 
LC-MS and HPLC-UV respectively were tested using two-way analysis of variance (two-way 
ANOVA with Bonferroni post-hoc test) for multiple comparison.  To compare the data means, 
two-way ANOVA was used with testing the effect of two variables (treatment and brain 
region) also, observing the interaction effect between these factors or variables.  All data 
were presented as means ± standard errors of the mean (SEM) for each group.  Statistically 
significant difference was considered at a value of p < 0.05.  In addition, sample content of 
sphingosine or ceramide was calculated as mg sphingosine or ceramide/mg protein for all the 










6.2.2. Sphingosine analysis following acute carmofur treatment by LC-MS: 
6.2.2.1. Sample preparation and lipid extraction: 
After completing the monoaminergic analysis and following the removal from - 80°C, the 
frozen tissue pellets were used to perform the lipid extraction procedure in each sample 
which is described in detail in Chapter Two, section 2.3.2.  Then, the prepared brain samples 
were utilized for the subsequent sphingosine analysis in both control and treatment groups 
following acute carmofur administration using LC-MS. For detailed description of the LC-MS 
protocol used, including mobile phases, column type and LC-MS conditions see Chapter Two, 
section 2.3.3. 
 
6.2.2.2. Calibrations and determination of sphingosine concentrations: 
For quantification of sphingosine concentration in the brain samples, standard curves were 
plotted for each analysed group. Sphingosine standards were dissolved in methanol to 
produce stock solutions at 200 mg/L followed by storage at - 80˚C.  Then immediately before 
the analysis, 50 mg/L working stock and subsequent fresh serial dilutions were made in 
methanol to provide concentrations ranging from 0.2 – 15 mg/L (Figures 2.13, 2.14 and 6.16).  
Validation of the method was examined by observing the linearity of the standard curves and 
their R2 values (see Chapter Two, section 2.3.4).   
 
6.2.3. Ceramide analysis following acute carmofur treatment by HPLC-UV: 
6.2.3.1. Sample preparation and benzoylation of ceramide:  
For the measurements of ceramide in brain lipid extracts using HPLC-UV, regional brain 
samples from the carmofur treated rats and their corresponding controls had to be 
benzoylated by a derivatization reaction using benzoyl chloride and pyridine, for detailed 
description of this process see Chapter Two, section 2.4.2. After reconstitution with 
acetonitrile, the aliquots (35 µl of the benzoylated ceramide) were injected into the HPLC-UV 
system for ceramide analysis.  Further, the HPLC protocol including the mobile phases, the 






6.2.3.2. Calibrations and determination of ceramide concentrations: 
To analyse the ceramide concentration in all of the brain samples, standard curves were 
plotted before the analysis of each experimental group. Thus, the ceramide standard was 
dissolved in methanol to produce a stock solution at a concentration of 1000 mg/L which was 
stored at - 80˚C. For the generation of standard curves, a working stock solution of 50 mg/L 
and subsequent fresh serial dilutions were made up in methanol to obtain concentrations 
ranging from 0.5 – 40 mg/L (Figure 2.17).  Validation of the method was assessed by the level 
of linearity of the standard curves and their R2 values (see Chapter Two, section 2.4.3). 
 
6.3. Results: 
6.3.1. Analysis of monoamine and metabolite levels following acute carmofur 
treatment using HPLC-ECD: 
Using the HPLC-ECD technique, a reliable detection and measurement of the following 
monoamine neurotransmitters was achieved: 5-HT, dopamine (DA) and noradrenaline (NA) 
as well as the metabolites of 5-HT and DA: 5-hydroxyindoleacetic acid (5-HIAA) and 3, 4-
dihydroxyphenylacetic acid (DOPAC) respectively (Figures 6.1-6.10). Using this method, the 
present experiment shows that carmofur, a potent ceramidase inhibitor when administered 
acutely results in increases of monoamine (5-HT, DA and NA) levels in regional brain samples 
as compared to their levels in brain samples harvested from the corresponding vehicle 
injected controls (Figures 6.1, 6.8 and 6.10).  This effect was however only minor for DA and 
NA and only significant for 5-HT (Table 6.2) and for this indole monoamine, carmofur induced 
a marked increase in all three brain regions analysed (Figure 6.1).  Specifically, the results 
from this study show that a single injection of carmofur (20 mg/kg, i.p) induced a significant 
increase in 5-HT content in the three explored brain regions (PFC, HP and ST) compared to 
their corresponding controls.  In the prefrontal cortex, acute carmofur treatment resulted in 
significantly increased 5-HT levels in comparison with the relevant controls (p = 0.025, t = 
2.628, df = 10) (Table 6.1, Figures 6.1 and 6.3). Similarly, in tissue extracts from the 
hippocampus, a significant elevation of 5-HT content was detected in the treatment group 
compared to the corresponding vehicle-treated controls (p = 0.032, t = 2.491, df = 10) (Table 
6.1, Figures 6.1 and 6.4). Likewise, to the prefrontal cortex and the hippocampus, in the 





drug-treated rats compared to their controls (p = 0.027, t = 2.585, df = 10) (Table 6.1 and 
Figure 6.1).      
 
Figure 6.1: 5-HT content in (ng/g tissue wet weight) in rat brain regions following acute 
carmofur treatment. All values represent mean ± SEM (n = 6).  Abbreviations: PFC, prefrontal 
cortex; HP, hippocampus and ST, striatum. * P < 0.05 (Student’s t-test). 
 
Furthermore, in the present study the effect of carmofur on the 5-HT metabolite 5-HIAA was 
also examined in regional brain extract.  Interestingly, in contrast to whole tissue levels of the 
indolamine neurotransmitter 5-HT itself, levels of its acidic main metabolite 5-HIAA were 
consistently reduced in brain samples from carmofur treated rats compared to the 
corresponding control samples (Table 6.1 and Figure 6.2).  Following statistical analysis and 
using Student’s t-test, these carmofur induced reductions of 5-HIAA levels were highly 
significant in all three brain regions analysed; in the prefrontal cortex (p = 0.004, t = 3.687, df 
= 10) and striatum (p = 0.001, t = 4.554, df = 10) and in the hippocampus (p = 0.0005, t = 5.015, 
df = 10) see Table 6.1 and Figure 6.2.  In contrast, carmofur failed to significantly alter levels 
of the DA metabolite DOPAC in brain regional tissue extracts from the PFC and ST but both 









Figure 6.2: 5-HIAA content in (ng/g tissue wet weight) in rat brain regions following acute 
carmofur treatment. All values represent mean ± SEM (n = 6).  Abbreviations: PFC, prefrontal 




Figure 6.3: HPLC-ECD chromatogram of frontal cortical samples obtained from (A) control 
and (B) treated animals following acute carmofur administration showing 5-HT peak at a 












Figure 6.4: HPLC-ECD chromatogram of hippocampal samples obtained from (A) control and 
(B) treated animals following acute carmofur administration showing 5-HT peak at a 
retention time of 2.83 and 2.79 minutes respectively.  
 
 
Figure 6.5: DOPAC content in (ng/g tissue wet weight) in rat brain regions (PFC and ST but 
DOPAC was undetectable in the HP) following acute carmofur treatment. All values 







































Figure 6.6: (A) HPLC-ECD chromatogram showing 5-HT and 5-hydroxyindoleacetic acid (5-
HIAA) standard peaks at a concentration of 20 ng/ml and a retention time of 2.78 minute 
and 4 minutes respectively. (B) HPLC-ECD chromatogram showing dopamine (DA) standard 











Figure 6.7: HPLC-ECD chromatogram of striatal samples obtained from (A) control and (B) 
treated animals following acute carmofur administration showing dopamine (DA), 3,4-
dihydroxyphenylacetic acid (DOPAC) and 5-hydroxyindoleacetic acid (5-HIAA) peaks at a 
retention time of 1.913, 3.10 and 4.10 minutes respectively.  
  
 
Figure 6.8: Dopamine content in (ng/g tissue wet weight) in rat brain regions (PFC and ST 
but DA was undetectable in the HP) following acute carmofur treatment. All values 












Figure 6.9: HPLC-ECD chromatogram of hippocampal samples obtained from (A) control and 
(B) treated animals following acute carmofur administration showing noradrenaline (NA) 
peak at a retention time of 5.25 minute. (C) HPLC-ECD chromatogram showing NA standard 
peak at a concentration of 50 ng/ml and a retention time of 5.224 minute.   
 
 
Figure 6.10: Noradrenaline content in (ng/g tissue wet weight) in rat brain regions following 
acute carmofur treatment. All values represent mean ± SEM (n = 6). Abbreviations: PFC, 













Table 6.1: Summary of changes in rat brain levels of monoamine neurotransmitters and their 
metabolites following acute carmofur treatment (20 mg/kg, i.p). 
 
Values indicate monoamines and metabolite concentrations (ng/g tissue wet weight) as mean 
± SEM (n = 6), carmofur treatment versus corresponding control group; * p < 0.05; ** p < 0.01; 







(ng/g   
wet weight) 
Treatment group 
(ng/g         
wet weight) 
    
   P-value 
1 5-HT Prefrontal cortex 388.9 ± 59.05 777.6 ± 135.6 0.025* 
  Hippocampus 373.5 ± 40.67 525.1 ± 45.22 0.032* 
  Striatum 329.7 ± 39.11 474.9 ± 40.34 0.027* 
2 5-HIAA Prefrontal cortex 129.1 ± 13.53    58.32 ± 13.6    0.004** 
  Hippocampus 191.2 ± 8.532 128.3 ± 9.209 0.0005*** 
  Striatum  147.6 ± 13.5 81.14 ± 5.581    0.001** 
3 Noradrenaline Prefrontal cortex  54.38 ± 7.475 56.18 ± 9.183 0.882 
  Hippocampus  298.1 ± 52.35    337 ± 53.25 0.613 
  Striatum  253.7 ± 43.26 263.5 ± 66.48 0.904 
4 Dopamine Prefrontal cortex  120.8 ± 12.64 135.5 ± 8.692 0.363 
  Striatum 1588 ± 181.5 1882 ± 292.4 0.413 
5 DOPAC Prefrontal cortex    70.7 ± 11   81.43 ± 17.71 0.618 





6.3.2. Analysis of sphingosine in rat brain following acute carmofur treatment 
using LC-MS:  
In this chapter, carmofur has been shown to induce significant increases of 5-HT and 
reductions of its main metabolite 5-HIAA from brain regional whole tissue samples. 
Interestingly these data show that carmofur leads to increased storage of 5-HT and decreased 
metabolism, which indicates that inhibition of acid ceramidase (AC) decreases 5-HT 
neurotransmission. To confirm that carmofur indeed inhibits AC in the brain and hence 
increases ceramide and decreases sphingosine levels, it was deemed important to measure 
both of these lipids in the same brain samples that were analysed for levels of monoamines 
and metabolites in section 6.3.1 of the current chapter.  This was achieved by means of the 
LC-MS and HPLC-UV techniques for the analysis of sphingosine and ceramide respectively. 
Statistical analysis of the generated data was performed using two-way analysis of variance 
(two-way ANOVA with Bonferroni post-hoc test) to assess the effect of treatment (carmofur 
versus vehicle administration) and brain region (PFC, HP and ST).  In the present experiment, 
two-way ANOVA indicated a highly significant effect of brain region on the measured 
sphingosine level following acute carmofur treatment (p = 0.006, F (2,30) = 5.996) with a 
significant interaction effect between treatment and brain region (p = 0.039, F (2,30) = 3.616).  
A subsequent post hoc analysis using the Bonferroni t-test recorded a highly significant 
reduction of sphingosine content in both the prefrontal cortex (Table 6.2 and Figures 6.11, 
6.12 and 6.13) and hippocampus (Table 6.2 and Figures 6.11, 6.14 and 6.15) (for both brain 
regions, p < 0.001) in the treatment group compared to the vehicle-treated controls following 
acute carmofur administration. However, the drug’s effect on sphingosine levels in the 
















Figure 6.11: Sphingosine content in (mg/mg protein) in rat brain regions following acute 
carmofur treatment. All values represent mean ± SEM (n = 6).  Abbreviations: PFC, prefrontal 
cortex; HP, hippocampus and ST, striatum. *** P < 0.001 for both the PFC and HP, but not 
significant for the striatum (two-way ANOVA test with Bonferroni t-test).  
 
Table 6.2: Effect of acute carmofur treatment (20 mg/kg, i.p) on sphingosine content in rat     








Control     28.76 ± 1.830      24.19 ± 3.318 15.86 ± 0.972 
Acute carmofur     12.43 ± 2.425 ***     11.74 ± 2.187 *** 10.79 ± 1.069 
 
Values indicate sphingosine content (mg/mg protein) as mean ± SEM (n = 6), carmofur 








Figure 6.12: LC-MS chromatogram of frontal cortical tissue samples obtained from upper: 
control and lower: treated rat following acute carmofur administration showing 
sphingosine peak at a retention time of 4.191 and 4.195 minutes respectively. 
 
 
Figure 6.13: LC-MS chromatogram of frontal cortical tissue samples obtained from upper: 
control and lower: treated rat following acute carmofur administration showing 






Figure 6.14: LC-MS chromatogram of hippocampal tissue samples obtained from upper: 
control and lower: treated rat following acute carmofur administration showing 









Figure 6.15: LC-MS chromatogram of hippocampal tissue samples obtained from upper: 
control and lower: treated rat following acute carmofur administration showing 






Figure 6.16: LC-MS chromatogram showing sphingosine standard peak at a concentration of 
15 mg / L and a retention time of 4.187 minute.  
 
6.3.3. Analysis of ceramide in rat brain following acute carmofur treatment 
using HPLC-UV: 
The AC inhibition induced by carmofur is expected to be accompanied by an increase of 
ceramide levels (Realini et al., 2013).  Therefore, in order to confirm this, a chromatographic 
system (HPLC-UV) was used to measure ceramide levels in our brain samples following 
benzoylation which indeed was successfully performed.  Statistical analysis of the generated 
data was achieved using two-way analysis of variance (two-way ANOVA) to test for the effect 
of treatment (carmofur versus vehicle administration) and brain region (PFC, HP and ST).  As 
expected, and as a further proof that carmofur indeed entered the brain of our experimental 
rats, acute carmofur administration (20 mg/kg, i.p) resulted in increased ceramide levels in 
samples from the selected brain regions. Likewise, for carmofur induced reductions of 
sphingosine (Figure 6.11), in the prefrontal cortex and hippocampus, these increases were 
highly significant.  In contrast, carmofur (similarly to the reduction of sphingosine levels) failed 








Figure 6.17: Ceramide content in (mg/mg protein) in rat brain regions following acute 
carmofur treatment.  All values represent mean ± SEM (n = 6).  Abbreviations: PFC, prefrontal 
cortex; HP, hippocampus and ST, striatum. *** P < 0.001 for both the PFC and HP, but not 
significant for the striatum (two-way ANOVA test with Bonferroni t-test).  
 
Following acute carmofur treatment, data analysis by two-way ANOVA showed a highly 
significant effect of brain region (p < 0.0001, F (2,36) = 31.46) on the central ceramide content 
with a clearly significant interaction between treatment and brain region (p = 0.0004, F (2,36) 
= 9.727).  The Bonferroni post hoc analysis reported a highly significant increase of ceramide 
level in the prefrontal cortex (p < 0.001) and the hippocampus (p < 0.001) compared to the 
relevant controls without any observed changes in the striatum in the carmofur-treated rats 
compared to their corresponding vehicle-treated animals (Table 6.3 and Figures 6.17, 6.18 
and 6.19).  
Table 6.3: Effect of acute carmofur treatment (20 mg/kg, i.p) on ceramide content in rat brain.  
Abbreviations: PFC, prefrontal cortex; HP, hippocampus and ST, striatum.   







Control    43.76 ± 1.324    31.08 ± 2.134 23.91 ± 1.769 
Acute carmofur    85.26 ± 7.356 ***   77.17 ± 7.884 *** 31.23 ± 3.449 
 
Values indicate ceramide content (mg/mg protein) as mean ± SEM (n = 6), carmofur treatment 





















Figure 6.18: UV-HPLC chromatogram of frontal cortical samples obtained from upper: control 
and middle: treated animal following acute carmofur administration showing ceramide peak at 
a retention time of 5.94 and 5.98 minutes respectively. Lower: UV-HPLC chromatogram showing 








Figure 6.19: UV-HPLC chromatogram of hippocampal samples obtained from upper: control and 
middle: treated animal following acute carmofur administration showing ceramide peak at a 
retention time of 5.79 and 5.75 minutes respectively. Lower: UV-HPLC chromatogram showing 





6.4. Discussion:  
6.4.1. Principal findings: 
The key aim of this study was to investigate the effect of acute administration (20 mg/kg, i.p) of 
the known AC inhibitor, carmofur on central monoaminergic neurotransmission. This was 
performed by analysing the carmofur (20 mg/kg, i.p., one hour after the injection) induced effect 
on monoamine (5-HT, NA and DA) levels as well as some of their metabolites (5-HIAA and DOPAC) 
in regional brain samples (PFC, HP and ST) from rats treated with the drug or their corresponding 
vehicle treated controls using HPLC-ECD.  In order to provide evidence that carmofur indeed 
entered the brain regions investigated and hence inhibited AC, the effect of carmofur on levels of 
the two sphingolipid molecules of interest for AC inhibition; ceramide and sphingosine were also 
investigated using the analytical techniques of HPLC-UV and LC-MS respectively.  The generated 
data revealed that acute carmofur treatment resulted in a notable increase of 5-HT content in all 
of the three brain regions examined (PFC, HP and ST).  In contrast, carmofur failed to significantly 
alter levels of the two catecholamines, DA and NA.  Interestingly, the carmofur induced increase 
of regional whole tissue levels of 5-HT coincided with a marked reduction of the main metabolite 
of 5-HT, 5-HIAA in these samples (Figures 6.1 and 6.2).  In comparison, the DA main metabolite 
DOPAC remained unaltered following carmofur administration. On the other hand, this 
experimental set also showed that following acute carmofur treatment levels of the two 
sphingolipids likely to be affected by acute inhibition of AC, namely ceramide and sphingosine 
were also altered by acute carmofur treatment. Thus, following carmofur injection, ceramide 
levels increased while sphingosine decreased in brain samples collected from carmofur treated 
rats compared to levels in the corresponding control samples.  While these changes were highly 
significant in tissue samples collected from the prefrontal cortex and the hippocampus, carmofur 
failed to significantly alter sphingolipid levels in the striatum (Figures 6.11 and 6.17).  These 
finding are in line with a previous albeit more limited study in mice showing that acute carmofur 
injection (10 mg/kg and 30 mg/kg, i.p) likewise to the current study resulted in increased levels 





6.4.2. Acute carmofur administration induced alterations of 5-HT and its main 
metabolite 5-HIAA: 
The present experimental work revealed that carmofur induced increases of ceramide levels 
coincided with changes of brain levels of 5-HT and its main metabolite 5-HIAA indicating a 
decrease of 5-HT transmission (i.e. increased whole tissue levels of 5-HT and decreased 5-HIAA). 
In comparisons, levels of the two catecholamines: DA, NA and the DA metabolite DOPAC were 
unaltered following carmofur administration.  In the light of depression and it’s treatment, the 
central 5-HT system is widely suggested to play a vital role (aan het Rot et al., 2009; Elhwuegi, 
2004; Krishnan and Nestler, 2008; Nemeroff, 2002). Thus, the 5-HT transporter represents the 
main target of many currently available antidepressant medications such as the SSRIs (Nemeroff, 
2002; Oosterhof, 2016). Additionally, it has been reported that depletion of the monoamine 
neurotransmitters, in particular 5-HT results in a mood lowering state in both depressed patients 
undergoing remission as well as in the non-depressed controls (Merens et al., 2008; Oosterhof, 
2016).  Despite growing evidence indicating that ceramide could also play a vital role in depression 
and its treatment, no evidence exists regarding the direct effect of a ceramide imbalance on 
neurotransmission of monoamines.  In this context, it was shown in Chapter Four, sections 
4.3.1.2, 4.3.1.3 and 4.3.2 of this thesis that chronic but not acute treatment of two antidepressant 
drugs, paroxetine and desipramine decreased levels of ceramide and its metabolite sphingosine 
in brain areas related to the symptoms of depression.  
 
In the central nervous system, among all of the known 5-HT receptors, the 5-HT1A receptor 
subtype plays a key role in signal transduction as well as its implication in various behavioural and 
cognitive functions including mood, sleep and learning (Marona-Lewicka and Nichols, 2011; 
Müller et al., 2007; Singh et al., 2012).  This 5-HT receptor subtype is expressed both pre and post 
synaptically and belongs to the G-protein-coupled receptor family (GPCRs, that are coupled to the 
Gi/Go protein) (Oosterhof, 2016; Singh et al., 2012). The pre-synaptic 5-HT1A receptors are 
expressed predominantly on the soma and dendrites of the 5-HT neurons in the raphe nuclei of 
the mid brain. The somatodendritic located 5-HT1A receptors when stimulated results in an 





In addition, the regulation of these receptors has been implicated in the known delay in full 
therapeutic effect of antidepressant drugs. Thus it has been shown that following acute 
antidepressant drug treatment, initially there is a significant elevation of extracellular 5-HT levels 
in the raphe nucleus which is caused by the inhibition of somatodendritic located 5-HT 
transporter (Artigas, 2013; Nemeroff, 2002; Oosterhof, 2016).  Concomitantly, this effect results 
in the activation of the inhibitory 5-HT1A autoreceptors, hence attenuating the firing activity of 
the serotonergic neurons temporarily. On the other hand, chronic antidepressant drug 
administration induces adaptive changes of the serotonergic neurons, leading to a subsequent 
desensitization of the 5-HT1A autoreceptors which results in decreased responsiveness of these 
receptors following their sustained activation. Consequently, a slow recovery of the discharging 
activity of the 5-HT neurons occurs, which is reflected in a gradual increase of 5-HT 
neurotransmission (Nemeroff, 2002; Oosterhof, 2016).  Of key relevance for the present work, it 
has recently been reported that the essential lipid-protein interaction of cell membranes is driven 
by an interaction between GPCRs (as integral membrane proteins) with the surrounding 
membrane sphingolipids including ceramide.  This process has for example been shown to have 
a pivotal role in modulating the interaction between the G-proteins and GPCRs and hence 
maintaining the structure of the receptors and their function.  Interestingly, it has been 
postulated that these receptors via sphingolipids including ceramide undergo conformational 
alterations that are essential to maintain their signaling function (Singh et al., 2012; Unal and 
Karnik, 2012).  In addition, it was observed that the indicated lipid-protein interaction is necessary 
for the ligand binding activity of 5-HT1A receptors. Thus, depletion of these membrane 
sphingolipids may result in impairment of this activity accompanied by a reduction in the 
expression of these autoreceptors at the level of the cell membrane (Jafurulla et al., 2008; Singh 
et al., 2012). Moreover, ceramide has been shown to alter the transport of monoamine 
neurotransmitters, particularly 5-HT either through a direct or indirect action.  Directly, it acts by 
binding membrane ceramide enriched macrodomains to the transporter molecule (Dinoff et al., 
2017; Gangoiti et al., 2010), or indirectly by activating various intracellular phosphatases and 





reuptake of 5-HT via altering the transporter function (Dinoff et al., 2017; Kornhuber et al., 2009; 
Riddle et al., 2003).  
 
In the present study, the recorded findings displayed a pronounced increase in whole tissue 5-HT 
content with a significantly decreased 5-HIAA level in all the analysed brain regions (PFC, HP and 
ST) following acute carmofur treatment.  Consequently, there was a clear reduction of the 5-
HIAA/5-HT ratio (the serotonin turnover ratio) (Hussain and Butt, 2008; Shannon et al., 1986), 
indicating a reduced concentration of the 5-HT metabolite, 5-HIAA. Therefore, reflecting a 
reduced 5-HT catabolic rate and possibly a decreased serotonergic activity in these brain regions. 
While levels of the 5-HT metabolite 5-HIAA have been found to be reduced in the cerebrospinal 
fluid of depressed patients (Åsberg et al., 1984).  A number of studies have indicated an increase 
in 5-HIAA/5-HT ratio i.e. 5-HT turnover in plasma samples from patients diagnosed with 
depression which resulted mainly from a significant increase in the plasma concentrations of 5-
HIAA  (Barton et al., 2008; Shannon et al., 1986).  In this context, a previous study using an animal 
model of depression observed that the 5-HIAA/5-HT ratio was significantly lower in a part of the 
brain namely, the nucleus accumbens of “depressed” rats compared to the corresponding 
controls.  Further, this reduction of 5-HT turnover in the nucleus accumbens was found to be 
normalized following chronic treatment with the antidepressant desipramine (5 mg/kg/day) for 
18 days (Zangen et al., 1997).  Our data show that carmofur increases ceramide levels and that 
this effect reduces the 5-HIAA/5-HT ratio but not the DOPAC/DA ratio, hence suggesting that 5-
HT neurotransmission is primarily affected by enhanced ceramide levels. The mechanism behind 
this effect is not fully clear, it could however, be speculated that both an effect on 5-HT transport 
as well as an enhanced activity of the 5-HT1A autoreceptor via enhanced ceramide concentration 
could be involved in the mediation of the reduced 5-HT turnover.  Thus, as mentioned already 
ceramide has been shown to affect neuronal monoamine transport (Dinoff et al., 2017; Westwick 
et al., 1995). Moreover it has been demonstrated in synaptosomal preparations that ceramide 
decreases DA transport while it in contrast, increases 5-HT transport (Riddle et al., 2003).  Further, 
such effect is likely to enhance whole brain tissue levels of 5-HT as detected following treatment 





shown to be stimulated by ceramide, a lipid-protein interaction enhancing ligand binding activity 
of the 5-HT1A receptor.  In accordance with these reported findings, it could be speculated that 
a carmofur induced enhancement of brain ceramide levels would enhance the activity of 5-HT1A 
autoreceptor function. An effect which would lead to a decreased firing of 5-HT neurons in the 
raphe nuclei and reduction of 5-HT release and metabolism in the forebrain.  Ultimately, resulting 
in enhanced storage of 5-HT and reduced levels of the intracellularly produced 5-HT metabolite 
5-HIAA.  
 
6.4.3. Carmofur administration alters brain ceramide and sphingosine content:  
In this study, our data demonstrated that an acute injection of the AC inhibitor carmofur at one 
hour after the injection resulted in a significant increase of ceramide levels in samples collected 
from treated animals as compared to their corresponding vehicle injected controls.  This effect 
was accompanied by a pronounced decrease in the levels of the main ceramide metabolite 
sphingosine.  These effects were highly significant in brain samples from the prefrontal cortex and 
hippocampus but in the striatum the drug only produced small and non-significant effects (Figures 
6.11 and 6.17).  Acid ceramidase is a lysosomal polypeptide that acts in an acidic environment (pH 
= 4.5) to catalyze the degradation of ceramide into sphingosine and fatty acid (Saied and Arenz, 
2014; Shtraizent et al., 2008). In our study, the detected alteration in the two targeted 
sphingolipid molecules (ceramide and sphingosine) is likely to result from carmofur-induced 
inhibition of AC activity following a single intraperitoneal injection of the drug at a dose of 20 
mg/kg. Consistent with our findings, a recent animal study reported a significant elevation in 
tissue ceramide level in the cerebral cortex and lung of mice, this together with a decreased 









6.5. Conclusion:    
The current study revealed that acute carmofur treatment compared to the corresponding 
controls resulted in a pronounced increase of 5-HT levels which was accompanied by a significant 
reduction of levels for the 5-HT metabolite 5-HIAA.  Importantly, this effect was seen in three 
brain regions (prefrontal cortex, hippocampus and striatum) implicated in depression and its 
treatment.  In contrast, carmofur failed to induce any significant alterations in the levels of the 
two catecholamine neurotransmitters: DA and NA as well as for the DA metabolite DOPAC.  
Further, measurement of brain ceramide and sphingosine levels in the same regional tissue 
samples significantly showed increased ceramide levels with a concomitant reduction of the 
sphingosine content in the PFC and HP of the carmofur treated rats in comparison with their 
vehicle-treated controls. The observed carmofur-induced decrease of the 5-HIAA/5-HT ratio could 
indicate a reduction of 5-HT neurotransmission.  This effect might be induced by an enhanced 
activation of the inhibitory 5-HT1A autoreceptors via increased ceramide levels and/or changes 
of 5-HT reuptake. However, a more detailed investigation is still necessary to provide further 
insight into the neurochemical relevance of the carmofur-induced increase of ceramide and how 































































7.1. Background:  
Depression is a common psychiatric disorder with increased risk of disability and suicidal 
mortality. The condition further results in a considerable economic impact and the total reported 
number of suicidal deaths across the world is approximately 800 000 per year.  Globally, it was 
estimated that depressive disorder affects over 300 million people worldwide which is equivalent 
to 4.4% of the total world’s population with a higher prevalence rate among female patients 
compared to males (according to the WHO, 2017) (Organization, 2017).  Currently, the available 
antidepressant medications act predominantly by facilitating 5-HT and or NA neurotransmission 
either via inhibiting their re-uptake back into the presynaptic nerve terminals e.g. SSRIs, SNRIs 
and TCAs (Cheung et al., 2006) or by inhibiting their enzymatic catabolism e.g. MAOIs (Fowler et 
al., 2010).  However, it has been reported that more than 50% of all depressed patients do not 
successfully respond to multiple trials of the currently prescribed antidepressant drugs (failure to 
achieve remission), thus representing a well-known class of the disease termed as treatment 
resistant depression (Dinoff et al., 2017; McIntyre et al., 2014).  Indeed, it is also well-recognised 
that all the currently available antidepressant medications takes an average time of 4-6 weeks to 
exhibit their full therapeutic effect (Tylee and Walters, 2007).  In this context, the low response 
rate to the conventional therapy, the delayed onset of therapeutic action as well as the uncertain 
underlying aetiology of depression, altogether have triggered an extended investigation in the 
specific field of research of the present project, namely the possible involvement of sphingolipid 
turnover as part of the mechanism of action by antidepressant drugs. Sphingolipids, in particular 
ceramide has been suggested to have a role in depression (Kornhuber et al., 2009, 2014).  In this 
context, ceramide has been linked to critical neurobiological mechanisms including cell signaling 
and monoamine neurotransmission (Dinoff et al., 2017; Müller et al., 2015), membrane 
permeability (Tsui-Pierchala et al., 2002) and apoptosis (Ruvolo, 2003).  Accordingly, the primary 
aim of the present study was firstly to investigate the short and long-term effects of two currently 
used antidepressant drugs namely, the TCA desipramine and the SSRI paroxetine on water soluble 
brain metabolites (Chapter Three) and sphingolipid turnover (Chapter Four).  Secondly, the study 
also sought to investigate the mechanism of action by such an effect (Chapter Five) as well as the 





study provides further evidence in support of the possible involvement of brain sphingolipids in 
antidepressant drug mechanism of action.   
 
7.2. Summary of the major findings: 
7.2.1. Effects of antidepressant drugs on brain metabolites depend on treatment 
regime, type of drug and brain region investigated: 
In Chapter Three, metabolic changes were explored in rat brain regions following acute and 
chronic administration of two antidepressant drugs (paroxetine and desipramine). For this 
purpose, 1H NMR spectroscopy was employed to investigate the effect of treatment with 
paroxetine and desipramine on water soluble metabolite/biomolecule levels in plasma and brain 
regions implicated in the pathogenesis of depression including the prefrontal cortex (PFC), 
hippocampus (HP) and the striatum (ST) (Drevets et al., 2008; McEwen and Morrison, 2013). In 
these experiments the tested drug doses of both paroxetine (5 mg/kg) and desipramine (10 
mg/kg) were adopted on the bases of previously published studies (Detke et al., 1997; Hajós-
Korcsok et al., 2000; Mathes and Spector, 2011). Thus, these previous studies had shown 
behavioural as well as biochemical changes following similar drug regimes in animal models of 
depression.  Moreover, the doses used in the present study have be shown to reach plasma levels 
in rats similar to those obtained in depressed patients (Benmansour et al., 1999). More 
specifically, plasma levels of 30-120 ng/ml for paroxetine and 50-300 ng/ml for desipramine have 
been associated with therapeutic response in humans  (Gillman, 2007; Hiemke et al., 2011).    
 
Briefly, in Chapter Three of this thesis, it was shown that by using 1H NMR acute antidepressant 
drug administration resulted in widespread changes of several water-soluble brain metabolites. 
Furthermore, these changes were frequently specific to both brain region and the type of 
antidepressant drug used (i.e. paroxetine or desipramine).  In this regard, data from this chapter 
indicate that acute paroxetine and desipramine treatment significantly alter the brain levels of a 
number of metabolites that are involved in important metabolic pathways of the brain including: 





glutamine) as well as neuronal integrity (e.g. NAA).  On the other hand, data analysis of plasma 
samples obtained from the acute paroxetine-treated rats revealed only significant changes for a 
few metabolites (i.e. creatine and succinate) compared to the corresponding controls without any 
significant metabolic changes in the plasma following acute desipramine administration.  Other 
neurochemical type studies have also investigated the metabolic effects that may be associated 
with depression and its drug treatment using different type of imaging technologies (Brody et al., 
1999; Chiappelli et al., 2015; Yüksel and Öngür, 2010; Zhao et al., 2015).  In this context, a previous 
clinical imaging study using MRI (magnetic resonance imaging) scans revealed a decreased 
metabolic activity in the dorsolateral prefrontal cortex, as well as an increased metabolic activity 
in the ventrolateral prefrontal cortex, the orbitofrontal cortex and the inferior orbital gyrus in 
depressed subjects.  Importantly, changes in metabolic activity in the ventrolateral prefrontal 
cortex and the orbitofrontal cortex were normalized following successful paroxetine treatment 
(40 mg/day), emphasising the potential clinical importance of brain metabolites for the symptoms 
of  depression (Brody et al., 1999).  In Chapter Three, it was also shown that in contrast to the 
acute treatment data which displayed significant drug-associated metabolic responses, the 
detected alterations were not maintained in the chronically treated rats (once daily injections for 
15 days) compared to their corresponding controls in the explored brain regions and in the 
plasma. Taken together, this could possibly reflect the occurrence of neuroadaptive changes 
following repeated drug exposure.  
 
7.2.2. Effects of acute and chronic antidepressant drug administration on 
sphingosine and ceramide content in rat brain regions: 
Accumulated evidence suggests that sphingolipids particularly ceramide could be implicated in 
depression and its pharmacotherapy.  Hence, an important goal of the current study was to 
investigate the effect of acute and chronic antidepressant drug treatment (once daily for 15 days) 
on brain levels of two bioactive sphingolipid molecules, namely: ceramide and its major 
metabolite sphingosine in regional tissue samples from treated and control rats by means of the 
HPLC-UV and LC-MS methods respectively.  In this context, it was reported in Chapter Four that 





on sphingosine level.  A significant reduction of sphingosine content was detected in samples 
from two of the explored brain regions of the rat: the prefrontal cortex and the hippocampus (a 
stronger effect was observed in the prefrontal cortex).  In comparison, both drugs (paroxetine 
and desipramine) failed to significantly reduce sphingosine levels in the striatum. Further, chronic 
treatment with the SSRI paroxetine appeared to be more effective in comparison to chronic 
administration of the TCA desipramine.  While chronic paroxetine administration resulted in a 
significant reduction of sphingosine levels in the PFC and HP, a non-significant trend for a reduced 
sphingosine levels was recorded following chronic desipramine treatment. Interestingly, the 
marked decrease in sphingosine level was recorded following chronic but not after acute 
treatment. A limitation of the LC-MS system used for the detection of sphingosine in our 
laboratory was the inability to measure molecules with a molecular weight exceeding 500 g/mol.  
Since the molecular weight of ceramide is 566 g/mol, the measurement of ceramide was 
therefore performed by the modification of a previously published HPLC-UV method (Couch et 
al., 1997; Ogawa et al., 2010; Tepper and Blitterswijk, 2000).  This method involved extensive 
sample preparation and hence, was only applied for two groups of samples namely, hippocampal 
samples from the chronically paroxetine treated rats and their corresponding controls.  
Consistent with the paroxetine-induced reduction of hippocampal sphingosine levels, this drug 
also significantly reduced the concentration of ceramide in samples collected from the 
hippocampus. To confirm that the ceramide metabolite sphingosine could indeed be used as a 
reliable marker of ceramide, the present study found a significant correlation between 
hippocampal ceramide and sphingosine levels in both paroxetine-treated and control rats.  
Further, the observed findings from the current study are in correspondence with a previous 
study reporting a similar reduction of mice hippocampal ceramide level following long-term 
antidepressant drug therapy (Gulbins et al., 2013).  This study shows however, for the first time 
that antidepressant drugs also reduce sphingolipid levels in the prefrontal cortex while levels in 






7.2.3. Effect of chronic antidepressant drug treatment on gene expression for two 
key enzymes of the brain sphingolipid pathway: 
Research to date, regarding the involvement of sphingolipids in mental health related conditions 
have focussed on the significance of the membrane sphingolipid ceramide; its synthesis, 
catabolism as well as its biological correlates (e.g. monoamine neurotransmission and apoptosis) 
(Canals et al., 2011; Müller et al., 2015; Osherovich, 2013; Ruvolo, 2003). However, further 
evidence on the potential link between the dysregulation of ceramide and the related lipid-
processing enzymes with depression and the mechanism of action underlying its drug treatment 
is still limited and hence, require more investigations.  Thus, in Chapter Five, experiments were 
designed to investigate the effect of chronic antidepressant drug administration (once daily for 
15 days) on gene expression for the two-main sphingolipid-regulating enzymes; acid 
sphingomyelinase (encoded by the SMPD1 gene) and acid ceramidase (encoded by the ASAH1 
gene) in the three examined brain regions using the RT-qPCR technique.  Our reported findings 
from Chapter Five revealed that chronic administration of both antidepressant drugs (i.e. 
paroxetine and desipramine) induced a significant reduction of the gene expression level for acid 
sphingomyelinase in the hippocampus of the drug-treated rats compared to the corresponding 
saline-injected controls. Similarly, long-term treatment with both paroxetine and desipramine 
resulted in a reduction of SMPD1 mRNA level in the prefrontal cortex this effect however, failed 
to reach significance and in the striatum both drugs had only minor effects.  In Chapter Five, 
measurements of gene expression for the ceramide metabolising enzyme acid-ceramidase was 
also performed after chronic antidepressant drug treatment. The data from these experiments 
showed that chronic desipramine but not paroxetine treatment (non-significant reductions only) 
significantly reduces expression level of the ASAH1 gene in the hippocampus and the prefrontal 
cortex. However, likewise for the gene encoding acid sphingomyelinase, this effect was significant 







7.2.4. Effect of acute carmofur treatment on monoamines and their metabolites 
in rat brain regions: 
It is well known that monoaminergic neurotransmission is closely linked to depression and its 
therapeutic intervention (aan het Rot et al., 2009; Brigitta, 2002; Hirschfeld, 2000).  A number of 
studies including this study suggest the involvement of the central sphingolipid system (e.g. 
ceramide) in the symptoms and treatment of depression as recently reviewed by Gulbins et al, 
2015. Beyond doubt, the majority of currently available antidepressant drugs influences 
monoaminergic neurotransmission, however, little information is available regarding a potential 
interaction between monoamines and sphingolipids. To examine the potential relationship 
between these two biochemical systems, in Chapter Six, we tested the effects of the potent acid 
ceramidase inhibitor carmofur (a drug that has previously been used to treat some types of cancer 
including colorectal) on regional brain levels of monoamines and their metabolites. For this 
purpose, rats were injected with carmofur (20 mg/kg, i.p), sacrificed one hour later, tissue 
samples prepared from PFC, HP and ST and monoamine levels (5-HT, DA and NA) and some of 
their metabolites (5-HIAA and DOPAC) measured using HPLC-ECD.  In order to confirm the brain 
entry of carmofur, its effect on brain levels of sphingosine and ceramide was evaluated by LC-MS 
and HPLC-UV respectively. As predicted, these experiments showed that carmofur by inhibiting 
AC significantly increased levels of ceramide and decreased levels of sphingosine.  Interestingly 
Chapter Six appeared to demonstrate a relationship between ceramide levels and 5-HT 
neurotransmission.  Thus, the carmofur induced enhancement of ceramide levels coincided with 
a significant increase of the whole tissue 5-HT content in all of the three brain regions examined 
(PFC, HP and ST).  In contrast, carmofur failed to significantly alter levels in any of the brain regions 
examined of the two catecholamines, DA and NA or the DA metabolite DOPAC.  Interestingly, the 
carmofur induced increase of regional whole tissue levels of 5-HT coincided with a marked 
reduction of the main 5-HT metabolite, 5-HIAA in these analysed samples.  Thus, the 5-HIAA/5-
HT ratio was reduced, suggesting a reduction of 5-HT neurotransmission following acute carmofur 
treatment.  In comparison, the DA main metabolite (DOPAC) level remained unaltered after acute 
carmofur administration.  As already mentioned briefly above, findings from Chapter Six also 





acute inhibition of AC, namely ceramide (increased) and sphingosine (decreased) in brain samples 
from PFC and HP.  Although carmofur also altered levels of the two sphingolipids in the striatum, 
these effects failed to reach statistical significance in this brain region. Moreover, in 
correspondence with our results, a previous animal study conducted on mice indicated that acute 
carmofur administration at two different doses (10 mg/kg and 30 mg/kg, i.p) resulted in increased 
levels of ceramide in mouse tissues including lungs as well as in one part of the brain (i.e. the 
cerebral cortex) (Realini et al., 2013). 
 
7.3. General discussion and implications of the main findings: 
Generally, alterations in monoaminergic functions particularly the serotonergic and 
noradrenergic systems have been found to be implicated in the pathogenesis of depression as 
well as the mechanism of antidepressant drug action (aan het Rot et al., 2009; Brigitta, 2002; 
Hirschfeld, 2000; Sun et al., 2017). So far, a well-recognised neurobiological mechanism 
underlying the disease together with the reasons behind the low response rate to the currently 
used antidepressant medications and their actual mechanism of action are still undetermined. 
Limited previous research have attempted to explore a metabolic brain profiling of depression 
and how this is changed following short and long-term administration of antidepressant 
medications.  To date, however, previous neurochemical studies failed to reveal any consistent 
pattern of brain metabolic changes related to depression or the available drug therapy (Bai et al., 
2015; Gołembiowska and Dziubina, 2000; Jia et al., 2013; Yoo et al., 2018; Zhao et al., 2015).  As 
indicated earlier, data from Chapter Three showed that acute but not chronic antidepressant drug 
administration induced significant metabolic changes in a wide range of metabolites in the brain 
regions examined.  Interestingly, the observed drug-associated metabolic responses were often 
both brain region (mostly decreases in hippocampus and prefrontal cortex while levels of most 
metabolites tended to increase in the striatum) and drug specific. These differential effects 
possibly reflect the fact that paroxetine and desipramine primarily block different types of 
transporters; SERT and NET and therefore, preferentially increase the extracellular levels of 5-HT 
and NA respectively.  It is likely that, this initial enhancement of the synaptic monoamine levels 





HT1A and α2 adrenergic receptors) thus, resulting in decreased serotonergic as well as 
noradrenergic neurotransmission following short-term drug exposure (David et al., 2003; Hyman 
and Nestler, 1996).  It is possible that such acute inhibition of monoamine neurotransmission is 
related to the acute downregulation of a number of metabolites in the hippocampus and the 
frontal cortex.  In contrast to the acute effect, chronic antidepressant drug administration failed 
to show any significant metabolic alterations in the investigated brain regions, suggesting the 
onset of neuroadaptive changes following repeated drug administration (Lefkowitz, 1993; 
Sacchetti et al., 2001).  Given that, the sustained activation of the 5-HT1A and α2 autoreceptors 
after chronic antidepressant drug administration are well known to results in their desensitization 
(Artigas, 2013; Hyman and Nestler, 1996; Sacchetti et al., 2001), it is possible that such effect is 
related to the reversal of the metabolic effects after chronic drug treatment in the present study. 
 
Next, the effect of acute and chronic antidepressant drug treatment was investigated on the 
abundance of two bioactive sphingolipid molecules namely: ceramide and its main metabolic 
product sphingosine in the three brain regions examined here. Results from Chapter Four 
demonstrate that chronic antidepressant drug administration induced a significant reduction of 
the ceramide metabolite sphingosine in the prefrontal cortex and hippocampus but not in the 
striatum (a region-specific effect).  Importantly, the decrease of sphingosine levels was detected 
following chronic but not after acute treatment.  In addition, and based on the generated data of 
this thesis, sphingosine was proven to be a reliable indicator of ceramide in the analysed brain 
extracts. In correspondence with the sphingosine data, chronic paroxetine administration 
resulted in a significant reduction of hippocampal ceramide level, a finding consistent with a 
recent animal study reporting a decreased ceramide content in mice hippocampus following long-
term antidepressant drug therapy (Gulbins et al., 2013). The recorded reduction by the 
antidepressant drugs of the targeted sphingolipids namely; ceramide and sphingosine could 
partly be explained by a dysregulation of the main sphingolipid-regulating enzymes. Thus, in 
Chapter Five, it was shown that antidepressant drugs have the ability to downregulate the mRNA 
expression of SMPD1 and ASAH1, two genes encoding acid sphingomyelinase and acid 





Consistent with the presents results, a recent study also indicated that chronic treatment with 
the antidepressant drugs: fluoxetine and amitriptyline at doses similar to those which  induce 
therapeutic plasma levels in depressed patients resulted in a reduction of ceramide abundance 
in the hippocampus, a decline of ASM activity and a concomitant reduction of depression-related 
behaviours in a mouse model of depression (Gulbins et al., 2013).  In this context, various 
antidepressant drugs are recently identified as functional or indirect inhibitors of acid 
sphingomyelinase activity, which as discussed in Chapter Five, could be caused by the intra-
lysosomal accumulation of the protonated (i.e. charged form of the drug molecule). Thus, 
resulting in a subsequent detachment and inactivation of the enzyme inside the acidic lysosomal 
lumen (Kornhuber et al., 2008, 2010, 2014).  On the other hand, data from the gene expression 
study of the present project (Chapter Five) displayed significantly reduced ASAH1 mRNA levels 
(encodes acid ceramidase) in the hippocampus after long-term desipramine administration, 
whereas a non-significant trend towards a reduced expression level of this gene was observed 
following paroxetine treatment in this specific brain region.  Also, a similar trend, albeit a non-
significant reduction was detected for ASAH1 mRNA levels of the prefrontal cortex but not in the 
striatum after chronic administration of both antidepressant drugs.  Accordingly, desipramine 
may induce a non-selective inhibition of the genes encoding the lysosomal enzymes, ASM and AC.  
This was not the case with paroxetine, which seems to mediate a preferential inhibition of the 
gene encoding the ASM enzyme.  In this context, the ASM specific activity in the brain was 
reported to be higher compared to AC (Kornhuber et al., 2010).  Overall, long-term antidepressant 
drug treatment may induce a pronounced down-regulation of acid sphingomyelinase and to a 
lesser extent acid ceramidase mRNA expression levels specifically in the hippocampus. In 
contrast, both drugs failed to alter gene expression levels for ASM and AC in the striatum, a brain 
region possibly less directly implicated in the symptoms of depression (Drevets et al., 2008) 
compared to the prefrontal cortex and hippocampus.  In this context, findings from the present 
study that the striatum generally expresses lower levels and shows less antidepressant induced 






Further, a postulated relationship between ceramide and monoamine levels was tested by 
measuring the whole tissue level of monoamines (5-HT, DA and NA) and some of their metabolites 
(5-HIAA and DOPAC) in the investigated brain regions at one hour following a single injection of 
the acid ceramidase inhibitor carmofur.  Interestingly, results from these experiments pointed to 
an inverse relationship between 5-HT neurotransmission and ceramide levels. Thus, data from 
Chapter Six showed that increased levels of ceramide in the brain coincided with increased whole 
tissue 5-HT content in the three brain regions investigated (PFC, HP and ST) and a significant 
reduction of the main 5-HT metabolite 5-HIAA.  This together with a reduced 5-HIAA/5-HT ratio 
suggested an initial reduction of 5-HT neurotransmission after an acute carmofur injection.  In 
contrast, carmofur treatment failed to significantly alter levels of DA and its main metabolite 
DOPAC as well as the neurotransmitter NA in all brain regions examined.  
  
Previous studies have indicated that in the cell membrane, the interaction between the G-protein-
coupled receptors (GPCRs) (e.g. 5-HT1A receptors) and the surrounding membrane sphingolipids 
including ceramide encompass an essential lipid-protein interaction that is important in 
maintaining the structure of the receptors as well as their function specifically their ligand binding 
affinity (Singh et al., 2012).  In addition and relevant to the results of this thesis, it has been shown 
that ceramide may affect the transport of monoamine neurotransmitters, particularly 5-HT via 
activation of 5-HT transporter (SERT) function (Dinoff et al., 2017; Westwick et al., 1995). 
Moreover, it has previously been shown that acute carmofur administration by inhibiting the 
activity of acid ceramidase, primarily increases ceramide abundance of cell membrane lipid rafts 
(Dinoff et al., 2017; Realini et al., 2013). Thus, suggesting that the carmofur-induced enhancement 
of brain ceramide levels could directly result in changed activity of proteins located in the cell 
membrane lipid rafts including: the 5-HT1A autoreceptor and the 5-HT transporter.  It is therefore 
possible that the carmofur induced reduction of the 5-HIAA/5-HT ratio, (an index of 5HT-
neurotransmission; (Hussain and Butt, 2008) seen in the present study represents  a reduction of 
serotonergic activity via ceramide induced increase of 5-HT transport and/or enhanced activity of 






7.4. Concluding remarks: 
In summary, the data presented in the current thesis have shown a reduction of two functionally 
active sphingolipids, namely ceramide and sphingosine in rat brain following chronic but not acute 
antidepressant drug treatment.  This effect is likely at least in part to be explained by the drugs 
ability to inhibit the lipid-metabolizing enzyme, acid sphingomyelinase in brain regions implicated 
in depression, in particular the hippocampus. In comparison, the antidepressant drugs had only 
minor effects on sphingolipid pathways of the striatum, a brain region possibly less associated 
with the symptoms of depression.  Also, of importance the present thesis, by using the acid 
ceramidase inhibitor carmofur, show data which indicate an inverse relationship between 
ceramide levels and 5-HT neurotransmission. Given that, a reduced 5-HT neurotransmission and 
enhanced ceramide concentrations have both been implicated in the pathogenesis of depression, 
these data strengthen the involvement of sphingolipids in the mode of action of antidepressant 
drugs.  Future studies will however, be necessary to further support the ceramide hypothesis of 
depression.  In conclusion, data of the current thesis indicate that potential new drugs for the 
treatment of depression could be molecules targeting either acid sphingomyelinase or acid 
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